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PREFACE
In the Netherlands more than 1600 patients are newly diagnosed each year with esophageal 
cancer (www.kankerregistratie.nl). Cancers of the esophagus comprise two major histologi-
cal entities, squamous cell carcinoma and adenocarcinoma. Most patients with esophageal 
cancer have advanced disease at the time diagnosis, because symptoms (such as dysphagia) 
arise late in the course of the disease. At the time of diagnosis, two of three patients will have 
tumors that are considered inoperable because of patient co-morbidities or tumor extension. 
Over the past two decades, treatment has evolved from single (surgery alone) to multimodal-
ity therapy (surgery in combination with chemotherapy or chemoradiotherapy) and become 
the standard of care for curative treatment. Despite improvements in both diagnostic and 
therapeutic techniques over the years, esophageal cancer continues to have a poor progno-
sis, with 5-year survival rates between 10 and 13%.
Although the incidence of esophageal adenocarcinoma (EAC) has steeply increased over 
recent years, little is known about the molecular mechanisms underlying the genesis of these 
tumors. It has been thought that symptomatic gastroesophageal refl ux leads ultimately to 
pre-malignant metaplastic epithelium, also called Barrett’s esophagus that predispose for 
EAC. Understanding of the genetic alterations that underlie these tumors could contrib-
ute to the identifi cation of potential targets for therapy. In this context, cell lines derived 
from adenocarcinoma of the esophagus, could be powerful tools in the search for genetic 
alterations that are potentially involved in the carcinogenesis of EAC and to investigate novel 
therapeutic strategies.
This thesis focuses on cell lines as pre-clinical model for adenocarcinoma of the esophagus 
and on the role of preoperative chemotherapy in treatment of patients with esophageal 
cancer. A database from the department of surgery, containing clinical and pathological 
data on all patients operated on esophageal carcinoma, was used for studying diff erent 
clinical aspects of esophageal cancer treatment.  Most laboratory experiments described in 
this thesis were done at the laboratory for molecular diagnostics, department of pathology, 
Erasmus University Medical Center, Rotterdam. Furthermore, the author of this thesis was 
able to perform two months of research at the pathology department of the Memorial Sloan 
Kettering Cancer Center (New York), to verify the authenticity of two EAC cell lines.
J. J. Boonstra,
Berkel en Rodenrijs, May 2011
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General Introduction 
GEN ERAL INTRODUCTION
Epidemiology
Worldwide esophageal cancer is a signifi cant and an increasing health problem. In 2005, 
there were 497,700 new cases, and the prevalence is expected to increase by approximately 
140% by 2025 (1). Esophageal squamous cell carcinoma (ESCC) accounts for most of the cases 
of esophageal cancer worldwide (2); however, in a number of Western countries, including 
the Netherlands, there has been a modest decline in the incidence of ESCC and a steep rise in 
the frequency of esophageal adenocarcinoma (EAC) (Figure 1).
Etiology
Chronic infl ammation plays a key role in the initial development of both ESCC and EAC. In 
ESCC, the chronic infl ammation is thought to be precipitated by toxins, including cigarettes 
and alcohol. Carcinogens produced by tobacco, particularly nitrosamines, are known to pro-
duce the precise types of guanine nucleotide conversion found in crucial genes involved in 
HNSCC development, such as TP53 (3). The mechanisms by which alcohol consumption exerts 
its carcinogenic eff ect have not been defi ned fully. One of the mechanisms by which alcohol 
exert their carcinogenic eff ect is by acetaldehyde, the main metabolite of ethanol, which can 
damage DNA and trap glutathione, an important peptide in detoxifi cation of carcinogens (4). 
In EAC, the infl ammation is thought to be triggered by gastro-esophageal refl ux, abdominal 
obesity, and cigarette smoking (5). The refl uxate contains numerous substances in addition 
gastric acid, including bile salts, pancreatic enzymes, and ingested foods and their metabo-
lites, which can cause acute and chronic infl ammation of the oesophageal epithelium (6). 
 
 
Figure 1. Incidence rates of esophageal cancer according to histological subtype
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Abdominal obesity, in addition to promoting gastroesophageal refl ux, is increasingly being 
recognized as causing a state of low-level systemic infl ammation, characterized by increased 
plasma levels of pro-infl ammatory cytokines and receptors (7). In addition, cigarette smoking 
can cause infl ammation both systemically and in the oesophageal epithelium in response 
to swallowed smoking products (8). In turn, a chronic state of systemic and localized infl am-
mation promotes DNA damage, DNA replication stress and genomic instability (9), which 
increase the risk of developing clones containing small- and large-scale genomic alterations, 
eventually leading to EAC (Figure 2). 
Molecular pathogenesis
Both EAC and ESCC are thought to develop through a series of acquired mutations or epi-
genetic changes. These genetic changes allow normal squamous epithelial cells to progress 
towards cancer cells by acquiring eight essential physiologic capabilities: proliferation with-
out exogenous stimulation, resistance to growth inhibitory signals, avoidance of apoptosis, 
unlimited replication, angiogenesis, invasion and metastasis, reprogramming of energy 
metabolism and evading immune destruction (10). Many of the genetic changes, which lead 
to these physiologic capabilities, will confer a growth advantage on the mutated cells, and 
lead to clonal expansion at the expense of other cells. Figure 2 shows the changes that have 
been shown to occur in the pathogenesis of EAC and ESCC. 
In ESCC this multistep process is morphologically characterized by esophagitis followed 
by basal cell hyperplasia, squamous dysplasia, carcinoma in situ and advanced carcinoma 
(11). EACs are thought to arise from Barrett’s epithelium, which is characterized by columnar 
metaplasia with intestinal diff erentiation that has replaced the normal squamous cell lining 
of the esophagus. Progression is thought to follow the metaplasia, dysplasia, adenocarci-
noma sequence (12). 
The majority of ESCC are located in the upper and middle esophagus (from the level of the 
manubrium sterni to the trachea bifurcation). Most EACs arise in the distal esophagus (which 
starts at the level of the trachea bifurcation and extends to the gastro-esophageal junction). 
The gastro-esophageal junction is characterized by the “Z” line, which forms the transition 
zone from squamous cell epithelium to cylindrical epithelium from the stomach. Some 
clinicians and scientists distinguish carcinomas that arise in the distal esophagus from car-
cinomas that arise in the proximal stomach, the so called “gastric cardia” (13).  However, this 
classifi cation seems artifi cial, because epidemiological, histomorphological and molecular 
genetic data suggest that this is one clinical entity (14, 15). In addition, the therapeutic ap-
proach for both types of tumors is identical. Therefore, the term esophageal adenocarcinoma 
(EAC) in this thesis comprises both carcinomas of the distal esophagus and gastric cardia. 
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Clinical manifestations and diagnosis
Most patients with esophageal cancer have advanced disease at the time diagnosis, because 
symptoms, such as dysphagia, odynophagia and weight loss develop late in the course of 
the disease when the tumor is large and obstruction the esophageal lumen. The diagnosis is 
established by pathological assessment of biopsies obtained by gastro-duodenoscopy. Then, 
assessing the operability of the patient (is the patient fi t for surgery) and tumor staging need 
 
Figure 2. The common and distinct known etiology and carcinogenesis of esophageal squamous cell car-
cinoma (ESCC) and adenocarcinoma (EAC). Summary of the genetic alterations involved in the progression 
of normal squamous cell epithelium towards EAC and ESCC. The areas in which EAC and ESCC overlap are 
indicated in light blue (partly adapted from Bird-Lieberman et al (22)). 
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Figure 3. Number of publications listed by the National Library of Medicine library for the search term 
“esophageal cancer”, from 1960 to 2009, by decade. Not the doubling of publication over each decade. 
Figure 4. National Institute of Health esophageal cancer research portfolio. Indicated are the percentage of 
total dollars by scientifi c area in the year 2009 (http://fundedresearch.cancer.gov).
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to be done. Staging of esophageal cancer is based on the tumor-node-metastasis (TNM) clas-
sifi cation (16). The depth of tumor invasion (T-stage) can accurately assessed by endoscopic 
ultrasonography (EUS) (17). Lymph node involvement (N-stage) can be determined by com-
puted tomography (CT) of chest and abdomen, CT-scan combined with positron emission 
tomography (PET) and EUS (with or without fi ne-needle aspiration). However these staging 
modalities have a limited sensitivity and specifi city for detection of lymph nodes metastases 
(17). The presence of distant metastases (M-stage) can accurately assessed by CT-scan of 
chest and abdomen, CT-scan combined with PET and external ultrasound of the neck. At 
the time of diagnosis, two of three patients will have tumors that are considered inoperable 
because of patient co-morbidities or tumor extension (18).
Treatment
Treatment of patients with cancer of the esophagus is complex and needs a multidisciplinary 
approach (19). Only a minority of patients present with an early cancer of the esophagus. 
These patients, with high grade dysplasia and intramucosal carcinomas, require endoscopic 
therapies (such as endoscopic mucosal resection, radiofrequency ablation, or cryotherapy) 
in experienced centers (as reviewed by (20)). However, the fast majority of patients present 
with advanced esophageal carcinoma. Surgical resection remains an essential cornerstone 
in the treatment of localized disease especially in patients with adenocarcinoma. Recently, 
the preliminary results of the phase III multicenter CROSS trial, involving 364 patients in the 
Netherlands with resectable EAC and ESCC have been presented (21). The median survival of 
patients randomized for preoperative chemoradiotherapy was 49 months, compared to 26 
months 26 months for those who were allocated to surgery alone. In the Netherlands, these 
results have changed the standard of care for patients with advanced esophageal carcinoma 
from surgery alone into neoadjuvant chemoradiotherapy followed by surgical resection. 
Research
In the past decades the number of publications has increased tremendously.(Figure 3) The 
number of publications recorded by the NCBI in 2009 on esophageal cancer (using MESH term 
esophageal neoplasms) was 1387 (0,2% of the total number of publications recorded). In the 
United States, the National Cancer Institute invested in 2009 about 28.8 million in esophageal 
cancer research (http://www.cancer.gov/aboutnci/servingpeople/cancer-statistics/snapshots), 
which comprises 0.6% of the total investment in cancer research. As illustrated by fi gure 4, most 
research is focused on biology, etiology and diagnosis and prevention (accounting for 75%) of 
esophageal cancer.
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OUT LINE OF THE THESIS
This thesis is divided into two major parts:  Human esophageal adenocarcinoma cell lines and 
Clinical aspects of esophageal cancer treatment. 
Human esophageal adenocarcinoma cell lines
Model research on esophageal adenocarcinoma (EAC) relies entirely on a relatively small set 
of established tumor cell lines, because appropriate animal models and familial cases for EAC 
are lacking. Chapter 1 reviews the history of the EAC cell lines and their utility in translational 
research and biomedical discovery. 
To study the histological characteristics of EAC cell line TE-7, tumor cells were injected 
subcutaneously into nude mice. To our surprise the xenograft of EAC cell line TE-7 showed 
the histological characteristics of a squamous cell carcinoma and not of an adenocarcinoma. 
This prompted us, in chapter 2, to investigate the authenticity of all 15 TE cell lines by short 
tandem repeat (STR) profi ling, mutation analyses, xenografting and array-CGH. In chapter 3, 
all available EAC cell lines are verifi ed. In collaboration with the establishers of the cell lines, 
the original EAC tissues for 13 of the 14 cell lines have been traced in pathology archives and 
made available for study. The availability of the primary tissues make it possible to authen-
ticate these EAC cell lines by comparing the genotype of the cell line with the genotypes of 
patient’s normal and tumor tissue. 
So far, little is known about the cellular and molecular mechanisms that underlying the 
origin of adenocarcinoma of the esophagus. Cell lines and xenografts derived from human 
EAC consist of pure populations of tumor cells without admixture of normal stromal or 
infl ammatory cells, which makes detection of molecular genetic changes much easier. In 
chapter 4, these verifi ed EAC cell lines (and xenografts) are used to screen for homozygous 
deletions. These somatically acquired homozygous deletions are one of several mutational 
mechanisms through which the proteins encoded by tumor-suppressor cancer genes are 
inactivated. Mapping of these deletions in the cancer genome could potentially lead to the 
identifi cation of new potential tumor suppressor genes that play a role in the carcinogenesis 
of adenocarcinoma of the esophagus. 
Clinical aspects of esophageal cancer treatment
Treatment of patients who present with cancer of the distal esophagus and positive celiac 
lymph nodes is controversial. According to the TNM classifi cation (5th edition) established 
by the UICC and the AJCC, lymph nodes around the celiac axis are considered non-regional 
nodes and as such classifi ed as M1a disease. But are M1a patients truly metastatic (and 
thus not approachable for cure) or do they have extensive locoregional disease and thus 
are potentially curable? In Chapter 5, we evaluated our treatment strategy of neoadjuvant 
chemotherapy followed by surgery with curative intent in this subset of patients.
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Chapter 6 describes the long-term results of a large randomized controlled trial in patients 
with squamous cell carcinoma of the esophagus who were assigned to chemotherapy fol-
lowed by surgery or surgery alone. Even after twenty years, these results contribute to the 
ongoing debate about the optimal (preoperative) therapy for patients with ESCC.
Single nucleotide polymorphisms (SNPs) in the germline are the most common type of 
host genetic variations. Gene-related functional SNPs can potentially lead to diff erences in 
protein expression and/or function. In this way, SNPs in proto-oncogenes and tumor sup-
pressor genes can potentially alter the risk for metastatic or aggressive tumor, resulting in 
diff erences in clinical outcome. In Chapter 7, we determine whether clinical outcome after 
surgical resection of EAC or ESCC is associated with functional polymorphisms in diff erent 
proto-oncogenes and tumor suppressor genes. 
Finally, chapter 8 is a summary of the preceding chapters and the major conclusions are 
drawn. In chapter 9, the results of the thesis are discussed and directions for future research 
are provided. 
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ABSTRACT
Human esophageal adenocarcinoma (EAC) cell lines have made a substantial contribution to 
elucidating mechanisms of carcinogenesis and drug discovery. Model research on EAC relies 
almost entirely on a relatively small set of established tumor cell lines, because appropri-
ate animal models are lacking. Nowadays, more than 20% of all fundamental translational 
research studies regarding EAC are partially or entirely based on these cell lines. The ready 
availability of these cell lines to investigators worldwide have resulted in more than 250 pub-
lications, including many examples of important biomedical discoveries. The high genomic 
similarities (but certainly not completely identical) between the EAC cell lines and their origi-
nal tumors provide rational for their use. Recently, in a collaborative eff ort all available EAC 
cell lines have been verifi ed resulting in the establishment of a reliable panel of ten EAC cell 
lines. It could be expected that the value of these cell lines increases as unlimited source of 
tumor material, because new biomedical techniques require more tumor cells and the supply 
of viable tumor cells is diminishing due to neoadjuvant chemo(radio)therapy of patients with 
EAC. Here, we review the history of the EAC cell lines and there utility in translational research 
and biomedical discovery. 
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Value of cell lines as in vitro model for esophageal adenocarcinoma
INTRODUCTION
Esophageal cancer is a signifi cant and increasing health problem. In 2008, there were 
450.000 new cases worldwide, which rank this tumor type among the world’s most frequent 
malignancies (1). Although esophageal squamous cell carcinoma (ESCC) cases have steadily 
declined, the incidence of esophageal adenocarcinoma (EAC) has increased more rapidly 
than for any other cancer type. This has led to increased interest in fundamental research 
on molecular mechanisms underlying the origin of EAC. The current scale of biomedical 
cancer research on EAC requires an extensive source of tumor materials. It would appear 
that resection specimens of EAC could satisfy such needs. However, the extensive use of neo-
adjuvant chemo(radio)therapy, severely limits the availability of viable tumor cells. This has 
increased the importance of preoperative biopsies, only these biopsies contain a relatively 
small portion of tumor cells which can be used for research (as for example SNP-arrays or 
genome-wide sequencing). Larger biopsies are optional, but increase the risk of gastrointes-
tinal bleeding and perforation. Taking more biopsies (for research purposes) is impaired by 
in creasingly stringent requirements for protection of patients’ privacy rights by institutional 
review boards and by government legislation. These developments generate an increasing 
and ongoing demand for in vivo and in vitro models of EAC. Thus fare, only a small set of EAC 
cell lines is available for experimental cancer research and appropriate animal models are 
lacking. Recently, we verifi ed the authenticity of all available EAC cell lines and confi rmed the 
authenticity of ten EAC cell lines (2). In this review, we focus on the utility of these cell lines 
that have been derived from human EAC for the study of this tumor type. 
METHODS
Two searches were performed of the National Library of Medicine database (http://www.
nlm.nih.gov/pubs/). The fi rst search was done to determine the total number of publications 
(published in English) on esophageal adenocarcinoma in the period between 1 January 2000 
and 31 December 2009. Therefore, we used the following medical search heading terms 
(MESH-terms): “esophageal neoplasms” and “adenocarcinoma”. This search yielded 3229 
publications. Eighty-three articles were excluded, because the subject was not EAC. Then, 
we subdivided the publications (N=3146) into three categories namely 1) review articles 
(reviews, comments, editorials, letters and news); 2) clinical research articles (clinical trials, 
clinical database research and epidemiological studies); 3) fundamental and fundamental 
translational articles (DNA, RNA, protein, in vitro and animal studies). Within this last category, 
we searched for studies in which EAC cell lines were used. 
A second search was performed to identify the majority of publications that used EAC cell 
lines. The following MESH terms were used “esophageal neoplasms” and “adenocarcinoma” 
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and “tumor cells, cultured”. On May 1, 2011, this search yielded 251 publications.  Because 
we were involved in the establishment of the majority of EAC cell lines, we used our knowl-
edge of literature to select relevant articles that illustrate the major purpose of this review, 
the utility of cell lines for the study of EAC. It should be noticed that this article is not a 
comprehensive review of all the literature. References and topics were selected to serve as 
representative examples. 
The use of EAC cell lines over the past decade
The increase of interest in research on EAC is illustrated by Figure 1. Over the past decade, the 
total number of studies has increased with 34%. Interestingly, the distribution of the three 
study types (reviews, clinical research or fundamental research) does not change. Also the 
use of EAC cell lines in publications has increased (Figure 2). In almost 20% of all fundamental 
research studies on adenocarcinoma of the esophagus, EAC cell lines have been used (Figure 
3). These fi gures refl ect the extent of EAC cell line use in research on this tumor type. 
History of esophageal adenocarcinoma (EAC) cell lines
Human EAC cells were fi rst successfully cultured in Japan, in 1984 ((3, 4); Figure 4). The fi rst 
cell line derived from a primary EAC was TE-7.  Thereafter, only 16 EAC cell lines have been 
established namely: SK-GT-4, SK-GT-5 and BE-3 (5); SEG-1, BIC-1 and FLO-1 (6);  JROECLl9 
(OE19), JROECL33 (OE33), JROECL47 and JROECL50 (7); OACM5.1 and OACP4CE (8); KYAE-1 
(9); JH-EsoAd1 (10); ESO26 and ESO51 (2). 
Figure 1. Depicted are the mean number of publications/per year on esophageal adenocarcinoma in two 
time periods.  In the last fi ve-years there is an increase of publications of 35%. The distribution of type of 
publications is nearly unchanged.
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There are several reasons for the limited number of available human EAC cell lines. At fi rst, 
the establishment of cell lines is mainly based on trial and error, with relatively low success 
rates for EAC. The known number of attempts to establish cell lines is most likely far below 
the total number of attempts since most failed eff orts will not have appeared in literature. 
Why cell lines from EAC are so hard to establish is poorly understood. It depends on many 
factors like the number of viable tumor cells and the ratio between these tumor cells and 
fi broblasts in the sample. Furthermore, a variety of nutritional and environmental conditions 
must be met for cells to thrive in culture which are often enigmatic to the establishers result-
ing in failure of in vitro growth of tumor cells. The major cause of failure appears to be the 
lack of tumor cell attachment to the plastic fl asks and fi broblast overgrowth, as reported by 
several investigators (5, 7, 8). Secondly, before the era of multimodality treatment of EAC, the 
availibiliy of resection specimens with large amouts of viable tumor cells was abundant. The 
need for an infi nite source of material (one of the major advantages of cell lines) was limited, 
which resulted in a lack of drive among researchers to establish EAC cell lines. At third, several 
Figure 2. The percentage of publications on esophageal adenocarcinoma (EAC), wherein EAC cell lines 
have been used. Note the steadily incline of the use of cell lines among the years.
Figure 3. Depicted (with the numbers above the bars) are all the fundamental/translational research stud-
ies per year. Fundamental/translational research studies using cell lines are blue. Fundamental/translational 
research studies that did not use cell lines are white. Note that over de past six years, in almost 20% of all 
fundamental research studies on adenocarcinoma of the esophagus, EAC cell lines have been used.
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cases of cell line contamination among EAC cell lines has been identifi ed, which reduced 
the number of reliable EAC cell lines. Approximately three years after the fi rst publication of 
the fi rst European series of cell lines, we discovered that cell lines JROECL47 and JROECL50 
were admixtures of the human colon carcinoma cell line HCT 116 (11). In 2007, we revealed 
that EAC cell line TE-7 had the phenotype of a squamous cell carcinoma after xenografting 
and shared the same genotype as four other esophageal squamous cell lines of the Japanes 
TE series (12). In a very recent report, we showed that three of the most commonly used 
EAC cell lines (SEG-1, BIC-1 and SK-GT-5) were misidentifi ed and were actually derived from 
other forms of human cancers. Ten cell lines, FLO-1, KYAE-1, SK-GT-4, OE19, OE33, JH-EsoAd1, 
OACP4C, OACM5.1, ESO26, and ESO51 were proven to derive from their original tissues. All 
these EAC cell lines, together with their genotyping information, have been deposited in 
publicly available cell line repositories to promote and facilitate future solid research on EAC. 
In the remaining part of this review, only studies and data of the verifi ed cell lines will be 
discussed. 
Cell lines as experimental systems to study cancer biology and for translational research
EAC cell lines off er certain advantages and disadvantages when compared to tumor materi-
als. An excellent discussion on these issues is presented in a recent review (13). Cell lines are 
populations of pure tumor cells without admixed stromal or infl ammatory cells, which greatly 
aiding tumor cell characterization. Furthermore, cell lines are capable of infi nite replication, 
providing a limitless source of materials and permitting their dispersion to laboratories 
worldwide. This allows scientists to compare their results from identical materials. 
The relevance of human EAC cell lines depends on how representative these cell lines are 
as model for all adenocarcinomas of the esophagus, and on how closely they resemble the 
tumors from which they were derived. Most EAC cell lines were derived from poorly diff eren-
Figure 4. Timeline esophageal adenocarcinoma cell line development.
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tiated adenocarcinoma (except cell line JH-EsoAD1 that is derived from a moderately diff er-
entiated adenocarcinoma), which illustrates that these cell lines represent only a subtype of 
all EAC. In general it has been thought that cell lines arise from subpopulations of the original 
tumor that have inherent properties that allow them to grow as immortal cultures. As a result 
of selection of the most robust fast growing subpopulation, cell lines may also be relatively 
undiff erentiated. Thus, from an already poorly diff erentiated EAC the most undiff erentiated 
subpopulation grows out to a cell culture. 
The EAC cell lines retain properties of the cells of origin; however, they show also diff erences 
compared to the in vivo tumors. Previously, we have demonstrated that the EAC cell lines 
retain the TP53 mutations that were detected in the primary tumors (2). Furthermore, a study 
that genetically characterized four EAC cell lines (OE19; OE33; OACP4CE and OACM5.1) by 
24-color FISH and array-CGH, showed multiple chromosomal regions of gains and losses. 
Among these aberrations, losses on 3p, 4, 5q, 9p, 13q, 18q, and 21 were detected in at least 
3 out of the 5 samples. Likewise, gains were detected on 1q, 8q, 17q, 19q, 20, and X (14). 
These fi ndings are consistent with data obtained by array-CGH and SNP-arrays in studies 
using primary tumor tissue (15). However, also diff erences between primary tumors and the 
corresponding cell lines have been observed. As for example, expression of surface marker 
HLA-DR has been observed in the primary tumor of which cell line OE33 has been derived, 
however, the cell line does not express this marker (7). These results emphasise the need for 
more investigations regarding the question how representative these EAC cell lines are for 
their primary tumor. Moreover this kind of research has become feasible, since the patient’s 
derived tumor materials have been traced. 
The role of EAC cell lines in elucidating mechanisms of carcinogenesis
Chronic infl ammation seems to have a central role in the development of EAC and its precur-
sor lesions (16).  A great part of the experimental evidence that supports the hypothesis that 
chronic gastro-esophageal refl ux causes genetic and epigenetic changes that lead to the 
onset of Barrett’s metaplasia and its progression to carcinoma relies on EAC cell line research. 
Experiments using EAC cell line FLO-1 and a non-cancer derived SV40 immortalized squamous 
epithelial cell line HET1A (established by Harris et al. (17)) showed that specifi c components 
of the refl uxate (especially sodium deoxycholate) can induce double strand DNA breaks (18). 
In addition, deoxycholic acid exposure is genotoxic to EAC cells (OE33) through induction 
of reactive oxygen species (19). In vitro experiments using EAC cell lines have signifi cantly 
contributed to the identifi cation of signalling pathways that are being activated by exposure 
to acid and bile. One of the pathways is the arachidonic acid pathway. The key enzyme in 
this pathway is cyclooxygenase-2 (COX-2), which catalyzes the conversion of arachidonic 
acids into prostaglandins. Cell line SK-GT-4 served as in vitro model in the fi rst study that 
investigated the eff ect of bile acids on expression of COX-2 in human EAC (20). It was shown 
that dihydroxy bile acids activate transcription of COX-2 in SK-GT-4 cells. Soon thereafter, 
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studies using large collections of endoscopic biopsies of patients with Barrett’s esophagus, 
Barrett’s dysplasia, and EAC revealed enhanced COX-2 gene or protein expression in a large 
proportion of EAC (21, 22). Also the nuclear factor-kappa-B (NF-kB) pathway is thought to 
play a pivotal role in mucosal infl ammatory response to (duodeno) gastro-esophageal refl ux. 
NF-kB comprises a ubiquitous transcription factor that regulates host infl ammatory and im-
mune responses by aff ecting the expression of a wide range of genes coding for cytokines, 
enzymes, apoptosis, proliferation and adhesion molecules (23). The fi rst experimental evi-
dence for activation of the NF-kB pathway came from a surgical model of refl ux esophagitis 
(24). The link between NF-kB pathway activation in EAC comes from studies using EAC cell 
lines (as reviewed by Abdel-Latif et al (25)). In vitro studies using cell lines OE33 and SK-GT-4 
demonstrated that acid and bile have the capacity to induce NF-kB expression (26).
The role of EAC cell lines in drug testing
EAC cell lines have been used for many years as drugs discovery tools. As reviewed by Sharma 
et al. (27), the rapidly expanding use of cancer cell lines to predict the clinical effi  cacy of 
new agents is already aff ecting the course of drug development and is now becoming an 
important tool for the biotechnology and pharmaceutical industries, in which eff orts that are 
focused on molecularly targeted cancer therapies are accelerating. Genome-wide profi ling of 
copy number alterations of EAC samples and cell lines have identifi ed regions that harbour 
potential targets for therapy, such as amplifi cations on chromosomes 7q21-22 and 17q21 
harboring the c-MET  and ERBB2 genes, respectively (14, 15). Overexpression and amplifi ca-
tion of c-ERBB2 in EAC was described fi rst in resection specimens (28, 29). Several years later, 
c-ERBB2 gene amplifi cation and overexpression was reported in EAC cell lines OE19 and 
OE33. In vitro testing of a monoclonal antibody against the c-ERBB2 receptor showed marked 
growth inhibition in both EAC cell lines (30). These results led to the design of a phase I-II 
clinical trial among patients with EAC (31, 32). The c-MET oncogene is also frequently over-
expressed and amplifi ed in EAC samples and cell lines (33, 34). In vitro experiments showed 
that the c-MET inhibitor PHA665752 induced apoptosis and reduced cell motility and inva-
sion in cell line FLO-1 (35). These results led to the initiation of a phase II trial to evaluate the 
therapeutic benefi t of c-Met inhibition in EAC and gastric adenocarcinoma (NCT00725712; 
http://clinicaltrials.gov/). 
EAC cell lines do also play a role in studying mechanisms of chemo- and/or radioresistance, 
which remains a signifi cant clinical problem, with only ~25% of patients achieving a com-
plete pathological response after neoadjuvant chemoradiation therapy (36). By continuously 
exposing drug and/or radiosensitive EAC cells to treatment in vitro over a period of time, it is 
often possible to eliminate the majority of cells while selecting for the expansion of relatively 
rare drug resistant clones. Recently, a radio resistant sub line of cell line OE33 has been estab-
lished (37). In addition, a recent patent claimed the establishment of 5-fl uorouracil resistant 
sub lines of cell lines OE19 and OE33 (http://www.freepatentsonline.com/; United States 
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Patent Application 20110014303). Further investigations are needed to compare the various 
properties of the parental cells and the selected chemo- or radio resistant cells, to identify 
specifi c molecular mechanisms of drug resistance. 
Xenografts from EAC cell lines
The major limitations of tumor cell lines are their lack of stromal, vascular, and infl ammatory 
components. These defi  ciencies can be partially overcome by xenograft transplantation of 
EAC cell line suspensions into immunodefi cient mice. Ectopic xenografts could be generated 
from all EAC cell lines ((2); xenografts from cell line FLO-1 were recently obtained by us in 
mouse strain NOD/SCID/IL2-Rγ(null) (NSG)). The most widely used translational application 
of these EAC cell line xenografts has been the in vivo testing of diff erent chemotherapeutic 
agents such as trastuzumab or temozolomide (38, 39). Furthermore xenografts have also 
been used to identify biomarkers for response to chemotherapy. In a recent study, EAC cell 
line xenografts (derived form cell line OE19) were used to identify plasma protein biomarkers 
in response to treatment with epirubicin, cisplatin or 5-fl uorouracil. Three of seven plasma 
protein markers identifi ed in the mouse xenograft model were also detected in patient 
samples, which refl ect the usefulness of this mouse model in modeling EAC (40). 
Recently, an orthotopic mouse model has been generated by transplanting esophageal 
tumor fragments (derived from a previous subcutaneously injection of OE19 cells into the 
fl anks of a female NMRI nude mice), into the abdominal esophagus of the mice (38). Up to 
71% of the animals showed metastases. Orthotopic transplantation models are thought to 
represent a more clinically relevant tumor model with respect to tumor site and metastasis; 
however its limitations include technical skill, time and cost. Also the therapeutic effi  cacy is 
more diffi  cult to assess in contrast to the relative ease of subcutaneous tumor measurements. 
CONSIDERATIONS
There remains considerable skepticism in the scientifi c community about the validity result-
ing from the use of cell lines. The major concerns are genetic instability during long time 
culture, selective growth of subpopulations and cross contamination or misidentifi cation. 
Almost all EAC arise in association with chromosomal instability that leads to gains, losses 
or loss of heterozygosity (LOH) of large regions of chromosomes (41, 42). Chromosomal 
instability might be caused by TP53 mutations (43). The presence of TP53 mutations in all 
original tumors of which the EAC cell lines were derived, indicate that genomic instability is 
already present at time the cell lines were established. This inherent genomic instability and 
the considerably shorter population-doubling times of cell lines may result in an increased 
frequency of mutational changes during in vitro growth. However, it has been demonstrated 
that the mutation rate during prolonged cell culture is limited (44, 45). Cancer cell lines con-
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stantly generate variants with phenotypic and/or genotypic diff erences from the predomi-
nant population caused by exposure to diff erent conditions (such as media, sera, trypsin, 
carbon dioxide levels, humidity and temperature). Similar to tumor cells in vivo, cells in vitro 
adapt their phenotype, by epigenetic (potentially reversible) or genetic mechanisms (irre-
versible), to the conditions to which they are exposed. Variants that are better adapted to the 
new conditions are likely to be selected. Despite our eff orts to authenticate all available EAC 
cell lines, cross-contamination or misidentifi cation of EAC cell lines is a continuous threat. The 
best prevention to overcome, at least partially, most of these concerns is to limit the number 
of passages and to always come back to cells frozen during the early passages. However, 
most of the cancer cell lines used have been passaged hundreds of times. So this precaution 
may be applied in the future but does not apply to the cell lines as they are commonly used. 
CONCLUSIONS
Human EAC cell lines, while not ideal model systems, off er a robust model to study pathogen-
esis and that can serve as a fi lter to fast track the most promising compounds and enables 
high-throughput science over short periods (such as c-MET and c-ERBB2 inhibitors). It could 
be expected that the value of these cell lines increases as unlimited source of tumor material, 
because new biomedical techniques require more tumor cells and the supply of viable tumor 
cells is diminishing due to neoadjuvant treatment of patients with EAC.
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ABSTRACT
Cancer of the esophagus is the 7th leading cause of cancer death worldwide. Esophageal 
carcinoma cell lines are useful models to study the biological and genetic alterations in these 
tumors. An important prerequisite of cell line research is the authenticity of the used cell 
lines, because the mistaken identity of a cell line may lead to invalid conclusions. Estimates 
indicate that up to 36% of the cell lines are of a diff erent origin or species than supposed. 
The TE-series, established in late 70s and begin 80s by Nishihira et al in Japan, is one of the 
fi rst esophageal cancer cell line series that was utilized throughout the world. Fourteen TE 
cell lines were derived from human esophageal squamous cell carcinomas and one, TE-7, was 
derived from a primary esophageal adenocarcinoma (EAC). In numerous studies this TE-7 
cell line was used as a model for EAC since it is one of the few EAC cell lines existing. We 
investigated the authenticity of the EAC cell line TE-7 by xenografting, short tandem repeat 
profi ling, mutation analyses and array-CGH and demonstrated that cell line TE-7 shared 
the same genotype as the esophageal squamous cell carcinoma cell lines TE-2, TE-3, TE-12 
and TE-13. In addition, for more than a decade independent TE-7 cultures from Japan, USA, 
UK, France and The Netherlands had the same genotype. Examination of the TE-7 cell line 
xenograft revealed the histology of a squamous cell carcinoma. We conclude that the TE-7 
cell line, used in several laboratories throughout the world, is not an adenocarcinoma - but a 
squamous cell carcinoma cell line. Furthermore, the cell lines TE-2, TE-3, TE-7, TE-12 and TE-13 
are one identical squamous cell carcinoma cell line from unknown origin.
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INTRODUCTION
Cancer of the esophagus is the 7th leading cause of cancer death worldwide (1). Although 
esophageal squamous cell carcinoma (ESCC) cases have steadily declined, the incidence of 
esophageal adenocarcinoma (EAC) has increased more rapidly than for any other cancer 
type and parallels rises in obesity and refl ux disease (2). Despite the common occurrence 
of ESCC and EAC, little is known about the molecular mechanisms underlying the genesis 
of these tumors. Tumor-type specifi c cell lines are useful models to study cell biological and 
molecular characteristics of the comparable tumors. Therefore, established tumor cell lines 
are of great importance, especially from tumor types from which only few lines exist. An 
important prerequisite of cell line research is the authenticity of the used cell lines, because 
the mistaken identity of a cell line may lead to invalid conclusions (3). Estimates indicate that 
up to 36% of the cell lines are of a diff erent origin or species to that being claimed (4-6). One 
of the major causes is cross-contamination between cell lines (see for example: http://www.
sanger.ac.uk/genetics/CGP/Genotyping/synlinestable.shtml)(3, 7). Cross-contamination of 
cell lines can be the result of poor culture technique when a cell line culture is contaminated 
with another cell line. Alternatively, cross-contamination of cell lines can be due to clerical 
error by mislabeling of cell cultures or frozen stocks. 
The TE-series, established by Nishihira et al in Japan, is one of the fi rst esophageal cancer cell 
line series that was utilized throughout the world (8, 9). Of the 15 TE cell lines generated 14 
were derived from human ESCC and one, TE-7, from a primary EAC (10). This last cell line is 
one of the few EAC cell lines generated and therefore frequently used as an in vitro model 
of EAC throughout the world. The high incidence of cross-contamination prompted us to 
investigate the authenticity of the TE-series and especially the TE-7 cell line by xenograft-
ing, short tandem repeat (STR) profi ling, mutation analyses and array-comparative genomic 
hybridisation (array-CGH). 
MATERIALS AND METHODS
Cell cultures, DNA isolation and xenografts
Cell lines TE-1 – TE-15, except TE-7, were obtained from the Japanese Cell Resource Centre for 
Biomedical Research (Sendai). Cell line TE-7 was obtained from the originator Dr T. Nishihira. 
Cells were cultured under standard conditions in RPMI 1640 supplemented with 10% Fetal 
Calf Serum. To study the histological characteristics of the TE-7 cell line, 5 x 106 trypsinized 
tumor cells were injected subcutaneously in female NMRI nude mice. Xenografts were re-
moved and routinely processed for histological and immunohistochemical examination. The 
animal experiments were licensed and done in accordance with approved protocols by the 
Erasmus MC, University Medical Center Rotterdam, The Netherlands. DNA was isolated from 
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cultured cells and xenografts using the PureGene Genomic DNA isolation Kit (Qiagen, Venlo, 
The Netherlands). DNA was diluted to a concentration of 100ng/μl to perform PCR.
STR profi ling
The cell lines TE-1 – TE-15 were genotyped by a short tandem repeat profi ling system using 
the loci of the Powerplex 16 System (Promega Madison WI, USA). The Powerplex 16 system 
comprises fi fteen STR loci, including Penta E, D18S51, D21S11, TH01, D3S1358, FGA, TPOX, 
D8S1179, vWA, Penta D, CSF1PO, D16S539, D7S820, D13S317, D5S818 and the sex chromo-
some marker Amelogenin. Amplifi cation was performed using 1 ng of template DNA ap-
plying the Powerplex 16 system following the manufacturer’s recommendation. Multiplex 
PCR reactions were carried out by using fl uorescent dye-linked primers. Labeled products 
were detected by electrophoretic size fractionation on an ABI 3100 genetic analyzer. The 
data were analyzed by using Genescan and Genotyper software (Perkin Elmer, Foster City, 
USA) to categorize peaks according to their size in relation to an internal standard run. This 
analysis enabled every peak to be allocated a size corresponding to the number of repeat 
units present. 
Mutation analyses
Because p53 is frequently mutated in both EAC and ESCC (14, 15) all exons and intron-exon 
boundaries of the p53 gene were commercially sequenced in the TE-7 cell line (Asper Biotech 
Ltd, Tartu, Estonia). The detected p53 mutation in TE-7 was investigated in the other 14 cell 
lines by in house sequencing at the Department of Pathology, Erasmus MC, University Medi-
cal Center Rotterdam. Primers used were p53 intron 3 forward 5’-CAACGTTCTGGTAAGGA-
CAAG-‘3 and intron 4 reverse 5’-GGGATACGGCCAGGCATTG-3’. PCR reactions were carried out 
in a volume of 15μl containing 100ng of genomic DNA, 8.3μl H2O, 5μl Mg2+free buff er, 25mM 
MgCl2, 0.3μl of 10mM deoxynucleotide triphosphates, 20pmol of each primer and 1U Taq 
polymerase (Promega, Madison WI, USA). PCR-conditions were 35 cycles of 95oC for 45 sec, 
61oC for 45 sec, 72oC for 30 sec, with a 10 min extension at 72oC for 10 min following the 
last cycle. Amplifi ed products were analyzed on 1.5% agarose gels. These PCR products were 
bi-directionally sequenced using an Applied Biosystems 3100 genetic analyser (Perkin Elmer, 
Foster City, USA). 
Cell lines TE-3, -7 and -12 have been described to harbor a heterozygous Cyclin D1 exon 5 
mutation (CCND1 NM_053056.2: c.861CAC; Pro287Ala), and cell lines TE-2 and -13 a homozy-
gous single nucleotide polymorphism (SNP) in exon 5 of the Axin1 gene (AXIN1 BC044648.1: 
c.1689C>T; Asp563Asp) (12, 13). Both these DNA variants were investigated by bi-directionally 
DNA-sequencing of PCR products, with the above-described procedure. PCR products were 
generated by standard procedures with primers forward 5’-GCAGAACATGGACCCCAAGG-3’ 
and reverse 5’- GACTGTCAGGGGAGCACCTG-3’ for Cyclin D1 and forward 5’-GTGGGCACGTG-
GCCAAGATG-3’ and reverse 5’-GCTGTGCTGTGGTGGACGTG-3’ for Axin1. 
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Array-CGH
The array-based CGH procedure was performed as described previously. Slides containing 
triplicates of approximately 3,500 large insert BAC clones spaced at density over the full ge-
nome were produced at the Leiden University Medical Center, Leiden, The Netherlands. The 
particular clone set used to produce these arrays is distributed to academic institutions by the 
Welcome Trust Sanger Institute (http://www.ensembl.org/) at no cost and contains targets 
spaced at a density of about 1 Mb over the full genome, a set of subtelomeric sequences for 
each chromosome arm, and a few hundred probes selected for their involvement in oncogen-
esis. After hybridization, the slides were scanned with a ScanArray Express HT (Perkin Elmer 
Life Sciences, Boston, MA) to collect 16-bit TIF images through Cy3 and Cy5 fi lter sets. The spot 
intensities were measured with GenePix Pro 5.1 software (Axon Instruments, Leusden, The 
Netherlands). Further analyses were performed using Microsoft Excel 2000 (16, 17).
RESULTS AND DISCUSSION
Human tumor cell lines are indispensable models to study molecular and cell biological 
characteristics of human tumors. For this, the correct identifi cation of a tumor cell line is 
crucial, as a mistaken identity of a cell line may lead to invalid conclusions with regard to 
the tumor-type studied. Well-established methods to investigate the authenticity of tumor 
cell lines are STR profi ling, SNP typing, mutation analyses and karyotyping (3-5, 18). Using 
diff erent methods, we demonstrated that cell line TE-7, widely used as an EAC cell line, is a 
squamous cell carcinoma cell line and shares the same genotype as four ESCC cell lines of 
the TE-series. 
Xenografting of cell line TE-7 resulted in a poorly diff erentiated SCC (Figure 1A). The xenografts 
were positive for cytokeratin 10 and 14 and involucrin and negative for CDX2 expression 
confi rming the squamous histology (Figure 1B, C, D). The genotype of the TE-7 xenograft and 
in vitro cell line were identical demonstrating that the xenograft tumor was derived from the 
TE-7 cell line. STR profi ling of the TE-series revealed identical genotypes for the cell lines TE-2, 
-3, -7, -12 and -13 (Figure 2). For all TE cell lines, the exact number of repeats at each locus 
is shown in table 1. Diff erences in the relative peak heights at heterozygous loci were seen 
in the STR profi le of the TE cell lines, probably caused by diff erential amplifi cation effi  ciency 
between heterozygous loci, or the presence of additional copies of one allele (Figure 2). This 
fi nding is typical for cancer cells refl ecting their relatively high genetic instability compared 
with normal cells. 
In addition, a homozygous p53 splice site mutation TP53 AF307851.1: c.375+1G>A in intron 
4, the previously in TE-3, -7 and -12, described heterozygous Cyclin D1 exon 5 mutation and 
a, in TE-2 and -13 described, homozygous SNP in exon 5 of the Axin1 gene were found in TE-2, 
-3, -7, -12 and -13 (Figure 3). 
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Array-CGH analysis confi rmed the similar genomic aberration patterns for TE-2, -3, -7, -12 
and -13, however, small diff erences were seen, probably due to genomic instability of these 
cell lines (Figure 4). Recent admixture of the cell lines in our institute was excluded by Dr. 
Y. Morita-Fujimura (Japanese Cell Resource Centre for Biomedical Research) who confi rmed 
these results with the TE cell lines present in the cell line bank in Japan using a STR multiplex 
system. Since the TE-7 cell line is widely used for decades as a model for EAC we investigated 
independent TE-7 DNA samples obtained from the laboratories of Dr P. Hainaut (France), 
Dr C. Tselepis (United Kingdom) and Dr. A. Lowe (USA). The earliest passage TE-7 DNA 
(1986) was obtained from the Japanese Cell Resource Centre for Biomedical Research (Dr. 
Y. Morita-Fujimura). All these TE-7 samples shared the same allelic pattern indicating that 
cross-contamination has occurred at the site of origin or in an early exchange of cell lines 
between laboratories. We were unable to compare the genotype of the cell lines with the 
patient’s tissues because these were not present anymore in the pathology archive of the 
Tohoku University School of Medicine, Sendai, Japan. 
Several literature data are in agreement with the fi nding that TE-7 is an ESCC cell line.  Gene 
expression profi ling revealed clustering of TE-7 with ESCC cell lines (KYSE series), and not with 
Figure 1. Histology of xenograft TE-7. A, Haematoxylin & Eosin staining showing a poorly diff erentiated 
squamous cell carcinoma, characterized by focal keratinization (Magnifi cation 40x). B, C and D, immunostain-
ing with involucrin, keratin 10 and 14, respectively, showing strong positive tumor cells (Magnifi cation 40x). 
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EAC cell lines (19). Another gene expression profi ling study found that TE-7 cells clustered 
with the ESCC cell line OE-21 and not with the EAC derived cell lines OE-33 and SEG-1 (20). 
Furthermore, an identical Cyclin D1 mutation has been described in TE-3, -7 and 12, and an 
Axin1 SNP in TE-2 and -13 (12, 13). However, these observations didn’t lead to questioning 
the authentication of these cell lines. 
The impact of our fi ndings comprises more than thirty-fi ve reports, which have been 
published the last decade, using the cell lines TE-2, -3, -7, -12 and 13. Many investigators 
Figure 2. STR profi le of cell line TE-7. STR loci are indicated in boxes above electropherogram; numbers of 
repeat units are indicated below the peaks. A, Amelogenin.
Figure 3. Mutation analyses of cell line TE-7. A, a homozygous p53 splice site mutation TP53 AF307851.1: 
c.375+1G>A in intron 4. B, heterozygous Cyclin D1 exon 5 mutation CCND1 NM_053056.2: c.861CAC 
(Pro287Ala). C, homozygous SNP in exon 5 of the Axin1 gene AXIN1 BC044648.1: c.1689C>T (Asp563Asp).
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Figure 4. Array-CGH results of cell lines TE-2, -3, -7, -12 and -13. Note the similar genomic profi les of these 
cell lines. 
Jurjen Boomstra bw.indd   45 03-10-11   15:44
Chapter 2
46
used these cell lines to study the in vitro eff ects of chemotherapeutical agents directed too 
specifi c cellular targets as for example, the nuclear retinoic acid receptor and peroxisome 
proliferators-activated receptor gamma (PPARγ) (21-23). The eff ects of retinoic acid receptor 
inhibition on the growth, diff erentiation and apoptosis on human esophageal cancer cells 
were investigated in cell lines TE-1, -2, -3, -7, -8, -12 and -13. The authors reported that retinoic 
acid induced growth inhibition occurred only in TE-2, -3, -7, -12 and -13, all with elevated 
retinoic acid receptor beta (RAR-beta) expression (21). The association between retinoic acid 
induced growth inhibition and RAR-beta expression can now be regarded as weak, since 
these fi ve responding cell lines are genotypically identical. Another investigation showed 
that expression of PPARγ protein was higher in an adenocarcinoma cell line (TE-7) than in 
a squamous cell carcinoma cell line (TE-1). The authors concluded that PPARγ inhibition in 
human EAC cells might due to induction of apoptosis, cell cycle arrest and reduced ornithine 
decarboxylase activity (22). In the light of our fi ndings these data are misleading, since TE-7 
is not an adenocarcinoma cell line. 
CONCLUSIONS
Based on the results of xenografting, STR profi ling, mutation analyses and array-CGH, we 
conclude that the currently used TE-7 cell line is not an EAC but a squamous cell carcinoma 
cell line. Furthermore, cell line TE-7 shares the same genotype as TE-2, -3, -12 and -13. These 
fi ve TE cell lines should be regarded as one single squamous cell carcinoma cell line of an 
unknown origin. Our study emphasizes that researchers should be careful in the way they 
establish and use cell lines, because a mistaken identity of a cell line may lead to invalid con-
clusions. Therefore, we suggest that future established tumor cell lines must be genotyped 
by SNP or STR analysis and compared with patient’s tumor and normal tissue genotype. This 
genotyping information must be made available for the cell line users so that regular checks 
on the identity can be performed.   
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ABSTRACT
For decades, hundreds of diff erent human tumor type-specifi c cell lines have been used in 
experimental cancer research as models for their respective tumors. The veracity of experi-
mental results for a specifi c tumor type relies on the correct derivation of the cell line. In a 
worldwide eff ort, we verifi ed the authenticity of all available esophageal adenocarcinoma 
(EAC) cell lines. We proved that the frequently used cell lines SEG-1 and BIC-1 (in more than 
100 publications) and the SK-GT-5 cell line are in fact cell lines from other tumor types. Ex-
perimental results based on these contaminated cell lines have led to ongoing clinical trials 
recruiting EAC patients, to more than 100 scientifi c publications and at least three NIH cancer 
research grants and 11 US patents, which emphasizes the importance of our fi ndings. Wide-
spread use of contaminated cell lines threatens the development of treatment strategies for 
EAC.
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INTRODUCTION
Cell lines derived from human cancers have been crucial to building our understanding of 
the molecular pathophysiology of cancer and its treatment. Of equal importance, they form 
an in vitro model system for rational drug discovery and development because they are easy 
to maintain and manipulate in vitro and in animal xenograft models. However, it has been 
estimated that up to one third of all cell lines have an origin other than that supposed (1). 
Cross contamination between cell lines and mislabeling of cultures lead to unrecognized 
cell line admixtures (1,2). In the past, the scientifi c community has recognized this problem, 
but decisive action has not been taken to date. Results based on experiments using con-
taminated cell lines might be translated to the clinic, forming the basis for clinical trials, and 
directly aff ecting the treatment of patients. 
Model research on esophageal adenocarcinoma (EAC), which is the cancer type showing 
the steepest rise in incidence in the Western world over recent years (3), relies entirely on a 
relatively small set of established tumor cell lines. Appropriate animal models and familial 
cases for EAC are lacking (4). Cell lines are very useful to investigate molecular pathways that 
are involved in EAC tumorigenesis and to test experimental drugs on EAC cells in vitro and in 
vivo. Despite intensive eff orts to culture EAC cells in vitro, only 14 permanent cell lines have 
been established: SEG-1, BIC-1, and FLO-1 (5), SK-GT-4, SK-GT-5 and BE-3 (6), KYAE-1 (7), OE19 
and OE33 (8), JH-EsoAd1 (9), OACP4C and OACM5.1 (10), and two newly established cell lines 
ESO26 and ESO51 (by Grupo de Estudos de Esófago de Barrett do IPOLFG, Lisbon, Portugal). 
In collaboration with the primary investigators who established the cell lines, the original 
EAC tissues for 13 of the 14 cell lines were traced in pathology archives and made available for 
study (anonymously): the original tissue for cell line BE-3 (6) was not found. The availability 
of the primary tissues made it possible to authenticate these EAC cell lines by comparing the 
genotype of the cell line with the genotypes of patient’s normal and tumor tissue. 
MATERIALS AND METHODS
Cell cultures, DNA isolation, and xenografts
Except KYAE-1, all cell lines were cultured under standard conditions in RPMI-1640, supple-
mented with 10% Fetal Calf Serum. Cell line KYAE-1 was cultured in Ham’s F12/RPMI-1640 1:1 
with the addition of 10% fetal calf serum. To verify the histomorphological characteristics of 
each cell line, 5 x 106 tumor cells were injected subcutaneously in two female NMRI nude 
mice (Taconic-M&B, Ry, Denmark) or two NOD-SCID mice (in-house breeding). Xenograft 
tumors were removed after reaching a visible size of 0.5–1 cm in diameter and were routinely 
processed for histological and immunohistochemical examination (10). The mouse experi-
ments were licensed and done in accordance with approved protocols by the Erasmus MC, 
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University Medical Center Rotterdam, the Netherlands. DNA was isolated from cultured cells, 
original tissues, and xenograft tumors using the PureGene Genomic DNA isolation Kit (Qia-
gen, Venlo, The Netherlands). DNA was diluted to a concentration of 100 ng/μL to perform 
polymerase chain reaction (PCR).
Short Tandem Repeat (STR) profi ling
All cell lines were genotyped by STR profi ling by using the Powerplex 16 System (Promega 
Madison WI). The Powerplex 16 system comprises fi fteen STR loci, including Penta E, 
D18S51, D21S11, TH01, D3S1358, FGA, TPOX, D8S1179, vWA, Penta D, CSF1PO, D16S539, 
D7S820, D13S317, D5S818, and the sex chromosome marker Amelogenin. Amplifi cation 
was performed using 1 ng of template DNA applying the Powerplex 16 system following 
the manufacturer’s recommendation. Multiplex PCRs were carried out with fl uorescent dye-
linked primers. Labelled products were detected by electrophoretic size fractionation on an 
ABI 3130xl genetic analyzer (Applied Biosystems, Foster City, CA). The data were analyzed by 
using Genemarker software (SoftGenetics LLC, State College, PA) to categorize peaks accord-
ing to their size in relation to an internal standard. This analysis enabled every peak to be 
allocated a size corresponding to the number of repeat units present.
Inability to amplify the larger STR fragments of DNA isolated from paraffi  n embedded 
archival tissues (due to degraded DNA) forced us to use PCR primers closer to the repeat 
structures in order to perform single STR profi ling. Using this method, eight single STR loci 
were investigated in the original tissue and in the corresponding cell line. The size of DNA 
fragments found in the cell lines could be linked to the number of repeats known from the 
Powerplex assay. This enabled us to correlate the length of the DNA fragments found in the 
original tissues to the number of repeats. 
Mutation analyses
Because TP53 is frequently mutated in EAC, all exons and intron-exon boundaries of the TP53 
gene were commercially sequenced in all the EAC cell lines (Asper Biotech Ltd, Tartu). The 
TP53 (Genbank accession number AF307851.1) mutations identifi ed in the cell lines were 
then investigated in the original tumor tissues from which the cell lines had been derived.
RESULTS
Ten of 13 cell lines unambiguously had the same genotype and harbored the same TP53 
mutation(s) as the original tissues, proving their correct derivation (Table 1 and Appendix 
Table 1). The most frequently used EAC cell lines SEG-1 and BIC-1 and the SK-GT-5 cell line 
had genotypes diff erent from the original tissue of which the cell line was stated. Compari-
son of the genotypes of SEG-1, BIC-1, and SK-GT-5 with genotypes available from databases 
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(http://www.lgcpromochem-atcc.com/common/cultures/str.cfm) revealed that SEG-1 is 
lung carcinoma (large cell lung cancer) cell line H460 (ATCC_HTB-177) and BIC-1 is colorectal 
adenocarcinoma cell line SW620 (ATCC_CCL-227). The genotype and TP53 mutation of the 
SK-GT-5 cell line matched with the tissue from which the cell line SK-GT-2 was derived indicat-
ing that cell line SK-GT-5 is actually the gastric fundus carcinoma cell line SK-GT-2 (Appendix 
Table 2). In independent experiments, the researcher who established cell lines SEG-1 and 
BIC-1 (Dr. Beer) confi rmed our results using the earliest passages of these cell lines. Clearly, 
Figure 1. Authentication of human esophageal adenocarcinoma cell line OE33. A and B, Hematoxylin & 
eosin stained sections of the original tissue and xenograft of OE33, showing a poorly diff erentiated adeno-
carcinoma. C, In vitro growth pattern of cell line OE33. D, STR profi le of the primary normal tissue (P) and 
cell line OE33 (C), indicating correct derivation of the cell line. Short term repeat loci are indicated in boxes 
above electropherogram; the number of repeat units are indicated below the peaks. Note: loss of hetero-
zygosity in the cell line at loci TH01 and FGA. The additional allele (11 repeat units) of D8S1179 observed 
in cell line OE33 is a known phenomenon is probably due to somatic mutation or localized chromosomal 
rearrangements at this heterozygous locus.
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contamination occurred early during establishment of the cell lines, and all of the cultures 
that were distributed subsequently to diff erent laboratories were contaminated. We obtained 
the earliest available passage of cell line SK-GT-5 (1993) from Dr. Schrump (on referral by Dr. 
Altorki). This sample matched tissue from which cell line SK-GT-2 was derived, indicating that 
cross-contamination had occurred at the site of origin or during the early interinstitutional 
exchange of cell line SK-GT-5.
DISCUSSION
After hundreds, perhaps thousands, culture passages of the 10 verifi ed EAC cell lines, it could 
be questioned how representative these cell lines still are as models for their original EAC tu-
mors. In the 10 verifi ed EAC cell lines, 11 TP53 mutations were identifi ed and all were found to 
be present in the respective original tumor tissues (Appendix Table 3), indicating consistency 
of the TP53 mutations during decades of in vitro propagation of the cell lines. Furthermore, 
xenografts obtained from nine of 10 verifi ed EAC cell lines all showed a phenotype identical 
to the original EAC tumors, demonstrating that the cellular features and architecture of the 
tumor are preserved even after long-term in vitro culture (Figure 1). 
The impact of our fi ndings is illustrated by two clinical trials that are currently recruiting EAC 
patients based on experimental results using the contaminated cell lines SEG-1 and BIC-1. 
The fi rst trial (http://clinicaltrials.gov/ct2/show/NCT00619242) investigates the eff ect of 
sorafenib (BAY 43-9006), a potent competitive small molecule multikinase inhibitor of the 
Raf/MAPK/ERK pathway, on Barrett-related EAC. Several studies suggested that exposure 
of cell line SEG-1 to acid increased proliferation and decreased apoptosis by activating the 
Raf/MAPK/ERK pathway (12-14). In addition, treatment of SEG-1 cells with Raf/MAPK/ERK 
inhibitors resulted in pronounced anti-proliferative eff ects (15-18). In the present study, we 
have proved that cell line SEG-1 does not represent EAC, but large cell lung carcinoma. This 
means that there is scant scientifi c evidence for activation of the Raf/MAPK/ERK pathway by 
acid or bile exposure in Barrett-related adenocarcinoma. The use of sorafenib in patients with 
Barrett-related EAC, and the recruitment of patients for this clinical trial should therefore be 
reconsidered. 
Another potential target for therapy in EAC, which is based mainly on research with contami-
nated cell lines SEG-1 and BIC-1, is telomerase (19, 20). In a recent study, investigators dem-
onstrated that treatment of SEG-1 xenografts with a specifi c telomerase inhibitor, GRN163L, 
led to loss of telomerase activity, reduction of telomere length, and inhibition of cell growth 
through induction of both senescence and apoptosis (21). Currently, EAC patients (among 
patients with other cancer types) are being recruited within a phase I clinical trial to study the 
eff ects of this telomerase inhibitor (http://clinicaltrials.gov/ct2/show/NCT00310895?term=G
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RN163L&rank=2). Our fi ndings suggest that there is little scientifi c evidence for treatment of 
EAC patients with telomerase inhibitor GRN163L. 
We have identifi ed more than 100 scientifi c publications in which the contaminated cell lines 
SEG-1, BIC-1, or SK-GT-5 were used (Appendix Tables 4 and 5). Almost half of these reports 
were based solely on the use of cell lines not representative for EAC and should therefore be 
re-evaluated because these cell lines in reality represent large cell lung carcinoma (SEG-1), 
colon adenocarcinoma (BIC-1), or gastric fundus adenocarcinoma (SK-GT-5). In addition, at 
least three NIH grants have been assigned to esophageal cancer research projects (http://
crisp.cit.nih.gov/), and 11 US patents (http://www.uspto.gov/) have been granted based on 
the use of cell lines SEG-1 and BIC-1. Following the lead of Walter Nelson-Rees, the fi rst person 
who urged scientists to stop using contaminated cell lines (22,23), this report is a call for all 
scientists to authenticate their cell lines. Recent advances in DNA-profi ling techniques make 
it possible to genotype cell lines simply and cheaply. The use of verifi ed cell lines is a shared 
responsibility for scientists, editorial boards of scientifi c journals and clinical and basic cancer 
research funding agencies.
CONCLUSIONS
In summary, cell lines SEG-1, BIC-1, and SK-GT-5 are not EAC cell lines, but large cell lung cancer 
cell line H460, colorectal adenocarcinoma cell line SW620, and gastric fundus carcinoma cell 
line SK-GT-2, respectively. Cell lines FLO-1, KYAE-1, SK-GT-4, OE19, OE33, JH-EsoAd1, OACP4C, 
OACM5.1, ESO26, and ESO51 are derived from human EACs. All of these 10 verifi ed EAC cell 
lines, together with their genotyping information, will be deposited in publicly available cell 
line repositories in the United States (http://www.lgcpromochem-atcc.com), Europe (www.
ecacc.org.uk), and Japan (www.brc.riken.jp), to promote and facilitate future solid research 
on EAC. 
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ABSTRACT
Human esophageal adenocarcinoma (EAC) cell lines and xenografts are powerful tools in the 
search for genetic alterations because these models are composed of pure human cancer cell 
populations without admixture of normal human cells. In particular detection of homozy-
gous deletions (HDs) is easier using these pure populations of cancer cells. Identifi cation of 
HDs could potentially lead to the subsequent identifi cation of new tumor suppressor genes 
(TSGs) involved in esophageal adenocarcinogenesis. 
Genome wide single nucleotide polymorphism (SNP) arrays were used to identify HDs in ten 
verifi ed EAC cell lines and nine EAC xenografts. In total, 61 HDs (range 1-6 per sample) were 
detected and confi rmed by PCR. Besides HDs observed in common fragile genomic regions 
(N=26), and gene deserts (N=8), 27 HDs were located in gene containing regions. HDs were 
noted for known TSGs, including CDKN2A, SMAD4 and CDH3/CDH1. Twenty-two new chromo-
somal regions were detected harboring potentially new TSGs involved in EAC carcinogenesis. 
Two of these regions of homozygous loss, encompassing the ITGAV and RUNX1 gene, were 
detected in multiple samples indicating a potentially role in the carcinogenesis of EAC. To 
exclude culturing artifacts, these last two deletions were confi rmed by fl uorescent in situ 
hybridization in the primary tumors of which the involved cell lines and xenografts were 
derived. 
In summary, in this report we described the identifi cation of HDs in a series of verifi ed EAC 
cell lines and xenografts. The deletions documented here are a step forward identifying the 
key genes involved in EAC development.
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INTRODUCTION
Esophageal adenocarcinoma (EAC) is the cancer type with the steepest rise in incidence 
in the Western world over recent years (1). With the increasing prevalence of contributing 
factors (i.e., obesity and gastro-esophageal refl ux disease) in developed countries, it is to be 
expected that the incidence will continue to rise. Despite the common occurrence of EAC, 
little is known about the molecular mechanisms underlying the genesis of these tumors. In 
the past fi ve years, several studies have identifi ed DNA copy number gains/amplifi cations 
amplifi cations on chromosomes 1q, 3q, 7p, 7q, 8q, 17q and 20q along with copy number 
losses (including loss of heterozygosity and homozygous deletions) on 3p, 4q, 5q, 9p, 14q, 
16q, 17p and 18q in the EAC genome (2). Mapping of regions with homozygous deletions 
(HDs) can potentially lead to the identifi cation of new tumor suppressor genes (3-6). How-
ever, in primary EAC tumor tissue samples HDs are diffi  cult to detect due to the presence of 
contaminating non-malignant cells. A more powerful tool in detection of HDs are the use of 
cell lines and xenografts, that consists of pure populations of cancer cells. 
To identify novel tumor suppressor genes involved in the carcinogenesis of EAC, we con-
ducted high-density single-nucleotide polymorphism (SNP) microarrays in 10 verifi ed EAC 
cell lines and 9 xenografts and focussed on areas of homozygous loss. Given the high resolu-
tion of the SNP arrays and the use of pure populations of cancer cells (without admixture of 
normal human tissue), we have been able to identify small homozygous deletions that have 
not been detected by previous studies. Furthermore, the availability of the primary tissues 
of which the cell lines and xenografts were derived, made it possible to verify a selection of 
these HDs by fl uorescent in situ hybridization (FISH). 
MATERIAL AND METHODS
Cell lines and xenografts
Verifi ed EAC cell lines, ESO-26, ESO-51, FLO-1, JH-EsoAd1, KYAE-1, OACP4C, OACM5.1, OE19, 
OE33 and SK-GT-4 were cultured under standard conditions in RPMI-1640 or Ham’s F12/RPMI-
1640 1:1 (for KYAE-1), supplemented with 10% Fetal Calf Serum (7). Xenografts P58x, P100x, 
P101x, P102x, P104x, P117x, P140x, P171x, P175x were obtained after transplantation of 
primary tumor tissue to female nude mice, 4-6 weeks of age (8). The animal experiments were 
licensed and done in accordance with approved protocols by the Erasmus MC, University 
Medical Center Rotterdam, The Netherlands. 
Paraffi  n embedded primary tumor tissue of all cell lines and xenografts was available. Normal 
frozen tissues were available for all xenografts and two EAC cell lines (OACP4C and OACM5.1); 
normal immortalized lymphocytes related to cell line JH-EsoAd1 were obtained from dr J. 
R. Eshleman (Johns Hopkins University School of Medicine, Baltimore, MD, USA). DNA was 
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isolated from cultured cells, original tissues and xenografts using the PureGene Genomic 
DNA isolation Kit (Qiagen, Venlo, The Netherlands). 
Single nucleotide polymorphim (SNP) array
The Aff ymetrix 500K SNP array, used for all tumor (N=19) and corresponding normal tissue 
samples (N=11), was performed by Myriad Genetics Inc. (Salt Lake City, UT, USA), according 
to the methods described by the manufacturer (http://www.aff ymetrix.com/products_ser-
vices/arrays/specifi c/500k.aff x). Total genomic DNA (250 ng) was digested with a restriction 
enzyme (Nsp I or Sty I) and ligated to adaptors that recognize the cohesive four base pair 
overhangs. All fragments resulting from restriction enzyme digestion, regardless of size, are 
substrates for adaptor ligation. A generic primer that recognizes the adaptor sequence was 
used to amplify adaptor ligated DNA fragments. PCR conditions have been optimized to 
preferentially amplify fragments in the 200 to 1,100 bp size range. The amplifi ed DNA was 
then fragmented, labeled, and hybridized to a GeneChip Human Mapping 250K Array. 
Identifying homozygous deletions by SNP-array analysis
Copy number intensities were calculated using the public domain software package CNAG 
(Copy Number Analyser for GeneChip), version 2.0, and detected using the implemented hid-
den Markow model (9, 10). To detect only the tumor-associated copy number changes, and to 
exclude naturally occurring copy number variation (CNV), the DNA of the cell lines OACP4C, 
OACM5.1 and all xenografts was compared with corresponding normal DNA (obtained from 
frozen normal squamous cell epithelium of the esophagus). In addition, cell line JH-EsoAd1 
was compared with the corresponding EBV- immortalized lymphocyte cell line. For the seven 
remaining cell lines, a database containing probe intensity and genotype data sets from the 
three normal tissue samples was generated and used as reference sample for copy number 
analysis. 
Each deletion is defi ned by whether the log 2 ratio of probe intensity is below the baseline 
log 2 ratio defi ned by the matched normal DNA. The baseline log 2 ratio has a theoretical 
value of zero. Homozygous deletions were identifi ed by CNAG2.0 with a copy number of 
the probes equal to zero in default settings with a smoothing window of 5-SNP probes. To 
validate the HDs detected by CNAG, we used NEXUS copy number software (11). The physical 
positions of the detected deletions were determined based on the Human hg18 assembly 
(NCBI Build 36.1 http://genome.ucsc.edu/). 
Confi rmation of the homozygous deletion by PCR and gene-expression
All homozygous deletions detected by SNP-array analysis were confi rmed by PCR. Primers 
were designed within and fl anking the homozygous deletions. In samples with a HD in a 
gene containing region, the expression of genes within this region is expected to be lower 
as compared with samples without the deletion. However, diff erences in gene expression 
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will only be detected when the particular genes are expressed in esophageal cancer; 
otherwise, if the genes are not expressed in esophageal cancer, no diff erences in gene-
expression between the cell lines will be observed. Of all EAC cell lines mRNA was isolated 
using the Qiagen RNeasy kit (Qiagen, Venlo, The Netherlands). RNA quality was assessed 
using the Agilent Bioanalyser, requiring RNA integrity >7.0 (12). All further processing of the 
samples was performed according the Aff ymetrix GeneChip whole transcript sense target 
labeling assay. Aff ymetrix GeneChip Human Exon 1.0 ST Arrays (http://www.aff ymetrix.com/
products_services/arrays/specifi c/exon.aff x) were used to determine the expression level of 
virtually all exons present in the human genome (1.4 million probe sets covering >1 million 
exon clusters). Expression data were analyzed by Partek® Genomics Suite™ 6.3 (Partek Inc., St. 
Louis, MO, USA). A standard algorithm was used to normalize exon signals to the gene-level 
signal for each sample. A t-test was performed to detect diff erences in gene-expression levels 
between samples harboring a HD (containing the gene of interest), and samples without HD. 
P-values <0.05 were considered as statistical signifi cant.
Selection of candidate genes for further analysis
Overlapping HDs in gene containing regions, present in multiple samples were selected for 
further analysis. A second selection criterion was a HD in a gene containing region present 
in a single sample and aberrant gene expression in another sample as detected by gene-
expression arrays. The HDs selected for further analysis, were validated in the cell lines and/
or xenografts and corresponding primary tumors, by fl uorescent in situ hybridization (FISH) 
experiments were performed according to standard protocols with minor modifi cations. For 
dual color FISH, on cell line metaphases and paraffi  n embedded tumor material, centromeric 
or telomeric and locus specifi c BAC and cosmid probes were selected as described previously 
(13). 
Mutation analysis of the candidate genes ITGAV, CDH1, CDH3, CTNNA1 and RUNX1 was done 
in all EAC cell lines (without HD in the particular gene region). Polymerase chain reactions 
(PCR) were carried out in a volume of 15μl containing genomic DNA, 8.3μl H2O, 5μl Mg
2+free 
buff er, 25mM MgCl2, 0.3μl of 10mM deoxynucleotide triphosphates, 20pmol of each primer 
and 1U Taq polymerase (Promega, Madison WI, USA). The primers and PCR conditions used 
were described previously (14-18). The PCR products were bi-directionally sequenced us-
ing an Applied Biosystems 3100 genetic analyser (Perkin Elmer, Foster City, USA). Detected 
mutations were validated in the primary tumors of which the cell line was derived. Protein-
expression of the candidate genes was investigated by immunohistochemistry (IHC), only if 
suitable antibodies were available. 
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RESULTS AND DISCUSSION
Human EAC cell lines and xenografts are indispensable models to study genetic alterations 
that potentially contribute to the carcinogenesis of this tumor type, because appropriate 
animal models and familial cases for EAC are lacking. In these pure populations of tumor 
cells identifi cation of HDs is feasible and potentially contribute to the discovery of new 
tumor suppressor genes. In addition, the availability of the primary tumors of all cell lines 
made it possible to confi rm the deletion in patient’s material, and thus excluding potential 
in vitro culturing artifacts. The clinical characteristics of all tumors from which the cell lines 
and xenografts were derived are depicted in Table 1. Median age at diagnosis was 67 years 
(range, 44-89). Most patients were male (84%). The majority of tumors had an advanced stage 
at pathological examination. In 11 (58%) patients Barrett’s mucosa was present. 
In total, 61 HDs were detected by SNP-array analysis. These deletions ranged in size from 32 
kb (OE33) to 4.1 Mb (OE19). Up to six deletions per sample were identifi ed. Twenty six HDs 
were found related to (overlapped or bordered) six common fragile regions (Appendix Table 
6). Deletions at these fragile sites have also been described by other investigators using pri-
mary EAC samples (2, 19-24). It has been thought that these deletions are a common an early 
event in EAC development (25). Furthermore, functional knockout mice studies indicate a 
Table 1. Clinical characteristics of esophageal adenocarcinoma cell lines and xenografts 
Cell line or Gender Age at Tumor Presence of Postoperative Number of
Xenograft diagnosis location Barrett’s epithelium stage HDs
ESO26 Male 56 Cardia AC No pT4N1M1 3
ESO51 Male 74 Distal EAC Yes pT3N1Mx 2
FLO-1 Male 68 Distal EAC No pT2N1M0 4
JH-EsoAd1 Male 66 Distal EAC Yes pT3N0Mx 4
KYAE-1 Male 60 Distal EAC No pT4N1M1 5
OE19 Male 72 Cardia AC No pT3N1Mx 4
OE33 Female 73 Distal EAC Yes pT3N0Mx 3
OACM5.1 Female 47 Distal EAC Yes pT3N1M1 4
OACP4C Male 55 Cardia AC No pT3N1M1 6
SK-GT-4 Male 89 Distal EAC Yes pT2N1Mx 3
P58x Male 44 Distal EAC Yes pT1N1M0 3
P100x Male 54 Distal EAC Yes pT3N1M0 4
P101x Male 65 Cardia AC No pT3N1M0 5
P102x Male 67 Distal EAC Yes pT3N0M0 1
P104x Male 70 Distal EAC No pT3N1M0 2
P117x Female 55 Cardia AC No pT3N1M0 6
P140x Male 67 Distal EAC Yes pT3N0M0 1
P171x Male 73 Distal EAC Yes pT3N1M0 1
P175x Male 73 Distal EAC Yes pT3N1M0 1
Abbreviations: cardia AC, cardia adenocarcinoma; distal EAC, distal esophageal adenocarcinoma; 
HDs, homozygous deletions
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potential tumor suppressor role of the fragile histidine triad gene (FHIT) located at FRA3B and 
the WWdomain–containing oxidoreductase gene (WWOX) at FRA16D in the development of 
forestomach adenocarcinoma (which is an equivalent of the human distal esophagus) (26, 
27). Eight HDs were located in gene deserts (Appendix Table 7). The remaining HDs (N=27) 
were located in gene containing regions (Table 2). These results are in concordance with large 
surveys on HDs in human cancer cell lines, in which the majority of deletions are detected 
in fragile sites (regions that show increased rates of chromosome breakage in normal cells 
in response to agents causing replicative stress) or in gene deserts (region that not harbor 
known genes) (28, 29). 
HDs in gene containing regions were noted for known TSGs involved in EAC carcinogenesis: 
CDKN2A/CDKN2B, SMAD4 and the DLC1 gene. To our knowledge, this is the fi rst report that 
describes inactivation of CDH3/CDH1 by homozygous deletion in EAC. Both genes play im-
portant roles in cell-cell adhesion, although the gene encoding P-cadherin (CDH3) is  poorly 
Table 2. Homozygous deletions in gene containing regions
Cytoband Start Stop Size (bp) Sample Representative gene within interval
Total no. 
genes
2q32.1 187115467 187240020 124553 ESO51 ITGAV 1
2q32.1 187160790 187225440 64650 KYAE-1 ITGAV 1
3p12.3 79526088 80745130 1219042 JH-EsoAd1 ROBO1 1
4q35.1 183083268 184639494 1556226 OACP4C ODZ3; DCTD; WWC2; CLDN22; CDKN2AIP 7
4q35.2 188635673 189826114 1190441 OACP4C ZFP42; TRIML2; TRIML1 3
5q11.2 58526447 58707182 180735 P117x PDE4D 1
5q31.2 138084150 138148730 64580 OACP4C CTNNA1 1
6p25.3 1533630 1785593 251963 OACP4C FOXC1; GMDS 2
8q24.3 140936025 141407844 471819 JH-EsoAd1 TRAPPC9 1
8p23.1-p22 12285856 13893340 1607484 P117x DLC1 5
8q13.3 71445803 72048237 602434 P117x NCOA2; TRAM1; LACTB2; XKR9 4
9p23 9450595 9627189 176594 OACM5.1 PTPRD 1
9p21.3 21673024 23252297 1579273 JH-EsoAd1 MTAP; C9orf53; CDKN2A; CDKN2B; DMRTA1 5
9p21.3 21815984 22231913 415929 P101x MTAP; C9orf53; CDKN2A; CDKN2B 4
9p21.3 21845431 22032346 186915 OACP4C MTAP; C9orf53; CDKN2A; CDKN2B 4
9p21.3 20656622 22584436 1927814 SK-GT-4 MTAP; CDKN2A; CDKN2B 25
9q21.2 79319412 79349466 30054 P117x GNA14 1
10q23.31 89543978 91973853 2429875 P117x PTEN; FAS-APO 26
12p13.31-p13.2 8600421 10063603 1463182 OACM5.1 A2M; CD69 23
12q12 37810640 39112297 1301657 OE19 KIF21A; ABCD2; C12orf40; SLC2A13; LRRK2 5
12q12-q13.11 41286253 45403376 4117123 OE19 IRAK4; NELL2 14
12q13.13-q13.2 52942936 53559293 616357 OE19 ITGA5; PDE1B 16
16q22.1 67226159 67351131 124972 P104x CDH3; CDH1 2
18q21.2 46859775 50908355 4048580 P58x SMAD4; DCC 11
21q22.12 35120118 35281843 161725 P100x RUNX1 1
21q22.12 35099379 35442696 343317 SK-GT-4 RUNX1 1
22q11.1 15774370 15841990 67620 OACM5.1 GAB4 1
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characterised in comparison too CDH1 (the gene that encodes E-cadherin). It has been sug-
gested that CDH3 act as an invasion suppressor in cancer cells in which it is down-regulated 
during progression, but as an invasion promoter in cancer cells in which aberrant expression 
occurs throughout progression (30). This could be an explanation for the results of a study 
that showed enhanced protein expression of CDH3 in 17/24 EAC samples (31). Germline 
mutations in the CDH1 gene have been associated with hereditary diff use gastric cancer 
and lobular breast cancer (32). Although other mechanism for silencing of the E-cadherin 
gene have been described in EAC, such as promoter hypermethylation or up-regulation of 
E-cadherin repressors like Slug-1 (33, 34), we revealed two overlapping deletions in cell line 
KYAE-1 and xenograft P104x on chromosome 16q22.1, harboring the CDH3 and CDH1 gene 
(Figure 1A). Staining for E- and P-cadherin revealed absent protein expression in KYAE-1 and 
P104x, and in their corresponding primary tumors (Figure 1B/C). Additional FISH analysis 
confi rmed these fi ndings. Phenotypically, loss of cell-cell adhesion by deletion of CDH3/
Figure 1. Analyses of a homozygous deletion on chromosome 16q22.1. A, Scatter plot of log2 copy number 
ratios (blue dots, left axis) for xenograft P104x showed a homozygous deletion overlapping the CDH3 and 
CDH1 gene. B and C, Staining for E-cadherin demonstrated absent protein expression in cell line KYAE-1 (B) 
and in the primary tumor of which xenograft P104x was derived (C).
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CDH1 is characterized by the round or spindle shaped appearance of the tumor cells and 
the capacity of the cells to disseminate (the primary tumors of cell line KYAE-1 and xenograft 
P104x, metastasized to lung and liver, respectively). In the cell lines without a CDH3/CDH1 
HD no mutations in these two genes were found, although in 4/9 cell lines LOH of the CDH3/
CDH1 locus was observed confi rming earlier studies (35). Furthermore, these fi ndings sug-
gest that somatic inactivation of E- and/or P-cadherin is not restricted to gastric cancer or 
lobular breast cancer but does also occur in esophageal adenocarcinoma. urthermore, these 
results validate the sensitivity of our strategy with respect to the detection of biologically 
important HDs in human cancer. 
Twenty-two homozygous deletions within gene-containing regions were identifi ed, harbor-
ing potentially new TSG involved in EAC carcinogenesis. Gene-expression data of the cell 
lines showed that the majority of the HDs identifi ed by SNP-array analysis resulted in reduced 
gene-expression; signifi cance was reached in 8 of 15 tested genes (table 3). Homozygous 
deletions aff ecting chromosome 4q35.2 (TRIML2), 5q11.2 (PDE4D), 6p25.3 (GMDS), 8q24.3 
(TRAPPC9),  9p23 (PTPRD), 9p21.3 (MTAP, CDKN2A etc), 18q21.2 (SMAD4) and 21q22.12 (RUNX1) 
are also described in other SNP-array studies using primary EAC samples  (2, 19-24).  This 
indicates that genes within these regions of homozygous loss could be potentially involved 
in EAC carcinogenesis. It can be speculated that most of the HDs within gene-containing re-
Table 3. Diff erences in gene-expression levels between cell lines harbouring a homozygous deletion (con-
taining the gene of interest), and cell lines without homozygous deletion.
Cytoband Cell line (harbouring a HD) Gene (within HD region) P-value*
2q32.1 ESO51; KYAE-1 ITGAV 0.046
3p12.3 JH-EsoAd1 ROBO1 0.29
4q35.1 OACP4C WWC 0.07
4q35.2 OACP4C TRIML2 0.76
5q31.2 OACP4C; ESO26† CTNNA1 <0.0001
6p25.3 OACP4C GMDS 0.0041
8q24.3 JH-EsoAd1 TRAPPC9 0.0016
9p23 OACM5.1 PTPRD 0.031
9p21.3 JH-EsoAd1; OACP4C; SK-GT-4 CDKN2A 0.0007
12p13.31-p13.2 OACM5.1 CD69 0.068
12q12 OE19 SLC2A13 0.19
12q12-q13.11 OE19 NNT 0.0018
12q13.13-q13.2 OE19 PDE1B 0.98
21q22.12 SK-GT-4 RUNX1 0.12
22q11.1 OACM5.1 GAB4 ND‡
Abbreviations: HD, homozygous deletion; ND, not determined
* A t-test was performed to detect diff erences in gene-expression levels between cell lines harbouring a HD 
(containing the gene of interest), and cell lines without HD
† In cell line ESO26, the reduced CTNNA1 expression is caused by a single nucleotide deletion in exon 6 
(c.850_delA/c.851_delA)
‡ No expression data were available of GAB4, because the gene was not covered by the Human Exon ST 1 Array
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gions, that are only described in the present study (and not in other reports), are “passengers”, 
refl ecting the genetic instability of these tumors and not involved in cancer development. 
However, it could also be possible that these deletions contribute to the carcinogenesis of 
this particular tumor, but do not play a major role in carcinogenesis of EAC in general (36). 
Here, we focused on overlapping deletions (same region of loss in multiple samples), because 
it can be expected that these regions harbor genes of interest (and to select a common 
denominator). Two chromosomal regions with homozygous deletions were selected for 
further investigation: chromosome 2q32.1 harboring the ITGAV gene (ESO51 and KYAE-1) and 
chromosome21q22.12 harboring the RUNX1 gene (SK-GT-4 and P100x). A third chromosomal 
(chromosome 5q31.2 containing the CTNNA1 gene) region was added because two cell lines 
(OACP4CE and ESO26) showed signifi cant reduced expression of CTNNA1 of which one 
(OACP4C) harboured a HD.  
Two overlapping HDs on chromosome 2q32.1 were detected in cell lines ESO51 and KYAE-1 
(Figure 2), aff ecting the promoter region and fi rst exons of the ITGAV gene. This gene, encodes 
the integrin αV chain, which can heterodimerize with fi ve diff erent integrin beta chains form-
ing transmembrane glycoprotein receptors for extracellular matrix proteins (37). Expression 
data showed a signifi cantly reduced expression of ITGAV in both cell lines with the HD, as 
compared with the other cell lines. FISH analysis confi rmed the presence of the HD in the 
primary tumor of ESO51, but not in the adjacent Barrett’s epithelium. In cell line KYAE-1 the 
deletion could not been confi rmed by FISH, due to the smaller size of the deletion (available 
probes in this region were too large for detection of the relatively small deletion). Mutation 
analysis of the cell lines without HD did not reveal mutations. Members of the integrin αV 
subfamily play critical roles in the homeostasis of stratifi ed squamous epithelium. Interest-
ingly and in contradiction to the vast majority of in vitro growing epithelial tumor cell lines, 
the αV integrin negative cell lines ESO51 and KYAE-1 both grow non-adherent to the culture 
fl asks in fl oating aggregates. This has also been reported for the αV integrin negative human 
tongue squamous cell carcinoma cell line H357 (38). This growth in suspension of the αV 
integrin negative epithelial tumor cell lines is in accordance with the reported inhibition of 
anoikis by absence of αV integrin expression. In concordance with the concept of αV integrin 
inactivation in squamous cell carcinoma, it could be speculated that bi-allelic loss of αV inte-
grin is an early event in EAC carcinogenesis, contributing to the disorganizing of the stratifi ed 
epithelium of the esophagus by uncoupling integrin-mediated adhesion and signaling.
Two overlapping HDs in cell line SK-GT-4 and xenograft P100x were located on chromosome 
21q22.12, containing the RUNX1 gene (Figure 3). This gene encodes a heterodimeric tran-
scription factor that binds to core binding factor beta (CFBbeta), and regulates downstream 
genes that are important in development and diff erentiation, as well as in cancer (39). PCR 
analysis confi rmed the deletions in SK-GT-4 and P100x, and screening of the series cell lines 
and xenografts showed an additional RUNX1 HD in EAC cell line OE33. Re-evaluation of the 
SNP-array data affi  rmed this HD; the size of the deletion was so small that it not reached 
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the initial threshold for detection (the deletion encompassed <5-SNP probes). FISH analysis 
revealed the presence of the HD in cell line SK-GT-4 and in the primary tissue of P101x. The 
presence of HDs in two EAC cell lines and one xenograft, indicate the possible tumor suppres-
sive role of RUNX1 in EAC carcinogenesis. Sequence analysis of the remaining cell lines and 
xenografts did not reveal additional point mutations. It could be that RUNX1 is silenced by 
promoter hypermethylation. This has been observed for the RUNX1 family member RUNX3, 
which was found to be subject of methylation in gastric cancer carcinogenesis (40). Besides 
the role of RUNX1 in human leukaemia, where functional disruption by chromosomal translo-
cation and somatic point mutation commonly occur (41), little is known about the role of the 
RUNX1 gene in epithelial cancer types. It has been demonstrated that RUNX1 is signifi cantly 
down-regulated in metastasis of diff erent types of adenocarcinoma (42). Therefore it could 
Figure 2. Analyses of a homozygous deletion on chromosome 2q32.1. A, Scatter plot of log2 copy number 
ratios (blue dots, left axis) for cell line ESO51 revealed a homozygous deletion containing a part of the ITGAV 
gene. B, FISH analysis on metaphase chromosomes and on the primary tumor of which cell line ESO51 is 
derived (left) demonstrated absence of the red-coloured probe (Fosmid G248P87126F7) which is located 
within the homozygous deletion. In the adjacent Barrett’s epithelium (right) the red-coloured probe is pres-
ent, which suggests that homozygous loss occurs late in EAC carcinogenesis. C, Expression analysis showed 
signifi cantly reduced expression of ITGAV in cell lines ESO51 and KYAE-1.
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be speculated that deletions of RUNX1 in esophageal adenocarcinoma potentially contribute 
to the aggressive metastatic phenotype of these tumors. 
A HD on chromosome 5q31.2 containing only the CTNNA1 gene was detected in cell line 
OACP4C (Figure 4). Alpha-catenin, encoded by the CTNNA1 gene, is known to anchor 
E-cadherin to the cytoskeletal actin bundle by binding the cadherin cytoplasmic domain 
(43). Additional gene-expression data showed a reduced expression of CTTNA1 in cell lines 
OACP4C and ESO26. In the latter cell line, a single nucleotide deletion was found in exon 
6 (c.850_delA/c.851_delA). However, this deletion mutation was not found in the primary 
tumor of cell line ESO26, suggesting that the mutation was acquired during in vitro culture or 
selection for cells harboring the CTNNA1 gene mutation has occurred during establishment 
of the cell line (which represents only a minor population of the primary tumor cells). These 
fi ndings are in line with reports in literature describing CTNNA1 gene mutations predomi-
nantly in cell lines (44, 45).
In summary, this study reports on the identifi cation of HDs in EAC cell lines and xenografts. 
Using these pure populations of cancer cells (verifi ed EAC cell lines and xenografts) 22 new 
chromosomal regions were detected, harboring potentially new TSGs involved in EAC carcino-
genesis. Here, we showed that the ITGAV and RUNX1 gene are frequently aff ected by HDs, indi-
cating a potential role in the carcinogenesis of EAC. Comprehensive genomic profi ling such as 
presented will allow a more defi ned approach to identifying and characterizing genes involved 
in EAC carcinogenesis, off ering the potential for improved clinical tests and treatments. 
Figure 3. Analyses of a homozygous deletion on chromosome 21q22.12. A and C, Scatter plot of log2 copy 
number ratios (black dots, left axis) of cell line SK-GT-4 (A) and xenograft P100x (C) revealed a homozygous 
deletion that over spanned the RUNX1 gene. B and D, FISH analysis on metaphase chromosomes of cell line 
SK-GT-4 (B) and on the primary tumor of which xenograft P100x is derived (D) demonstrated absence of the 
red-coloured probe (Fosmid G248P88378B1) which is located within the homozygous deletion. 
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Figure 4. Analyses of a homozygous deletion on chromosome 5q31.2. A, Scatter plot of log2 copy number 
ratios (black dots, left axis) of cell line OACP4C showed a homozygous deletion within the CTNNA1 gene. B, 
Expression analysis showed signifi cantly reduced expression of CTNNA1 in cell lines OACP4C and ESO26. C, 
Mutation analysis of cell line ESO26 showed a deletion of one base pair (c.850_delA or c.851_delA).
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ABSTRACT
Background: Patients with carcinoma of the distal esophagus and metastatic celiac lymph 
nodes (M1a) have a poor prognosis and are often denied surgery. In this study, we evaluated 
our treatment strategy of chemotherapy followed by surgery in patients with M1a disease. 
Methods: Thirty-eight patients who received chemotherapy for carcinoma of the distal 
esophagus with celiac lymph node involvement between 2000 and 2007 were identifi ed 
from a prospective database. Clinical and histopathological responses to chemotherapy were 
analyzed and follow-up comprised review of medical charts.  
Results: Twelve non-responding patients were not eligible for surgery. Twenty-six patients 
with partial responses or stable disease were operated on. The resectability rate was 96% 
(25/26) and tumor free resection margins (R0) were achieved in 68% (17/25). The overall 
survival of patients with M1a disease was 16 months. Patients who received chemotherapy 
alone had a median survival of 10 months; patients who underwent additional surgery had a 
median survival of 26 months (log-rank p<0.001).
Conclusions: The overall survival of patients with carcinoma of the distal esophagus and 
clinical celiac lymph node involvement is poor. Tumor free resection margins (R0) in M1a 
patients with clinical response to chemotherapy are likely to be achieved and contributes to 
prolonged survival.
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Patients with celiac lymph node involvement treated with curative intent
INTRODUCTION
Most patients with esophageal cancer have advanced disease at the time of diagnosis, 
because symptoms arise late in the course of the disease. The prognosis of patients with 
esophageal cancer is therefore poor (1,2). Lymphatic dissemination of a tumor in the distal 
esophagus occurs early and predominately to the paracardial lymph nodes, lymph nodes 
along the lesser curvature and to the celiac lymph nodes (CLNs) (3). According to the pTNM 
classifi cation established by the UICC and the AJCC, lymph nodes around the celiac axis are 
considered non-regional nodes and as such classifi ed as M1a disease (4). Controversy exists 
about the implications of positive CLNs. Some clinicians exclude these patients for curative 
treatment options, whereas others believe that these patients are still eligible for surgery (5-
7). Multi-modality treatment has been suggested by some (8-12), but the optimal treatment 
remains unclear due to the paucity of clinical studies and lack of randomized trials. In our 
institution, patients with tumor-positive CLNs with a diameter of less than 1.5 cm are consid-
ered eligible for primary surgery (13). In patients with CLNs larger than 1.5 cm chemotherapy 
is considered with the aim of inducing tumor shrinkage followed by surgery with curative 
intent. The aim of this study was to evaluate the pathological and clinical outcome of this 
strategy in patients with carcinoma of the distal esophagus and CLN involvement.
MATERIALS AND METHODS
The Erasmus University Medical Center is a tertiary referral center for patients with esopha-
geal carcinoma in the Netherlands. Clinical and pathological data on all patients are collected 
and prospectively stored in a database. To investigate the hypothesis that a subset of patients 
with large celiac lymph nodes (>1.5cm) treated with chemotherapy do benefi t from addi-
tional surgical resection, this database was scrutinized to identify patients with cancer of the 
distal esophagus who were deemed unresectable and received chemotherapy because of 
CLN involvement between the years 2000 and 2007. Because of the retrospective nature this 
study, ethical approval was not necessary. 
Only patients with histological proven squamous cell carcinoma, adenocarcinoma, or undif-
ferentiated carcinoma of the distal esophagus or gastro-esophageal junction (Siewert I/II), 
were included. For all patients, pretreatment staging according to TNM criteria (4), included 
a baseline upper gastrointestinal endoscopy, endoscopic ultrasonography (EUS), and com-
puted tomography (CT) of the neck, chest and the upper abdomen. Lymph nodes within a 
2 cm range of the celiac axis identifi ed by means of EUS were considered malignant if one 
or more of the following criteria were met: hypo-echoic texture, sharp border, round shape 
and at least 1.0 cm in size. In addition, the largest diameter of the CLNs was measured and 
nodes larger than 1.0 cm detected by CT imaging were considered as malignant. Fine-needle 
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aspiration, PET scan or laparoscopic staging was incidentally used for assessment of the 
nodal status.
CLN >1 cm measured by CT scan or EUS are considered as malignant. Patients with CLNs 1.0-
1.5 cm are deemed to be resectable, but CLNs >1.5cm are thought to hamper radical surgical 
resection and therefore this subset of patients received chemotherapy (Figure 1) (13). The 
chemotherapy regime consisted of paclitaxel 180 mg/m2 and cisplatin 60 mg/m2 in a biweekly 
schedule (14) or a combination of paclitaxel 100 mg/m2 and carboplatin targeted at an AUC of 
4 on days 1, 8, 15, 29, 36 and 43 (15). The planned number of treatment cycles was six. Toxicity 
was graded and reported using National Cancer Institute – Common Toxicity Criteria (NCI-CTC 
version 3). Tumor response, according the response evaluation criteria in solid tumors (RECIST) 
(16), was assessed after the third course of chemotherapy and included a CT scan of chest and 
abdomen. Patients with local disease progression or occurrence of distant metastasis received 
further palliative treatment. Patients showing response received three additional courses of 
chemotherapy and were then re-evaluated to determine tumor resectability. Surgery was 
proposed for patients that showed stable disease, partial or complete response.   
Figure 1. Flowchart of patients with clinical M1a disease treated with chemotherapy or chemotherapy 
followed surgery. CLN >1 cm are considered as malignant. Patients with CLNs 1.0-1.5 cm are deemed to be 
resectable, but CLNs >1.5cm are thought to hamper radical surgical resection and therefore this subset of 
patients received chemotherapy.
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In patients without enlarged lymph nodes in the mediastinum, a transhiatal esophagectomy 
(THE) was preferred (17). In patients with suspicious lymph nodes in the chest, a transthoracic 
resection (TTE) with two-fi eld lymphadenectomy was performed (18). The origin of the left 
gastric artery was routinely marked by the surgeon in the resection specimen and nodes 
within 2 cm of this location were marked as CLNs. The continuity of the digestive tract was 
restored by means of a gastric tube reconstruction with a cervical anastomosis. 
Resections were considered radical if microscopically examination revealed no tumor tissue 
at or less than 1 mm from the circumferential, proximal, or distal margins. Pathological staging 
was done according to the UICC 6th edition (4). In addition, histomorphological response of 
solely the primary tumor to chemotherapy, was assessed and classifi ed into four categories, 
grade I: more than 50% vital residual tumor cells; grade II: 10–50% vital residual tumor; grade 
III: less than 10% vital residual tumor cells; grade IV: complete tumor regression, no evidence 
of vital tumor cells (19).
Data on follow-up were collected from the prospective database and the medical charts. All 
patients were followed at an interval of three to four months during the fi rst year, every six 
months for the second year, and annually for up to 5 year post surgery. Recurrence of disease 
was diagnosed on clinical grounds. However, whenever a relapse was suspected, radiologic, 
endoscopic, or histologic confi rmation was sought. Recurrent disease was classifi ed as lo-
cal–regional (occurring in the upper abdomen or mediastinum) or distant (including cervical 
recurrences). 
Statistical analysis
Statistical diff erences were tested using the Fisher’s exact probability test for categorical 
variables and the t test for continuous variables. All statistical tests were two-sided. Statistical 
signifi cance was set at the 5% level. Survival and follow-up were calculated from the start of 
chemotherapy to the date of death or the last date of follow-up (1st May 2008) at which point 
the data were censored. The probability of survival over time was estimated with a Kaplan-
Meier curve and the log-rank test was used to determine statistical diff erences in survival.
RESULTS
Between January 2000 and January 2007, 38 patients underwent chemotherapy for carci-
noma of the distal esophagus with CLN involvement. These patients were not eligible for 
primary surgery because of large celiac lymph nodes (>1.5 cm). The baseline characteristics 
of these of patients are listed in Table 1.  All 38 patients were staged as cT2-3N0-1M1a. In 31 
patients complete EUS staging could be achieved, in fi ve patients the celiac region could 
not be inspected by EUS due to tumor obstruction and two patients underwent no EUS for 
unknown reasons. EUS guided FNA was introduced halfway 2004 in our institute. Of the 20 
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patients staged after May 2004, nine underwent EUS-guided FNA. Cytology of the aspirate 
was positive for tumor cells in seven patients and was inconclusive in two patients. Diagnos-
tic laparoscopy with histological confi rmation of CLN involvement was done in two patients 
because of incomplete EUS staging; another patient did not receive EUS but underwent a 
diagnostic laparoscopy in another hospital before being referred to our institution. (Table 2)
Chemotherapy
Thirty-fi ve patients were treated with a combination of paclitaxel and cisplatin; three patients 
received a combination of paclitaxel and carboplatin as part of a dose fi nding study (15). 
The mean and median number of treatment cycles was 5.4 and 6 (range 2-8), respectively. 
Twenty-fi ve patients (66%) received the planned dose and cycles of chemotherapy. In seven 
patients, who received chemotherapy without additional surgery (N=12), the number of 
treatment cycles was reduced because of disease progression (N=4), nephrotoxicity (N=1) 
and clinical deterioration (N=2). Five patients, who received chemotherapy followed by ad-
ditional surgery (N=26), did not complete the planned number of treatment cycles because 
nephrotoxicity (N=1), grade III sensory neuropathy (N=2) and clinical deterioration (N=2). 
One patient received eight treatment cycles. In two patients, the chemotherapy regime was 
switched from a cisplatin to a carboplatin regime, because of severe nephrotoxicity. Grade 
III or IV hematological toxicity consisted of leucopenia in fi ve patients (13%) and neutrope-
Table 1. Patient characteristics
All Patients CTX CTX + Surgery P-Value
Characteristics (N=38) (N=12) (N=26) (CTX vs CTX + Surgery)
Gender ns
Female 4 (11%) 0 (0%) 4 (15%)
Male 34 (89%) 12 (100%) 22 (85%)
Age (years) ns
Median 61 60 62
Range 44 - 73 50 - 70 44 - 73
Histology ns
Adenocarcinoma 31 (82%) 10 (83%) 21 (81%)
Squamous-cell carcinoma 5 (13%) 2 (17%) 3 (12%)
Undiff erentiated carcinoma 2 (5%) 0 (0%) 2 (7%)
Histological grade ns
Well diff erentiated 1 (3%) 0 (0%) 1 (3%)
Moderately diff erentiated 9 (24%) 1 (8%) 8 (31%)
Poorly diff erentiated 21 (55%) 8 (67%) 13 (50%)
Undiff erentiated 2 (5%) 0 (0%) 2 (8%)
Unknown 5 (13%) 3 (25%) 2 (8%)
Tumor length (cm) ns
Median 13 7 6
  Range 2 - 15 2 - 14 2 - 15  
Abbreviations: CTX, Chemotherapy; EUS, Endoscopic ultrasound; ns, not signifi cant
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nia in 24 patients (63%). One patient received anti-coagulant drug treatment because of a 
thrombo-embolic event. The most important non-hematological complication was a grade 
I-II sensory neuropathy, observed in 10 patients (26%). There was no mortality.
Clinical response assessment
Overall clinical response evaluation showed no complete responses; 20 patients had a (53%) 
partial response; 13 (34%) showed stable disease and fi ve (13%) had progressive disease. 
Response measurement of solely the celiac lymph nodes revealed complete disappearance 
in fi ve patients, partial response (30% decreases in celiac lymph node size) in 14 patients, 
and in 16 patients the nodes were unchanged or progressed in size. In three patients, who 
underwent a diagnostic laparoscopy with complete removal of the celiac lymph node, objec-
tive regression of the lymph node could not be measured. 
Surgery
Twelve patients (32%) were not referred for additional surgery because of progressive disease 
(N=5), stable disease with enlarged celiac lymph nodes size >1.5 cm (N=3) or clinical deterio-
ration (N=4). Twenty-six patients (68%) were selected for surgical resection, 20 patients had 
partial response and six showed stable disease (Figure 1). Except two patients, all had celiac 
lymph nodes <1.5 cm. 
Twenty-two (84%) patients underwent THE, and three (12%) TTE. One patient (4%) had liver 
metastases at laparotomy and no resection was performed. Of the 25 patients who under-
went surgical resection with curative intent, 17 patients (68%) had a R0 resection and eight 
patients (32%) had a R1 resection. The mean number of lymph nodes that were harvested 
Table 2. Pre-treatment staging of patients with clinical suspected celiac lymph node involvement
All Patients CTX CTX + Surgery
Characteristics (N=38) (N=12) (N=26)
Staging modality
CT 38 (100%) 12 (100%) 26 (100%)
EUS 36 (95%) 12 (100%) 24 (92%)
PET 1 (3%) 0 (0%) 1 (4%)
FNA 9 (24%) 4 (33%) 5 (19%)
Laparoscopy 3 (8%) 1 (8%) 2 (7%)
cTNM stage
cT stage
T2 1 (3%) 0 (0%) 1 (4%)
T3 37 (97%) 12 (100%) 25 (96%)
cN stage
N0 5 (13%) 0 (0%) 5 (19%)
    N1 33 (87%) 12 (100%) 21 (81%)
Abbreviations: CTX, Chemotherapy; CT, Computed tomography; EUS, Endoscopic ultrasound;
PET, Positron emission tomography; FNA, Fine needle aspiration
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was 14 (range 1-32). The in-hospital mortality rate was 4%. The most frequent complications 
were of pulmonary origin (24%), followed by anastomotic leak (19%).
Pathology
Histomorphological analysis of the primary tumor showed a regression grade IV in four 
patients (16%), a regression grade III in three patients (12%), a regression grade II in one 
patient (4%), and 17 patients (68%) had a histopathological regression grade I (Table 3). All 
patients with regression grade II-IV of the primary tumor, except one who had a diagnostic 
laparoscopy with complete removal of the CLN, had signs of tumor regression in their CLNs. 
Only one patient with regression grade III of the primary tumor had still vital tumor cells 
present in the CLNs. 
Thirteen resection specimens contained tumor positive CLNs; twelve resection specimens 
had tumor negative CLNs. Signs of histomorphological regression within the tumor negative 
CLNs were observed in six patients (who also showed regression of the primary tumor). His-
tomorphological regression was mainly characterized by extensive fi brosis, mucin lakes and 
presence of macrophages. Four patients had tumor negative CLNs without signs of regressed 
tumor tissue. Two patients, who underwent a diagnostic laparoscopy with complete removal 
of the CLN, were staged pathologically M0, but objective regression of tumor within these 
lymph nodes could not be measured. In four of 13 resection specimens with tumor positive 
CLNs, signs of tumor regression in the CLN were observed. 
After chemotherapy, in fi ve patients the celiac lymph nodes completely disappeared. Of 
these, two had tumor-positive CLNs without signs of regression in their resection specimens 
and three showed tumor-negative CLNs with histomorphological regressed tumor tissue.
Survival and pattern of failure 
The median survival of all 38 patients was 16 months (Figure 2). At the time of analysis, 12 of 
38 patients are alive. The median follow-up time of surviving patients was 55 months (range 
34-97 months). None of the patients who received chemotherapy alone survived more than 
two years (Figure 3). Patients who underwent additional surgery had a median survival of 
26 months; the 5-years survival was 19%. Patients with a R1 resection (N=8) or positive CLNs 
in the resection specimen (N=13) had similar survival curves as those who received chemo-
therapy alone (N=13) (Figure 4 and 5). The group of patients with histopathological response 
grade II-IV (N=8) had a signifi cant better survival as compared to the group of patients with a 
histopathological response grade I (N=17) (log-rank P=0.025). 
Most patients with M1a disease that were alive had a radical surgical resection (R0), had com-
plete or major response to chemotherapy (Grade II-IV) and had no tumor positive CLNs in 
their resection specimens (Table 3). Recurrent disease after surgery was found in 11 patients; 
three had distant metastases and eight had both loco-regional recurrence and distant metas-
tasis. One patient died due to surgical complications; one patient died because of unknown 
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reasons. Loco-regional recurrences were mediastinal lymph node metastases, retroperitoneal 
lymph node metastases and recurrences in the gastric tube. Distant metastases were found 
in liver, brain, adrenal gland and bone. 
Table 3. Pathological characteristics of patients with clinical suspected celiac lymph node involvement 
treated with chemotherapy and additional surgical resection
Study 
No.
Pre-treatment CLNs 
stage pTNM stage
Number of 
involved Resection
Regression 
grade Tumor regression signs 
  by FNA or Laparoscopy   lymph nodes margins primay tumor in CLNs
1 ND T0N0M0 0 / 16 R0 IV Yes
2 Laparoscopy T3N0M0 0 / 7 R0 I Prior laparoscopy
3 ND T3N1M1a 13 / 13 R1 I No
4 Laparoscopy T2N0M0 0 / 6 R0 III Prior laparoscopy
5* ND T3N0M0 0 / 8 R0 I No
6 ND T0N0M0 0 / 1 R0 IV Yes
7 ND T3N1M1a 16 / 18 R1 I No
8* ND T3N1M0 3 / 6 R0 I No
9 ND T3N1M1a 3 / 14 R0 I No
10 ND T0N0M1a 3 / 11 R0 IV
Yes (still vital tumor cells 
present)
11 ND T3N1M1a 8 / 17 R1 I No
12 ND T1N0M0 0 / 18 R0 III Yes
13 ND T0N0M0 0 / 14 R0 IV Yes
14 ND T3N1M0 1 / 16 R1 II Yes
15* FNA T3N0M0 0 / 14 R0 I No
16 FNA T3N1M1a 14 / 24 R0 I No
17 FNA T3N1M1a 11 / 14 R0 I
Yes (still vital tumor cells 
present)
18 ND T3N1M1a 3 / 8 R0 I
Yes (still vital tumor cells 
present)
19* ND T3N1M0 1 / 26 R0 I No
20 FNA T2N0M0 0 / 11 R0 III Yes
21 ND T3N0M1a 1 / 9 R0 I No
22 ND T3N1M1a 11 / 32 R1 I
Yes (still vital tumor cells 
present)
23 FNA† T3N1M1a 6 / 11 R1 I No
24 ND T3N1M1a 13 / 16 R1 I No
25 ND T3N1M1a 3 / 14 R1 I No
Abbreviations: CLN, Celiac lymph node; FNA, Fine needle aspiration ; ND, Not determined by FNA or lapa-
roscopy
* Patients with tumor negative CLNs and without any signs of histomorphological regressed tumor tissue, 
indicating that these patients had possibly no celiac lymph node involvement pre-treatment
† FNA was not conclusive
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Figure 2. Overall survival for patients with clinical suspected celiac lymph node involvement (N=38) treat-
ed with chemotherapy or chemotherapy followed by surgery.
Figure 3. Kaplan-Meier survival curves for patients who received chemotherapy alone (N=12), and for pa-
tients who received chemotherapy and surgery (N=26).
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Figure 4. Kaplan-Meier survival curves of patients who underwent chemotherapy followed by radical sur-
gical resection (N=17), patients who underwent R1 resection (N=8) and for patients who underwent no 
surgical resection (N=13).
Figure 5. Kaplan-Meier survival curve for patients with no positive CLNs in the resection specimen (N=12; 
blue line), patients with positive CLNs in the resection specimen (N=13) and for patients who underwent 
no surgical resection (N=13).
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DISCUSSION
Surgical treatment of patients with carcinoma of the distal esophagus with suspected celiac 
lymph node involvement is controversial. Radical resection of the primary tumor together 
with a radical lymph node clearance of the celiac axis is deemed impossible and the patient 
is denied surgery. In this study, we analyzed the results of 38 patients selected for chemo-
therapy followed by surgery in 26 patients, who showed clinical response to chemotherapy. 
The prognosis after chemotherapy followed by surgery is largely determined by tumor free 
resection margins, pathological response of the primary tumor and the CLN status (Table 3). 
Radical surgical resection (R0) in this selected group of patients was achieved in 68% (17/25). 
This percentage is comparable to the complete resection rates in patients with primary resect-
able esophageal cancer in larger series (18,20). The importance of radical surgical resection 
Table 4. Characteristics of patients with clinical suspected celiac lymph node involvement, alive or death 
after chemotherapy and additional surgical resection
    Alive Death P value
Characteristics (N=12) (N=13) (Alive vs Death)
Pre-treatment 
Gender ns
Women 1 (8%) 3 (23%)
Man 11 (92%) 10 (77%)
Age (years) ns
Median 58 63
Range 44 - 69 48 - 73
Histology ns
Adenocarcinoma 9 (75%) 11 (84%)
Squamous-cell carcinoma 2 (17%) 1 (8%)
Mixed or other 1 (8%) 1 (8%)
Pathological staging
Resection margins 0.03
R0 11 (92%) 6 (46%)
R1 1 (8%) 7 (54%)
Histomorphological regression 0.011
Grade I 5 (42%) 12 (92%)
Grade II-IV 7 (58%) 1 (8%)
Celiac lymph node status 0.001
M0 10 (83%) 2 (15%)
M1a 2 (17%) 11 (85%)
Time of follow-up (months)
Median 55 13
  Range 32 - 96 8 - 26  
Abbraviations: ns, not signifi cant
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is refl ected by the group of patients who underwent a R1 resection (tumor tissue at or less 
than 1 mm from the circumferential, proximal, or distal margins). The median survival rate of 
these patients (N=8) was 11 months, which is comparable with the median survival rate of 
12 months in patients who received chemotherapy alone. In contrast, the median survival 
in patients with a R0 has not been reached yet. Pathological response to chemotherapy is 
associated with long term survival; seven of eight patients (with grade II to IV pathological 
response) are alive after a median follow-up of 55 months. These results are comparable with 
another studies, in which patients who showed complete and or major pathological response 
to preoperative chemotherapy had 5 years survival rates between 60- 89% (21,22). Another 
important prognostic factor is the pathological CLN status. Patients with tumor positive CLNs 
in the resection specimen (N=12) had a median survival of 18 months. This is in concordance 
with survival rates of 14 and 23 months as described in literature, in patients with primary 
resectable esophageal cancer who underwent surgical resection and had microscopically 
positive celiac lymph nodes in the resection specimen (23,24). A recent study from our insti-
tution showed a median survival of 13 months and a 5-year survival of 8% in a cohort of 55 
patients with M1a disease treated with surgery alone (23). 
Twelve patients had tumor negative celiac lymph nodes, of which 4 patients had tumor 
negative CLNs without any signs of histomorphological regressed tumor tissue, indicating 
that these patients were possibly incorrectly staged as M1a. Of these patients, one patient 
did not underwent EUS-staging; in one patient the celiac region could not be inspected by 
EUS due to tumor obstruction; one patient underwent EUS-guided FNA with cytological 
confi rmation but possibly a local-regional lymph node has been evaluated; in one patient, 
the involved lymph node was located adjacent to the primary tumor but within 2cm of the 
celiac artery, therefore, this lymph node was probably misidentifi ed as CLN. Patients with 
complete response of the primary tumor or tumor negative CLNs with signs of tumor regres-
sion (N=8) had a signifi cant better survival as compared to the rest of the patients (N=17) 
(log-rank P=0.025).
In this study, patients with clinical response to chemotherapy and CLNs <1.5 cm were 
deemed eligible for surgery. Obviously, there is a large discrepancy between clinical and 
pathological response assessment to chemotherapy. CT scan is not accurate in determining 
the response to chemotherapy; this is probably related to the diffi  culty in the diff erentiation 
between viable tumor and reactive changes, including edema and scar tissue (25). Whereas 
the CLN status is as important as the response of the primary tumor on clinical outcome 
after surgery, assessment of the celiac lymph node status after chemotherapy by EUS guided 
FNA or diagnostic laparoscopic could improve selection of patients that are likely benefi t of 
additional surgical resection (26). 
To our knowledge, this is the fi rst study that reports on patients with M1a disease who re-
ceived chemotherapy followed by surgery. Most studies reported on small series of patients 
with M1a disease who receive chemoradiotherapy eventually followed by surgery. One of the 
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fi rst reports, by Christie et al (8), described the results of preoperative chemoradiotherapy in 
four patients with clinically M1a disease. Two patients with a complete pathological response 
were alive after 2 years of follow-up. One of the four patients died because of disease recur-
rence and another died without evidence of recurrence. In another study, 18 patients with 
M1a disease were treated with chemotherapy followed by defi nitive chemoradiotherapy 
(11). After completion of concurrent chemoradiotherapy, 9 patients had a clinical complete 
response, fi ve showed a partial response, two had stable disease, one progressive disease, 
and one was not assessed. The median overall survival rate was 13.8 months, and the 2 years 
survival rate was only 18.6%. In a study reported by Malaisrie et al. (9), 9 patients were treated 
with chemoradiotherapy followed by surgery and 9 patients received chemotherapy before 
concurrent chemoradiotherapy and surgery; the median survival was 9 and 26 months, 
respectively. Frizell et al. (10) reported a 2-year survival rate of 54% in 13 patients with clini-
cally involved celiac lymph nodes, who received a variety of treatment modalities including 
chemoradiotherapy alone and chemoradiotherapy followed by surgery. Eight patients de-
veloped distant disease recurrence, and one had both local and distant disease recurrence. 
In our opinion, the role of radiotherapy in patients with a carcinoma of the distal esophagus 
and CLN involvement is limited. For adequate radiotherapy a large radiation fi eld is needed 
that also includes a major part of stomach that later on is needed for gastro-intestinal tract 
reconstruction. In addition, adequate radiation doses are limited by inclusion of the abdomi-
nal viscera (27). A multi-center randomized trial is needed to compare chemotherapy with or 
without radiotherapy followed by surgery in responding M1a patients. 
This study has several limitations. In the majority of patients (N=28) the cytological or 
histological confi rmation of CLN involvement before the start of treatment is lacking and 
therefore CLN involvement could be questioned. However, CLNs larger than 1.5 cm do have 
a high a priori chance that the lymph node harbor malignant cells (28). Furthermore, patho-
logical examination of the resection specimens revealed in all, except four, tumor positive 
CLNs or tumor negative CLN with signs of tumor regression, indicating a diagnostic accuracy 
of pre-treatment CLN involvement of 85%. The small number of patients, the nonrandom-
ized setting and the retrospective nature of this study limits our ability to reach defi nitive 
conclusions, because many factors can contribute to improved survival in patients treated 
with chemotherapy followed by additional surgery. 
CONCLUSIONS
Despite these limitations, this study confi rmed that patients with carcinoma of the distal 
esophagus and CLN involvement have a poor prognosis. Radical esophagectomy in M1a 
patients with clinical response to chemotherapy is likely to be achieved and contributes to 
prolonged survival. Besides radical surgical resection, complete or major pathological re-
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sponse to chemotherapy and a negative CLN status in the resection specimen are associated 
with long-term survival. Assessment of the CLN status after chemotherapy by EUS-guided 
FNA could be useful to further optimize selection of M1a patients who are most likely to 
benefi t from additional surgery. 
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ABSTRACT
Introduction: This is a randomized, controlled trial of preoperative chemotherapy in patients 
undergoing surgery for esophageal squamous cell carcinoma (ESCC). Patients were allocated 
to chemotherapy, consisting of 2-4 cycles of cisplatin and etoposide, followed by surgery 
(CS group) or surgery alone (S group). Initial results reported only in abstract form in 1997, 
demonstrated an advantage for overall survival in the CS group. The results of this trial have 
been updated and discussed in the timeframe in which this study was performed.
Methods: This trial recruited 169 patients with ESCC, 85 patients assigned to preoperative 
chemotherapy and 84 patients underwent immediate surgery. The primary study endpoint 
was overall survival (OS), secondary endpoints were disease free survival (DFS) and pattern of 
failure. Survival has been determined from Kaplan-Meier curves and treatment comparisons 
made with the log-rank test. 
Results: There were 148 deaths, 71 in the CS and 77 in the S group. Median OS time was 16 
months in the CS group compared with 12 months in the S group; 2-year survival rates were 
42% and 30%; and 5-year survival rates were 26% and 17%, respectively. Intention to treat 
analysis showed a signifi cant overall survival benefi t for patients in the CS group (P=0.03, 
by the log-rank test; hazard ratio [HR] 0.71; 95%CI 0.51-0.98). DFS (from landmark time of 
6 months after date of randomisation) was also better in the CS-group than in the S group 
(P=0.02, by the log-rank test; HR 0.72; 95%CI 0.52-1.0). No diff erence in failure pattern was 
observed between both treatment arms.
Conclusions: Preoperative chemotherapy with a combination of etoposide and cisplatin 
signifi cantly improved overall survival in patients with ESCC.
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INTRODUCTION
Esophageal squamous cell carcinoma (ESCC) accounts for most cases of esophageal cancer 
worldwide (1, 2). Even after complete surgical dissection, the prognosis of patients with 
ESCC is poor, with 5-year survival rates of 20 to 30%. Factors that contribute to this dismal 
prognosis include presence of locally advanced disease and undetected metastatic cancer at 
diagnosis. Because of the high rates of locoregional and distant failure, there is much interest 
in the combination of systemic chemotherapy and local surgical treatment. 
The potential benefi ts of preoperative chemotherapy include increasing the likelihood of 
curative resection by downstaging the tumor and rapidly improving tumor-related symp-
toms. It is also been thought that systemic chemotherapy could contribute to the eradication 
of micrometastases and circulating tumor cells. More recently, the importance of systemic 
disease control has been emphasized by new insights in the metastasizing process of can-
cer (3). For decades, the dissemination of cancer has been considered the fi nal stage in a 
deteriorating process. Now, there is accumulating evidence that dissemination already can 
occur at an early stage of the disease (4). In theory, the use of preoperative chemotherapy 
may therefore have a positive impact on survival of patients with esophageal cancer. Here, 
we report the design and long-term results of a randomized controlled trial in patients with 
resectable ESCC, comparing preoperative chemotherapy with cisplatin and etoposide fol-
lowed by surgery to surgery alone. 
MATERIALS AND METHODS
All eligible patients had histologically confi rmed squamous cell carcinoma of the intra-tho-
racic esophagus. Patients were deemed resectable if the disease was clinically limited to the 
locoregional area (tumor stage 1, 2 or 3; any nodal stage and no metastases). Patients with 
carcinoma of the distal esophagus and suspected celiac lymph nodes involvement (M1a) 
were also considered eligible for surgery. Patients had to be below 80 years of age, in ade-
quate physical condition (Karnofsky score >70) to undergo surgery and had to have adequate 
hepatic, renal and bone marrow function. Exclusion criteria were synchronous cancer, tumor 
localization in the cervical esophagus (upper border, <18 cm from the incisor teeth), severe 
cardiovascular or pulmonary disease. Patients with previous malignancies were eligible if 
more than 5 years had elapsed from diagnosis without evidence of tumor recurrence; excep-
tions were made for adequately treated basal cell cancer of the skin or carcinoma in situ of 
the cervix. Preoperative work-up included clinical examination, esophago-gastroscopy with 
biopsies, chest radiography, external ultrasonography of the cervical and upper abdominal 
region and computed tomography (CT) of the chest and abdomen. Radionuclide bone scans 
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were performed if indicated. Bronchoscopy was performed when the primary tumor was 
adjacent to the trachea or main stem bronchus and invasion was suspected. 
Central randomization took place at the Erasmus University Medical Center in Rotterdam (by 
trial coordinator TCK). Random assignment was stratifi ed by age (<50; 51-60; >60), gender 
(male; female), weight loss (kg) in the past four months (0-5; 6-10; >10) and length of the 
tumor (cm) as measured by esophago-gastroscopy (1-3; 4-6; 7-10; >10). Patients as signed 
to preopera tive chemother apy were treated with two cycles, followed by a clini cal re sponse 
evaluation. Response evaluation was done three to four weeks after the last cycle of che-
motherapy. Clinical response after chemo therapy was evaluated by esophago-gastroscopy 
and CT of the chest and abdomen. Tumor responses were assessed according to the World 
Health Organization (WHO) criteria (5). Complete absence of any evidence of malignant 
disease, including negative biop sies from the former tumor area, was defi ned as complete 
re sponse (CR). Partial response (PR) was defi ned as >50% reduction of tumor bulk, without 
the appearance of new lesions. Stable disease (SD) was defi ned as <50% reduction of tumor 
bulk, without the appearance of new lesions. Progressive disease (PD) was defi ned as >25% 
progression of tumor bulk or the appearance of new lesions. Patients with complete or par-
tial responses received two additional courses of chemotherapy, whereas non-re sponding 
patients (stable disease or progressive disease) were referred for immediate surgery. Patients 
with progressive disease (T4 or M1 disease) were treated palliative and observed for survival. 
Patients, who were randomly assigned to undergo surgery alone, underwent the operation 
as soon as possible. Patients who received chemotherapy were operated 4 to 6 weeks after 
the last treatment cycle. The study protocol was approved by the ethics com mittee of all 
partici pating institutions and written informed consent was obtained from all patients. 
Chemotherapy
Cisplatin, at a dose of 80 mg/m2, was given intra venously over 4 hours on day one of each 
cycle preceded and followed by adequate hydration. Etoposide, at a dose of 100 mg/m2, was 
administered intra venously over 2 hours on day 1 (before cisplatin) and day 2, followed by 
etoposide 200 mg/m2 orally on days 3 and 5. This course was repeated in week 4. In case of 
clinical response, two subsequent cours es of chemotherapy were administered in week 8 and 
11. All patients received prophylactic anti-nausea treatment with 5-HT 3 receptor antagonists 
during chemotherapy. Treatment related toxicities were measured according to the WHO 
recommenda tions (5). Re-treatment with the next cycle was permitted only if the absolute 
neutrophil count was at least 3,500/mm3, and the platelet count was at least 100,000/mm3. 
A delay of treatment of up to 2 weeks was permitted. In patients with severe toxic renal or 
neurological eff ects (≥ WHO grade 3) chemotherapy was stopped and patients were referred 
for surgery.
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Surgery and pathological examination
For carcinomas of the upper half of the intra-thoracic esophagus a right-sided thoracotomy 
was performed. For carcinomas of the lower half of the intra-thoracic esophagus a transhiatal 
esophagectomy was done. The tumor and its adjacent lymph nodes were dissected en bloc. 
The left gastric artery was transected at its origin, with resection of local lymph nodes. The 
continuity of the digestive tract was restored by means of gastric tube reconstruction or co-
lonic interposition with a cervical anastomosis. The tumor stage after resection was classifi ed 
according to the TNM classifi cation of the International Union Against Cancer (6). Resections 
were classifi ed as radical when microscopical examination revealed all margins to be free of 
tumor (R0). Resections were considered not radical, if microscopically examination showed 
tumor-positive circumferential margin (R1) or presence of macroscopic disease (R2).   
Follow-up
All patients were followed at an interval of three to four months during the fi rst year, every 
six months for the second year, and annually for up to 5 years post surgery. After 5 years, 
follow-up data were obtained by telephone from the patient or his/her family practitioner. 
Recurrence of disease was diagnosed on clinical grounds. However, whenever a relapse was 
suspected, radiologic, endoscopic, or histologic confi rmation was sought for. 
Loco-regional disease recurrence was defi ned as relapse at the primary site including the 
anastomosis or in regional lymph nodes. Distant disease recurrence was defi ned as distant 
lymph node sites or involvement of distant organs including lung, liver, bone, and subcuta-
neous tissue. 
Statistical analysis
The planned number of patients to be entered in the study was 80 for each treatment arm. 
With these numbers of pa tients the statistical power should be suffi  cient (power = 0.8; signifi -
cance 0.05) to detect an increase of the median survival from 10 to 18 months. 
Overall survival (OS) was calculated from the date of random assignment to date of death 
from any cause and surviving patients were censored at the date they were last known to be 
alive. Disease-free survival (DFS) was calculated from a landmark time of 6 months after date 
of randomization to allow for the diff erence in timing of surgery between the two treatment 
groups (7). In this analysis, events including macroscopically incomplete resection, local and 
distant recurrence, and death arising within the fi rst 6 months after random assignment were 
regarded as events at this landmark time. Survival curves are presented by the Kaplan-Meier 
method and treatment comparisons are by the log-rank test. 
Statistical analyses were performed using the SPSS statistical package (SPSS Inc., Chicago, 
IL, USA). Hazard ratios (HR) were calculated with the use of a Cox regression model including 
treatment alone (primary analysis) and after adjustment for baseline stratifi cation factors. 
Categorical data were compared with the use of chi-square test or Fisher’s exact test, with a 
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test for trend over ordered categories. All statistical comparisons were made with two-tailed 
tests and P values <0.05 were reported as signifi cant.
RESULTS
Between January, 1989, and January, 1996, 169 patients from six Dutch University Hospitals 
(Rotterdam, Amsterdam, Utrecht, Groningen, Nijmegen and Maastricht) were randomly as-
signed to either chemotherapy followed by surgery (CS group, N=85) or surgery alone (S 
group, N=84; Figure 1). An additional number of nine patients were included to adjust for 
study drop-outs. The majority of patients (N=122) were included by the Erasmus Medical 
Center (EMC), Rotterdam. From all participating centers, the EMC is the only hospital that col-
lected outcome data (prospectively) for all patients with esophageal cancer referred in time 
this study was performed. Between January, 1989, and January, 1996, 257 patients with ESCC 
were referred to the EMC. Of these, 183 patients were deemed eligible for surgical resection, 
of which 122 (67%) were included in this trial. The reasons why 61 (33%) patients were not 
randomized for this trial are not well documented. 
Figure 1. CONSORT Flow-diagram: random assignment, and compliance to the allocated treatment. CTX, 
chemotherapy
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Table 1 show that the two groups were similar in terms of age, sex, and performance status. 
Distribution according to weight loss and size of the tumor was also balanced. One patient, 
allocated to preoperative chemotherapy, had a tumor located in the cervical part of the 
esophagus (the reason why this patient was included and randomized remains unclear, even 
after retrospective analysis of the patient’s record). Preoperative staging by CT of the chest 
and the upper abdomen was performed in 149 patients (88%); two patients (1%) died before 
the planned CT scan; six patients (4%) were staged by endoscopic ultrasound, external ultra-
sonography of the cervical and upper abdominal region and chest radiography. From twelve 
patients (7%) no additional information on preoperative staging was available.  
Table 1. Patient’s characteristics
Total CS group S group  
Characteristics (N=169) (N=85 ) (N=84) P-value*
Age, years 0,73
<50 31 (18%) 17 (20%) 14 (17%)
51-60 54 (32%) 25 (29%) 29 (34%)
>60 84 (50%) 43 (51%) 41 (49%)
Median 60 60 60
  Range 35 - 79 35 - 76 37 - 79
Sex 0,9
Male 126 (75%) 63 (74%) 63 (75%)
  Female 43 (25%) 22 (26%) 21 (25%)  
Weight loss (% of normal weight) 0,24
<5 56 (33%) 30 (35%) 26 (31%)
6-10 40 (24%) 16 (19%) 24 (29%)
>10 51 (30%) 30 (35%) 21 (25%)
  Not recorded 22 (13%) 9 (11%) 13 (15%)  
Tumor length (cm) 0,17
<3 27 (16%) 14 (17%) 13 (16%)
4-6 69 (41%) 36 (42%) 33 (39%)
7-10 55 (32%) 22 (26%) 33 (39%)
>10 6 (4%) 5 (6%) 1 (1%)
  Not recorded 12 (7%) 8 (9%) 4 (5%)  
Location of the tumor 0,66
Cervical 1 (1%) 1 (1%) 0
Upper third 7 (4%) 3 (3%) 4 (5%)
Middle third 76 (45%) 38 (45%) 38 (45%)
Distal third 71 (42%) 34 (40%) 37 (44%)
  Not recorded 14 (8%) 9 (11%) 5 (6%)  
Karnofsky score* 0,53
70 - 80 125 (74%) 60 (71%) 65 (77%)
90 - 100 38 (22%) 21 (24%) 17 (20%)
  Not recorded 6 (4%) 4 (5%) 2 (3%)  
Abbreviations: CS, Chemotherapy followed by surgery; S, Surgery alone
* Comparisons were made by the chi-square test
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Chemotherapy
Of the 85 patients assigned to preoperative chemotherapy, 80 (94%) received chemotherapy; 
75 (88%) patients had two or more cycles and 5 patients (13%) received one cycle. The rea-
sons why no chemotherapy or only one cycle was given were patient’s refusal (N=3), death 
(N=1), tumor bleeding (N=3) and renal toxici ty grade III (N=1). Two patients allocated to 
preoperative chemotherapy, were directly lost to follow-up after randomization. Tracing back 
the original patient’s fi les was impossible; therefore, it is not clear if these two patients truly 
received chemotherapy followed by surgery. 
Clinical response evaluation after two cycles of chemotherapy showed 43 patients with 
stable or progressive disease. Partial response to chemotherapy was observed in 32 patients. 
Of these, 30 patients received two additional cycles of chemotherapy; one received one ad-
ditional cycle and one had three additional cycles of chemotherapy. Clinical response evalua-
tion after the additional cycles of chemotherapy showed six patients with complete response; 
20 patients had partial response; fi ve showed stable disease and one had progressive disease. 
Detailed data on chemotherapy related toxicity is not available. In the prior phase II trial a 
high rate of grade III and IV nausea (38%) and vomiting (20%) was observed, probably due to 
the fact that 5-HT3 receptor blockers were rarely given throughout the study period (8). All 
patients in the current trial received prophylactic anti-nausea treatment with 5-HT 3 receptor 
antagonists during chemotherapy. No grade III or IV nausea and vomiting were observed. 
The major non-hematological toxicity (grade III) was alopecia. Hematological toxicity grade III 
was observed in 23 patients (one renal, twenty-two hematological). Eight patients had grade 
IV hematological toxicity. 
Outcome of surgery
Surgery was performed in 76 CS and 82 S patients (Table 2). Median time from randomization 
to surgery was 14 days in the S group. In the CS group, the median time from randomization 
to surgery was 63 days (36-123) for patients who received two cycles of chemotherapy, and 
114 days (54-165) for patients who received additional treatment cycles. Four patients (5%) in 
the CS group and three patients (4%) in S group died within 30-days after surgery. 
Data on postoperative complications was available of 67/76 (88%) of patients in the CS group 
and 75/82 (91%) patient in the S group. The frequency of nonfatal postoperative events was 
closely similar in both groups (Table 2). However, pulmonary complications were signifi cantly 
more observed in the CS group (P =0.041). 
Esophagectomy was performed in 91% (69/76) in the CS-group and 85% (70/82) in the S-
group. In the CS group, six patients did not receive an esophagectomy because of tumor 
growth in adjacent structures (aorta or bronchial tree) and one had tumor positive celiac 
lymph nodes at laparotomy. In the S group, seven patients did not undergo surgical resection 
because of tumor encase ment of the aorta or the bron chial tree and fi ve due to tumor posi-
tive celiac lymph nodes at laparotomy. Of the 69 patients in the CS group who underwent 
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surgical resection, 71% had R0 resections, 25% had R1 resections, and 4% had R2 resections. 
Of the 70 patients in the S group who underwent surgical resection, 57% had R0 resections, 
29% had R1 resections, and 14% had R2 resections. Although more patients in the CS group 
had R0 resections as compared with the S group, no signifi cant diff erences was observed 
(P=0.09). However, there was a signifi cant diff erence between the number of R2 resections in 
both treatment arm (P=0.04). Also the number of patients with lymph node involvement (N1 
or M1a) did not diff er between both treatment arms (43 and 46% in the CS group and S group, 
respectively). In the CS group, the pathological complete response rate (pT0N0M0) was 7%. 
Table 2. Surgical details
      Total CS group S group  
      (N=169) (N=85) (N=84) P-value
Surgery done 0,083
Yes 158 (93%) 76 (90%) 82 (98%)
No 9 (5%) 7 (8%) 2 (2%)
  Not recorded 2 (2%) 2 (2%) 0  
Reason no surgery undertaken  
Died before surgery 3 (2%) 1 (1%) 2 (2%)
Progressive disease
Tumor unresectable 3 (2%) 3 (4%) 0
    Distant metastases 3 (2%) 3 (4%) 0    
Type of resection* 0,38
Transhiatal 113 (71%) 55 (72%) 58 (71%)
Transthoracic 20 (13%) 9 (12%) 11 (13%)
Type not recorded 5 (3%) 4 (5%) 1 (1%)
Other 1 (1%) 1 (1%) 0
  No resection performed 19 (12%) 7 (10%) 12 (15%)  
Postoperative deaths (within 30 days)* 7 (4%) 4 (5%) 3 (4%) 0,62
Non-fatal postoperative complications*           0,64
None 68 (43%) 30 (40%) 38 (46%)
Any 67 (42%) 33 (43%) 34 (41%)
  Not recorded 16 (10%) 9 (12%) 7 (9%)  
Type of non-fatal postoperative complications*,†  
Pulmonary 25 (16%) 17 (23%) 8 (10%) 0,048
Cardiac 6 (4%) 3 (4%) 3 (4%) 1,0
Anastomotic
Subclinical 10 (6%) 5 (7%) 5 (6%) 1,0
Clinical 7 (4%) 3 (4%) 4 (5%) 1,0
Chylothorax 7 (4%) 4 (5%) 3 (4%) 0,70
Bleeding 5 (3%) 3 (4%) 2 (2%) 0,67
Vocal-cord injury 22 (14%) 10 (13%) 12 (15%) 0,82
  Other 10 (6%) 4 (5%) 6 (7%) 0,75
Abbreviations: CS, Chemotherapy followed by surgery; S, Surgery alone
* Percentages based on total patients undergoing surgery.
† Nonfatal postoperative events; comparisons were made by the Fisher’s exact test
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Pattern of failure
The outcomes of treatments were considered according to fi ndings at operation and to pat-
terns of disease progression (fi rst disease-free survival event; Table 3). The rates of unresect-
able tumors or macroscopically incomplete resections were higher in the S group (P=0.23; 
P=0.05, respectively). The pattern of fi rst disease progression was similar between both 
treatment groups; in particular there was no clear trend toward fewer patients with distant 
metastases as fi rst site of relapse in the CS group. Ten patients treated with preoperative 
chemotherapy developed a second primary tumor; seven squamous cell carcinomas of head 
and neck, one pancreatic, one lung and one breast carcinoma. In contrast, four patients who 
underwent immediate surgical resection developed a second primary tumor, all squamous 
cell carcinomas of head and neck. 
Table 3. Nature of fi rst disease-free survival event
  CS group S group  
Event (N=85) (N=84) P-value*
Disease free 12 (14%) 7 (8%) 0,33
No surgery performed 7 (8%) 2 (3%) 0,17
No resection performed 7 (8%) 12 (14%) 0,23
Macroscopic residual disease 3 (3%) 10 (12%) 0,05
2nd Primary 10 (12%) 4 (5%) 0,16
Local recurrence 16 (19%) 21 (25%) 0,36
Distant metastases 5 (6%) 5 (6%) 1
Local recurrence and distant metastases 9 (11%) 10 (12%) 0,81
Death with cancer but site of failure not reported 5 (6%) 7 (8%) 0,57
Death from other or unspecifi ed cause 11 (13%) 6 (7%) 0,31
* Comparisons were made by the Fisher’s exact test
Overall and disease-free survival
At the time of analysis, the median follow-up was 15 months in the CS group and 14 months 
in the S group. In an intention-to-treat survival analysis, two patients that were directly lost to 
follow-up were censored one month after the date of randomization. The OS of all random-
ized patients (N=169) on the intention to treat basis is shown in Figure 2. The median overall 
survival in the CS group was 16 months, and in the S group 12 months. Overall survival was 
better in the CS group than in the S group (P=0.03, by the log-rank test; HR 0.71; 95%CI [0.51-
0.98]; Figure 2A). Survival at one year was 64% for those allocated to chemotherapy, 52% for 
those allocated to surgery alone; at two years 42% and 30%; 5-years, survival was 26% and 
17%, respectively. 
DFS is shown in Figure 2B. For disease free survival, 59 patients in the CS group and 40 pa-
tients in the S group remained for analysis after the landmark period of six months. In 6/59 
(10%) patients in the CS group the date of disease recurrence was not documented. In these, 
the date of disease recurrence was estimated four months earlier than the date of death 
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(in the CS group the median time between date of recurrence and date of death was four 
months). In the CS group, there is prolonged disease-free survival compared with the surgical 
resection alone group (P=0.02, by the log-rank test; HR 0.72; 95%CI [0.52-1.0]). 
Overall survival according clinical response to preoperative chemotherapy showed that pa-
tients with clinical partial or complete response (those who received three or more cycles of 
therapy) had signifi cantly better overall survival then those with stable or progressive disease 
(P=<0.001, by log-rank test; HR 0.38; 95%CI [0.23-0.65]). 
Figure 3 shows no clear evidence that eff ect of chemotherapy varied in accordance with age, 
sex or length of the tumor. In this subgroup analysis, it appeared that patients with substan-
tial weight loss (>10%) treated with preoperative chemotherapy had better overall survival as 
compared to those who received surgery alone. Possibly, patients allocated to chemotherapy 
and in a poor nutrition status (eg weight loss >10%) were more likely to receive nutritional 
support over a longer period of time as compared to patients that were allocated to sur-
gery alone. This could have led to a better preoperative condition of patients who received 
chemotherapy, which could possibly contribute to improved overall survival.  Furthermore, 
patients with a tumor located in the middle thoracic esophagus who received preoperative 
chemotherapy had better overall survival then patients who received surgery alone. The 
explanation for the observed survival benefi t in this subgroup of patients is unclear. 
Figure 2. 
A) Overall survival of all allocated patients. The distribution curves represent the results of an intention-
to-treat survival analysis involving all patients. Patients who received preoperative chemotherapy had a 
median survival of 16 months; in comparison, patients who underwent only surgery had a median survival 
of 12 months (P = 0.03 by the log-rank test). 
B) Disease-free survival of all patients from a landmark time of 6 months after date of randomisation (P = 
0.02 by the log-rank test).
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DISCUSSION 
The long-term results of this randomized controlled trial demonstrated a survival benefi t for 
preoperative chemotherapy followed by surgery in patients with ESCC, when compared with 
surgery alone. This study has only been reported in abstract form, which hampers interpreta-
tion of our fi ndings in context of other randomized trials (9). Why it took so long to report the 
design and results of this study is not completely understood. The main reasons are change 
Figure 3. Survival by characteristics at randomisation and post-treatment. Centre of each square indicates 
hazard ratio, and area of square the amount of information. Lines on either side indicate 95 CI.
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of personnel (the trial coordinator [TCK] moved to another hospital) and loss of interest in the 
used chemotherapeutic regime. Nevertheless, we believe that these results contribute to the 
ongoing debate about the optimal (preoperative) therapy for patients with ESCC.
The results of this study should be interpreted in the timeframe in which this study was 
performed. This study is one of the three largest randomized controlled trials among patients 
with ESCC treated with preoperative chemotherapy followed by surgery or surgery alone 
(10, 11). All these large randomized controlled trials were performed in the early ‘90s. The 
Medical Research Council (MRC) trial included most patients with esophageal cancer (533 
esophageal adenocarcinoma (EAC) and 247 ESCC patients) and demonstrated a signifi cant 
survival benefi t for the use of preoperative chemotherapy (P=.004) (11, 12). Another large 
and well-conducted randomized controlled trial among patients with esophageal cancer 
(236 EAC and 204 ESCC patients), by the North American Intergroup (RTOG Trial 8911 or USA 
Intergroup 113 trial; further called the Intergroup trial), demonstrated no signifi cant diff er-
ence in survival between patients treated with preoperative chemotherapy and those who 
received surgery alone (10, 13). In the light of the results of both trials, we discuss the design 
and results of the present study. 
As most randomized controlled trials performed in the early ‘90, this study refl ects the 
methods for diagnosis, staging, treatment delivery and outcome measurement that indicate 
clinical practice during that period. In the present study, the majority of patients (88%) un-
derwent preoperative staging by esophago-gastroscopy and CT scan of the chest and upper 
abdomen. The same preoperative staging methods were used in the Intergroup trial. In the 
MRC trial, however, there was no standardization of preoperative staging. These diff erences 
in preoperative staging could, by selection of diff erent populations of ESCC patients, contrib-
ute to diff erences in results between the trials. 
In the Intergroup trial as well as in the MRC trial the chemotherapeutic regime consists 
of cisplatin combined with fl uorouracil; in the present study cisplatin was combined with 
etoposide. The ratio for this combination of chemotherapeutic agents was deducted from 
trials among patients with non-small-cell lung cancer in which this regime had showed to 
be safe and eff ective (14). Furthermore, a phase II trial in patients with advanced ESCC had 
shown that the response rate equals that of other cisplatin-based regimes and that the toxic-
ity profi le was mild (8). Patients without clinical response to chemotherapy received a total 
preoperative dose of 160 mg/m2 cisplatin and 1000 mg/m2 etoposide. The dose of cisplatin 
is similar as compared with the MRC trial (160 mg/m2). Patients with clinical response to 
chemotherapy received total doses up to cisplatin 320 mg/m2 and etoposide 2000 mg/m2. 
In this subgroup of patients, the total preoperative dose of cisplatin was slightly higher as 
compared to the Intergroup trial (300 mg/m2). The compliance to chemotherapy was 88% 
(patients who received two or more of the planned cycles of chemotherapy). This is similar 
to 90% of the patients that received both treatment cycles in the MRC trial, but diff ered from 
the Intergroup wherein 71% of the patients received all of three planned cycles of chemo-
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therapy. It has been suggested that the higher dose of chemotherapy in the Intergroup trial 
was detrimental to patients who underwent esophagectomy. Other factors related to the 
chemotherapeutic regimes that could contribute to the diff erences in outcome between the 
three studies, are the use of chemoradiotherapy in a subset of patients in the MRC trial and 
the use of postoperative chemotherapy in a subgroup of patients in the Intergroup trial. 
In our study the majority of patients underwent a transhiatal esophagectomy. This type of 
resection is associated with lower morbidity (and mortality) than a transthoracic resection 
((15)). In the other trials, the type of surgical resection that has been performed is not clear 
(MRC trial) or the exact numbers are not described (Intergroup trial). The postoperative 
mortality rate (<30 days after surgery) in the current trial was 5% (4/76) in the CS group and 
4% (3/82) in the S group and diff ered not among both groups. These rates are similar as those 
observed in the Intergroup trial, with 6% postoperative mortality in both treatment arms. In 
contrast, the MRC trial reported much higher postoperative mortality rate of 10% in the CS 
group and 11% in the S group. 
In the present study surgery was performed in 89% and 98% of patients in the CS group 
and S group, respectively. Similar rates have been reported by the MRC trial, with surgery 
rates in the CS group of 92% and in the S group of 97%. In the Intergroup trial fewer patients 
underwent surgery, 80% of the CS group and 92% of the S group. The rate of microscopically 
tumor free resection margins (R0) in the CS group was 71%, as compared to 60% and 62% 
in the CS groups of the MRC and Intergroup trial, respectively. In the S group it was 57%, as 
compared to 54% and 59% in the S groups of the MRC and Intergroup trial, respectively. The 
diff erence in R0 resection rates between the CS group and the S group is likely to contribute 
to the observed survival benefi t for patients treated with preoperative chemotherapy (as 
showed by the MRC trial; P<0.001), however, this diff erence was not statistical signifi cant in 
the present study (P=0.086). 
The median survival time of the CS group was 16 months, compared to 17 and 15 months 
in the MRC and Intergroup trial, respectively. The median survival time of the S group was 
12 months, compared to 16 and 13 months in the Intergroup and MRC trial, respectively. 
It appears that the S group in our study had the worst survival outcome, but this may be 
due to patient selection. Both the MRC as Intergroup trial included more EAC than ESCC 
patients. Subgroup analysis of the MRC trial, including only ESCC patients, showed a median 
survival time of 11 months for patients who underwent surgery alone (12). Remarkably, in 
the subgroup analysis there is no signifi cant survival benefi t for ESCC patients treated with 
preoperative chemotherapy (P=0.1). 
In line with the results of the MRC and Intergroup trial, there was no signifi cant diff erence in 
pattern of failure between both treatment arms in our study. The rate of distant metastases 
was equal in both treatment groups. These fi ndings provide no evidence for the general hy-
pothesis that preoperative chemotherapy eliminates systemic micro-metastases. The results 
of this trial and the MRC trial suggest that the biologic eff ect of preoperative chemotherapy 
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seems to specifi cally infl uence the extent of surgery (12). In the present study, the incidence 
of incomplete resections was greater in the S group, but sites of fi rst recurrence (local or 
distant) were similar. Furthermore, at 6 months, the DFS advantage is established for the CS 
group (Fig 2A) and remains consistent throughout follow-up as the survival curves remain 
approximately parallel. This suggests that the eff ect of preoperative chemotherapy is to 
reduce tumor volume and increase the potential for curative resection. 
This study has its limitations. At fi rst, the preoperative staging was hampered by the absence 
of endoscopic ultrasonography at the beginning of our trial. Therefore, the clinical T- and 
N-stage were not used as stratifi cation parameters before randomization. Secondly, the miss-
ing data on two patients that underwent preoperative chemotherapy and the lack of some 
clinical characteristics of the patients refl ect the diffi  culty of obtaining all data more than 
twenty years after the trial was performed. At third, it should be noticed that we selected 
patients who showed clinical response to chemotherapy based on esophago-gastroscopy 
and CT scan of the chest and upper abdomen, for additional cycles of chemotherapy. How-
ever, we did not correlate clinical response to pathological response. Therefore, selection of 
this subgroup could also refl ect better prognostic characteristics of patients who respond to 
chemotherapy, rather than an eff ect of chemotherapy itself. 
CONCLUSIONS
In summary, this study reports a signifi cant survival benefi t for ESCC patients treated with 
preoperative chemotherapy. The chemotherapeutic regime used in this trial (etoposide and 
cisplatin) is not used anymore in treatment of patients with ESCC. Today, in our institution 
(EMC) the majority of patients with ESCC (and EAC) receive preoperative chemoradiotherapy 
(a combination of carboplatin and paclitaxel, and concurrent radiotherapy).  
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ABSTRACT
Background: The aim of this study was to determine whether clinical outcome after surgical 
resection of esophageal adenocarcinoma (EAC) or squamous cell carcinoma (ESCC) could be 
predicted by functional polymorphisms in diff erent proto-oncogenes and tumor suppressor 
genes.  
Methods: Six single nucleotide polymorphisms (SNPs) in the AURKA (rs2273535), ERBB2 
(rs1136201), MDM2 (rs2279744), CDH1 (rs5030625), CDKN2A (rs11515) and the TP73 
(rs2273953) gene were genotyped in a consecutive cohort of 346 esophageal cancer pa-
tients, who were underwent surgical resection with curative intent.  Associations with disease 
free survival (DFS) were analyzed with Kaplan Meier curves and Cox regression, adjusting for 
potential confounders.
Results: Univariate analysis showed no signifi cant associations between the tested polymor-
phisms and DFS in patients with EAC or ESCC.  However, in a multivariate analysis, patients 
with EAC carrying the heterozygous MDM2 (rs2279744) T/G genotype had signifi cantly 
improved DFS compared with patients carrying the wild-type genotype (adjusted hazard 
ratio (AHR) 0.63, 95% confi dence interval [CI] [0.45-0.88]). Patients with EAC harbouring the 
homozygous CDH1 (rs5030625) GA/GA genotype had a signifi cantly reduced survival as 
compared with patients carrying the wild-type genotype AHR 4.0, 95% CI [1.4-11]. 
Conclusions: In a large cohort of esophageal cancer patients, the MDM2 T/G and CDH1 GA/GA 
genotype confer risk of death in patients with EAC. These data suggests that inter-individual 
diff erences in germ-line DNA have an impact on DFS in patients with EAC.
Jurjen Boomstra bw.indd   112 03-10-11   15:45
113
MDM2 and CDH1 gene variants defi ne esophageal cancer outcome
INTRODUCTION
Many therapeutic options are used to treat esophageal cancer, but traditionally surgery is 
used most frequently to obtain locoregional control and long-term survival (1, 2). Compre-
hensive preoperative staging has improved selection of patients for potentially curative sur-
gery, however, many patients present with recurrent disease within two years after operation. 
The majority of these patients develop loco-regional recurrences, but also distant metastases 
(such as liver, lung, pleural and/or peritoneal disease recurrences) are common (3-5). Despite 
attempts to improve the outcome of patients with esophageal cancer, prognosis remains 
poor with a 5-year overall survival of 20-30% (5, 6).
Well-known prognostic factors for esophageal cancer are summarized in TNM staging (7, 
8). Although TNM parameters have the advantage of simplicity, they do not seem to com-
pletely refl ect the biologic diversity of esophageal cancer (9, 10). The true drivers of this 
clinical biologic diversity include the molecular aberrations of the cancer and the genetic 
make-up of the patient. In this respect, the study of host genetic variability off ers worthwhile 
potential to identify individuals that may have the best chance of survival. Single nucleotide 
polymorphisms (SNPs) in the germ-line are the most common type of host genetic variations. 
Gene-related functional SNPs can potentially lead to diff erences in protein expression and/or 
function. In this way, SNPs in proto-oncogenes and tumor suppressor genes can potentially 
alter the risk for metastatic or aggressive tumor, resulting in diff erences in clinical outcome.
Altered expression of the AURKA, ERBB2, MDM2, CDH1, CDKN2A and the TP73 proteins has 
been correlated to disease progression and clinical outcome in patients with esophageal can-
cer (11-17). In addition, polymorphisms with eff ects on protein function have been identifi ed 
in these proto-oncogenes and tumor suppressor genes (18-23). Based on these results, we 
postulated that functional SNPs in the AURKA (AURKA_NM_003600.2; rs2273535 c.449 T>A), 
ERBB2 (ERBB2_NM004448.2; rs1136201 c.655 A>G), MDM2 (MDM2_NM002392.2; rs2279744 
309 T>G), CDH1 (CDH1_NM004360.3; rs5030625 -347 G>GA), CDKN2A (CDKN2A_NM000077.3; 
rs11515 c.712 C>G), and the TP73 (TP73_NM005427.1; rs2273953 81 G>A) genes may serve as 
molecular markers for clinical outcome in patients with EAC or ESCC who underwent surgical 
resection.
PATIENTS AND METHODS
Between 1996 and 2001, a total of 632 consecutive patients with esophageal cancer were 
evaluated for surgery with curative intent at the Erasmus University Medical Center (Figure 
1). Outcome for all patients with esophageal cancer referred to our hospital are collected 
prospectively and stored in a database by a data manager. The data collected encompassed 
all relevant diagnostic tests, scheduled treatments, and pathology. All patients were staged 
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using esophago-gastroscopy with biopsies, ultrasonography of the cervical and upper ab-
dominal region and computed tomography (CT) of the thorax and abdomen. Endoscopic 
ultrasonography for evaluation of T-stage and nodal status was routinely performed. 
Surgery
For carcinomas of the upper half of the intra-thoracic esophagus a right sided thoracotomy 
was performed. For carcinomas of the lower half of the intra-thoracic esophagus a transhiatal 
esophagectomy was preferred. The tumor and its adjacent lymph nodes were dissected en 
bloc; however no extended lymph node dissection was performed. The continuity of the di-
gestive tract was restored by means of a gastric tube reconstruction or colonic interposition 
with a cervical anastomosis. Resections were considered radical (R0) if microscopically exami-
nation revealed no tumor tissue at or less than 1 mm from the circumferential, proximal, or 
distal margins. Pathological staging was done according to the UICC 6th edition. The tumor 
stage after resection was classifi ed according to the TNM classifi cation of the International 
Union Against Cancer. 
Figure 1. Flow-chart of patients with esophageal cancer referred to the ErasmusMC for treatment between 
January 1996 and December 2001. Patients excluded from the present study are shown. 
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SNP genotyping
To determine the individual genotype for each SNP, genomic DNA was extracted from frozen 
or formalin fi xed and paraffi  n-embedded tissues. Normal tissue was obtained from the resec-
tion specimens (i.e., tumor-negative lymph nodes or tumor-negative resection margins). All 
the archival tissue samples were used according to the code for adequate secondary use of 
tissue, code of conduct: “Proper Secondary Use of Human Tissue” established by the Dutch 
Federation of Medical Scientifi c Societies (http://www.federa.org).  
Polymerase chain reactions (PCR) were carried out in a volume of 15μl containing genomic 
DNA, 8.3μl H2O, 5μl Mg
2+free buff er, 25mM MgCl2, 0.3μl of 10mM deoxynucleotide triphos-
phates, 20pmol of each primer and 1U Taq polymerase (Promega, Madison WI, USA). PCR-
conditions were standardized at 35 cycles of 95oC for 45 sec, 61oC for 45 sec, 72oC for 30 sec, 
with a 10 min extension at 72oC for 10 min following the last cycle. PCR primers for EACh SNP 
are shown in Table 1. For the polymorphism in CDH1 (rs5030625) amplifi ed PCR products 
were visualized on a denaturing polyacrylamide gel. For detection of the restriction length 
polymorphisms in ERBB2 (rs1136201) and AURKA (rs2273535), PCR products were digested 
for 16h at the appropriate temperature with 10 units of restriction endonuclease BsmAI, MspI 
or APOI (Promega, Madison, WI, USA), respectively. The DNA fragments were separated us-
ing 3% agarose gels. The polymorphisms in CDKN2A (rs11515), MDM2 (rs2279744) and TP73 
(rs2273953) were genotyped by bi-directional sequencing. 
Statistical analysis
Data on follow-up were collected from the prospective database and the medical charts. All 
patients were followed at an interval of three to four months during the fi rst year, every six 
months for the second year, and then at the end of each year until 5 years after treatment. 
Recurrence or disease progression was diagnosed on clinical grounds. Whenever a relapse 
was suspected, radiologic, endoscopic, or histologic confi rmation was sought. Recurrent 
disease was classifi ed as local–regional (occurring in the upper abdomen or mediastinum) or 
distant (including cervical recurrences). 
Study end-point was disease free survival (DFS) that was defi ned as the time from surgery 
until recurrent disease or death from any cause. The Kaplan-Meier survival function and 
log-rank tests were used to assess clinical outcome in relation to patient’s characteristics 
and individual polymorphisms. Cox proportional hazard ratios for patients with EAC were 
adjusted for weight loss prior to operation, tumor length, presence of Barrett’s epithelium, 
radicality of resection and pathological tumor stage. For patients with ESCC, cox proportional 
hazard ratios were adjusted for location of tumor, resection type, post-operative TNM stage 
and radicality of resection. Statistical signifi cance was set at the 5% level. We did not adjust 
for multiple testing since each gene - outcome was prespecifi ed and of interest in itself.
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RESULTS
A total of 346 esophageal cancer patients underwent surgical resection with curative intent. 
Of these, 25 patients were excluded from the current follow-up study because no tissue sam-
ples were available (N=9), genotyping failure (N=3) or incomplete follow-up (N=13) (Figure 
1). Of the 214 EAC and 97 ESCC patients remaining for analysis, the majority were male, 85% 
in EAC and 60% in ESCC. Median age at time of diagnosis was 64 and 61years, respectively. 
Of all patients with EAC, 84% underwent primary surgery and 16% received preoperative 
chemotherapy with or without radiotherapy. In contrast, 71% of patients with ESCC received 
preoperative chemotherapy with or without radiotherapy and 29% underwent primary 
surgical resection (Table 2).  
SNP genotyping
Genotyping was complete in 95% to 100% of EAC and ESCC patients. The genotype distribu-
tions did not deviate from HWE (P>0.05). The genotype distribution of each SNP is listed in 
Table 3. Tumor stage distributions were similar across all SNP genotypes, and there was no 
association between genotypes and age at diagnosis, sex, weight loss, smoking status or 
preoperative treatment.  
DFS and pattern of disease recurrence
The median DFS of EAC patients was 14 months (range 0.07-138 months), and for ESCC 
patients 16 months (range 0.5-148 months).  At the time of analysis, 37 (17%) EAC and 27 
(28%) ESCC patients were alive with a median disease free survival time of 93 (range 62-
138 months) and 104 months (range 79-148 months), respectively. The pattern of disease 
recurrence is depicted in Table 3. Loco-regional recurrences were mediastinal or abdominal 
lymph node metastases, and recurrences in the gastric tube. Distant metastases were found 
in liver, lung, brain, bone, adrenal gland, pleura, peritoneum and skin. Recurrent disease after 
surgery was found in 138 (78%) EAC patients; 40 patients had loco-regional recurrence, 51 
had distant metastasis and 46 had both loco-regional recurrence and distant metastasis. One 
patient had disease recurrence, but the site of failure was not recorded. Diseases recurrences 
were found in 51 ESCC patients; 28 patients had loco-regional recurrence, 10 had distant 
metastasis and 10 had both loco-regional recurrence and distant metastasis. Three patients 
had disease recurrence, but site of failure was not recorded. 
SNP genotype and DFS
Univariate analysis showed no signifi cant associations between DFS in patients with EAC or 
ESCC and the genotype distributions of the AURKA, ERBB2, MDM2, CDH1, CDKN2A and the 
TP73 gene polymorphisms (Table 4). However, in a multivariate analysis, patients with EAC 
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Table 2. Survival According to Patients’ and Tumor Characteristics
    Patients with EAC (N=214)   Patients with ESCC (N=97)
Variable No. (%) Median DFS P-value   No. (%) Median DFS P-value
Age in years 0,23 0,33
<65 years 111 (52) 19 64 (66) 21
≥65 years 103 (48) 12 33 (34) 12
Gender 0,41 0,44
Male 182 (85) 16 58 (60) 15
Female 32 (15) 11 39 (40) 20
Weight loss before operation 0,013 0,47
No loss or <5% 127 (59) 19 46 (47) 15
5%-10% 35 (16) 11 31 (32) 27
>10% 32 (15) 8 17 (18) 10
Not recorded 20 (10) 10 3 (3) 5
Smoking status 0,98 0,70
Current smoker 54 (25) 14 43 (44) 16
No current smoker 146 (68) 15 47 (49) 20
Not recorded 14 (7) 8 7 (7) 4
Location of tumor 0,150 0,008
Upper one third thoracic 
esophagus 3 (3) 4
Middle one third thoracic 
esophagus 3 (1) 11 39 (40) 12
Lower one third thoracic 
esophagus 68 (32) 24 45 (47) 20
GEJ 86 (40) 13 10 (10) 60
Gastric cardia 57 (27) 12
Tumor length 0,028 0,27
0-2 34 (16) 41 8 (8) 37
3-4 52 (24) 15 24 (25) 10
4-5 67 (31) 14 31 (32) 24
≥6 46 (22) 9 25 (26) 9
Not recorded* 15 (7) 16 9 (9) 11
Barrett’s epithelium 0,086
No 127 (59) 12
Yes 87 (41) 24
Treatment 0,83 0,18
Surgery alone 180 (84) 14 28 (29) 8
Chemotherapy + Surgery 23 (11) 15 65 (67) 15
Chemoradiotherapy + Surgery 11 (5) 21 4 (4) Not reached
Resection type 0,83 0,042
Transhiatal 187 (87) 15 53 (55) 37
Transthoracic 27 (13) 9 44 (45) 11
Postoperative UICC stage <0,001 <0,001
Complete response 8 (4) 40 13 (13) Not reached
I 24 (11) 98 13 (13) 86
IIA 43 (20) 37 34 (35) 12
IIB 8 (4) 15 4 (4) 26
III 74 (34) 11 17 (18) 8
IV 57 (27) 7 16 (17) 4
Radicality of resection <0,001 <0,001
R0 141 (66) 34 65 (67) 41
R1 70 (33) 7 29 (30) 6
  R2 3 (1) 9     3 (3) 5  
Abbreviations: EAC, esophageal adenocarcinoma; ESCC, esophageal squamous cell carcinoma; DFS, disease 
free survival
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carrying the heterozygous MDM2 (rs2279744) T/G genotype had signifi cantly improved DFS 
compared with patients carrying the wild-type T/T genotype (adjusted hazard ratio (AHR) 
0.63, 95% confi dence interval [CI] [0.45-0.88], P = 0.007). The post-operative TNM stage of the 
tumor and the radicality of resection were also found important factors for disease free sur-
vival (HR 1.4, 95% CI [1.2-1.6], P < 0.0001 and HR 2.3, 95%CI [1.7-3.1], P < 0.0001 respectively). 
Also, patients with EAC harboring the homozygous CDH1 (rs5030625) GA/GA genotype had a 
signifi cantly reduced survival as compared with patients carrying the wild-type G/G genotype 
AHR 4.0, 95% CI [1.4-11], P = 0.008. In multivariate analysis, the post-operative TNM stage of 
the tumor and the radicality of resection were found important factors for disease free sur-
vival (HR 1.4, 95% CI [1.2-1.5], P < 0.0001 and HR 2.4, 95%CI [1.7-3.2], P < 0.0001 respectively).
DISCUSSION
In the present study, we determined the relationship between inter-individual DNA varia-
tions in six bona fi de proto-oncogenes and tumor suppressor genes and DFS in a large cohort 
of Caucasian patients with esophageal cancer. After adjustment for potential confounders, 
the variant genotypes of SNPs located in the promoter region of the MDM2 and CDH1 gene 
were signifi cantly associated with DFS in patients with EAC. 
The results of the present study showed a signifi cant survival benefi t for patients harboring 
the MDM2 T/G as compared with patients carrying the wild-type T/T genotype. The MDM2 
protein is a nuclear phosphoprotein that binds and inhibits the tumor suppressor TP53 as 
part of an autoregulatory negative feedback loop. The most intensively characterized MDM2 
polymorphism is the T309G promoter SNP located in the fi rst intron (MDM2_NM002392.2; 
rs2279744 309 T>G) (20). The G variant of this SNP is known to increase promoter-binding af-
 Table 4. Pattern of failure
    EAC ESCC
    (N=214) (N=97)
Alive 37 (17) 27 (28)
Nature of fi rst failure
Local recurrence 40 (29) 28 (55)
Distant metastases 51 (37) 10 (20)
Local recurrence and distant metastases 46 (33) 10 (20)
  Disease recurrence but site of failure not reported 1 (1) 3 (5)
Total deaths 177 (83) 70 (72)
Cause of death  
Cancer-related 138 (78) 51 (71)
Surgery-related 14 (8) 7 (11)
2nd Primary 5 (3) 6 (8)
  Death from other cause (not cancer related) 20 (11) 6 (8)
Abbreviations: EAC, esophageal adenocarcinoma; ESCC, esophageal squamous cell carcinoma
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fi nity, leading to up-regulation of MDM2, and consequent inhibition and down-regulation of 
the p53 pathway. Therefore, it could be expected that the variant MDM2 genotypes (T/G and 
G/G) are associated with adverse outcome in esophageal cancer patients (as showed in other 
cancer types) (24). However, the present study showed improved survival in patients with 
Figure 2. 
A) Kaplan Meier analysis of disease free survival (DFS) in patients with esophageal cancer, by histological 
subgroup
B) Kaplan Meier analysis of disease free survival in patients with esophageal adenocarcinoma, by MDM2 
(rs2279744)
C) Kaplan Meier analysis of disease free survival in patients with esophageal adenocarcinoma, by CDH1 
genotype (rs5030625)
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the MDM2 T/G genotype compared with the wild-type T/T genotype. A possible explanation 
for our fi ndings is provided by a large study in breast cancer patients that reported strong 
interaction between the MDM2 SNP status and tumor TP53 status, which appeared to modify 
the association between TP53 status and breast cancer survival (25). Among breast cancer 
patients with the wild-type MDM2 genotype (T/T), a mutant TP53 status and aberrant TP53 
expression in breast tumors was associated with poor survival. The tumor TP53 status was not 
associated with breast cancer survival among carriers of the variant MDM2 allele (T/G or G/G). 
Since TP53 is the most frequently mutated gene in EAC, it could be hypothesized that the 
tumors of most patients with the T/T genotype harbor a TP53 mutation, which could lead to 
a reduced survival as observed in the present study. In a previously well-conducted study, the 
known TP53 codon 72 Arg/Pro and MDM2 polymorphisms were genotyped in 300 patients 
with EAC and 63 patients with ESCC (26). As in concordance with the results of the present 
study, patients with EAC harboring the MDM2 T/G genotype had a borderline improved over-
all survival as compared with patients carrying the wild-type genotype (AHR for death 0.70 
[0.50-0.99]; P = 0.04). But unlike the present study, the MDM2 variant genotype did correlate 
with marked reduced survival in patients with ESCC. This could be due to diff erences in study 
samples size, population selection, tissue handling and genotyping methods. 
In this study, patients carrying the CDH1 GA/GA genotype had a signifi cantly reduced survival 
as compared with patients with the wild-type G/G genotype. However, it should be noted 
that only four EAC patients carried the GA/GA genotype, which may represents a chance 
fi nding. Nevertheless, this -347 G/GA insertion polymorphism located in the promoter of 
the cell-cell adhesion gene CDH1 (CDH1_NM004360.3; rs5030625 -347 G>GA) has been 
reported to suppress CDH1 gene expression and was found to be associated with familial 
gastric cancer and sporadic colorectal cancer (27). The GA-allele has been associated with 
signifi cant suppression of CDH1 promoter activity in colorectal and gastric cancer cell lines 
(27). It can be hypothesized that the GA-allele might enhance the progression of esophageal 
cancer by reducing CDH1 transcription resulting in a decrease in CDH1 protein expression 
and impairment of cell-cell adhesion. All four patients harboring the GA/GA genotype died of 
recurrent disease; three had loco-regional and distant metastasis; one had only locoregional 
disease recurrence. 
To our knowledge this is one of the fi rst studies that investigated the relationship between 
polymorphisms and esophageal cancer outcome. Here, we studied (only) six polymorphisms, 
whereas SNP-arrays can determine more than a million of SNPs in one sample.  Although 
this technique is widely used on blood or fresh frozen samples, it is not very suitable for 
FFPE tissue samples (our series consisted primarily of FFPE samples). Therefore, collection of 
blood samples or fresh frozen tissues samples of esophageal cancer patients is necessary and 
should become standard procedure in order to perform genome-wide association studies. In 
this study, the majority of polymorphisms were not associated with disease free survival after 
esophagectomy. It could be well that our study, among a relatively large population (N=346) 
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of esophageal cancer patients, failed to observe a diff erence due to under powering. Since 
esophageal cancer has a relatively low incidence, consortia (of multiple hospitals) are needed 
to validate these associations. 
Recurrent cancer is the leading cause of death in patients undergoing surgical resection (3-
5). Although treatment options for esophageal cancer recurrences are limited, it could be 
proposed that early detection of recurrent disease is desirable because aggressive treatment 
may result in prolonged tumor-free survival or occasional cure. In this light, our fi ndings could 
contribute to the identifi cation of patients who are at high or low risk for the development of 
disease recurrences. It can also be proposed that patients with a certain genetic constitution 
that is associated with a high chance of (distant) disease recurrence should be given systemic 
adjuvant treatment after surgical resection. Furthermore, identifi cation of polymorphisms as-
sociated with disease free survival could serve well as hypothesis generating for prospective 
studies that evaluate the prognostic signifi cance of germ-line variants.  
CONCLUSIONS
In summary, our results indicate that two of six investigated functional polymorphisms are 
associated with disease free survival in patients who underwent esophagectomy for EAC. 
Patients with EAC carrying the heterozygous MDM2 T/G genotype had two-fold reduced 
risk of disease recurrence and patients with the homozygous CDH1 GA/GA had a four fold 
increased risk of disease recurrence. Additional prospective studies are necessary to validate 
both associations and to study the prognostic signifi cance of both germ-line variants. 
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SUMMARY
Although the overall incidence and mortality of cancer in general in the world have de-
creased over the past two decades, both the incidence and mortality of esophageal cancer 
have increased. Despite improvements in diagnosis and treatment, the prognosis of patient 
with cancer of the esophagus remains poor, with 5-year survival rates of 10-25%. Nowadays, 
esophageal adenocarcinoma (EAC) account for most cases of esophageal cancer in the West-
ern world. Most fundamental and translational studies on EAC focus on the identifi cation 
of genetic alterations that underlie the metaplasia – dysplasia - adenocarcinoma sequence. 
This led to an increased knowledge on molecular mechanisms underlying EAC development; 
however translation of these results into improved patient’s care and prognosis has been 
delayed. 
The studies in the fi rst part of this thesis intend to authenticate human EAC cell lines and 
to establish a reliable set of cell lines that can serve as tool for translational research and 
biomedical discovery.  Studies in the second part address clinical aspects of esophageal 
cancer treatment. 
Human esophageal adenocarcinoma cell lines
Chapter 1 reviews the history EAC cell lines and their utility in translational research and bio-
medical discovery. In the past decade, the use of EAC cell lines has increased rapidly. One of 
the reasons for the widely use of these cell lines is the lack of appropriate animal models for 
EAC. Cell lines have proved useful in elucidating important signaling pathways (such as COX-
2 and NF-kB pathway) in response to gastro-duodenal refl ux. Furthermore, the EAC cell lines 
off er a robust model that can serve as a fi lter to fast track the most promising compounds and 
enables high-throughput science over short periods (such as c-MET and c-ERBB2 inhibitors).
However, the veracity of experimental results relies on the correct derivation of the cell line. 
Literature fi ndings indicate that up to one third of all cell lines have an origin other than 
that supposed. The most common cause is cross-contamination or misidentifi cation of cell 
lines. Cross-contamination of cell lines can be the result of poor culture technique when a 
cell line culture is contaminated with another cell line. Alternatively, cross-contamination 
of cell lines can be due to clerical error by mislabeling of cell cultures or frozen stocks. In 
Chapter 2 the authenticity of EAC cell line TE-7 was investigated. Examination of the TE-7 
cell line xenograft revealed the histology of a squamous cell carcinoma. This prompted us 
to investigate all 15 TE-cell lines, by short tandem repeat (STR) profi ling, mutation analyses 
and array-CGH. The results of these investigations revealed that the currently used TE-7 cell 
line is not an EAC but a squamous cell carcinoma cell line. Furthermore, cell line TE-7 shared 
the same genotype as TE-2, -3, -12 and -13. These fi ve TE cell lines should be regarded as one 
single squamous cell carcinoma cell line of an unknown origin. Recent admixture of the cell 
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lines in our institute was excluded by an independent investigator (Dr. Y. Morita-Fujimura) 
who confi rmed these results with the TE cell lines present in the cell line bank in Japan using 
a STR multiplex system. Since the TE-7 cell line is widely used for decades as a model for EAC 
we investigated independent TE-7 DNA samples obtained from diff erent laboratories. The 
earliest passage TE-7 DNA (1986) was obtained from the Japanese Cell Resource Centre for 
Biomedical Research (Dr. Y. Morita-Fujimura). All these TE-7 samples shared the same allelic 
pattern indicating that cross-contamination has occurred at the site of origin or in an early 
exchange of cell lines between laboratories. 
In Chapter 3, we verifi ed the authenticity of all available EAC cell lines. Despite intensive 
eff orts, only 14 permanent cell lines have been established: SEG-1, BIC-1, FLO-1, SK-GT-4, 
SK-GT-5, BE-3, KYAE-1, OE19, OE33, JH-EsoAd1, OACP4C, OACM5.1 and two newly established 
cell lines ESO26 and ESO51. In collaboration with the primary investigators who established 
the cell lines, the original EAC tissues for 13 of the 14 cell lines were traced in pathology 
archives and made available for study: only the original tissue for cell line BE-3 was not found. 
The availability of the primary tissues made it possible to authenticate these EAC cell lines by 
comparing the genotype of the cell line with the genotypes of patient’s normal and tumor 
tissue. Using short tandem repeat (STR) profi ling and TP53 mutation analysis, we proved 
that the frequently used cell lines SEG-1 and BIC-1 (in more than 100 publications) and the 
SK-GT-5 cell line are in fact cell lines from other tumor types. Comparison of the genotypes 
of SEG-1, BIC-1, and SK-GT-5 with genotypes available from databases revealed that SEG-1 is 
lung carcinoma (large cell lung cancer) cell line H460 and BIC-1 is colorectal adenocarcinoma 
cell line SW620. The genotype and TP53 mutation of the SK-GT-5 cell line matched with the 
tissue from which the cell line SK-GT-2 was derived indicating that cell line SK-GT-5 is actually 
the gastric fundus carcinoma cell line SK-GT-2. Experimental results based on these contami-
nated cell lines have led to ongoing clinical trials recruiting EAC patients, to more than 100 
scientifi c publications and at least three NIH cancer research grants and 11 US patents, which 
emphasizes the importance of our fi ndings. Even more important, we established a set of 
ten EAC cell lines that are derived from human EACs. All of these 10 verifi ed EAC cell lines, 
together with their genotyping information, will be deposited in publicly available cell line 
repositories in the United States, Europe, and Japan, to promote and facilitate future solid 
research on EAC.
These verifi ed EAC cell lines, together with a number of xenografts, are used in Chapter 4 to 
screen for homozygous deletions (HDs) by genome wide single nucleotide polymorphism 
(SNP) arrays. In total, 61 HDs (range 1-6 per sample) were detected and confi rmed by poly-
merase chain reaction. Besides HDs in common fragile sites and gene deserts, 27 HDs were 
located in gene containing regions. HDs were noted for known tumor suppressor genes in-
volved in EAC carcinogenesis, including CDKN2A, SMAD4 and CDH3/CDH1. To our knowledge, 
this is the fi rst report that describes inactivation of CDH3/CDH1 by homozygous deletion 
in EAC. Both genes play important roles in cell-cell adhesion. Loss of cell-cell adhesion by 
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deletion of CDH3/CDH1 is characterized by the round or spindle shaped appearance of the 
tumor cells and the capacity of the cells to disseminate (the primary tumors of cell line KYAE-
1 and xenograft P104x, metastasized to lung and liver, respectively). Furthermore, 22 new 
chromosomal regions were detected harboring potentially new tumor suppressor genes 
involved in EAC carcinogenesis. Two of these regions of homozygous loss, encompassing the 
ITGAV and RUNX1 gene, were detected in multiple samples indicating a potentially role in the 
carcinogenesis of EAC. To exclude culturing artifacts, these last two deletions were confi rmed 
by fl uorescent in situ hybridization in the primary tumors of which the involved cell lines 
and xenografts were derived. These fi ndings warrant further investigations on the role and 
function of these genes in EAC development. 
Clinical aspects of esophageal cancer treatment
In Chapter 5, the clinical outcome of 38 patients who received chemotherapy for carcinoma of 
the distal esophagus with celiac lymph node involvement was evaluated. The median overall 
survival of these patients was 16 months. Patients who received chemotherapy alone (N=12) 
had a median survival of 10 months; patients who underwent additional surgery (N=26) had 
a median survival of 26 months (log-rank p<0.001). Radical esophagectomy in patients with 
celiac lymph nodes <1.5 cm and clinical response to chemotherapy is likely to be achieved 
and contributes to prolonged survival. Besides radical surgical resection, complete or major 
pathological response to chemotherapy and a negative CLN status in the resection specimen 
are associated with long-term survival. Assessment of the CLN status after chemotherapy by 
EUS-guided FNA could be useful to further optimize selection of M1a patients who are most 
likely to benefi t from additional surgery.
Chapter 6 describes the long-term results of a large randomized controlled trial among 
patients ESCC who were assigned to chemotherapy followed by surgery or surgery alone. 
Patients who received preoperative chemotherapy with a combination of etoposide and 
cisplatin had signifi cantly improved survival as compared to patients who underwent sur-
gery alone (P=0.03). In contrast with the general hypothesis that chemotherapy eliminates 
systemic micro-metastases (and thereby reducing the rate of distant metastasis), the results 
of this trial indicate that the eff ect of preoperative chemotherapy is to reduce tumor volume 
and increase the potential for curative resection. The relevance of this study (even after more 
than twenty years) is illustrated by the fact that the up-dated results directly have been 
incorporated into a new meta-analysis on survival after neoadjuvant chemo(radio)therapy 
by the Australasian Gastro-Intestinal Trials Group (ahead of publication in Lancet Oncology).
In Chapter 7 we investigated the association between six functional polymorphisms, located 
in diff erent proto-oncogenes and tumor suppressor genes, and clinical outcome after surgi-
cal resection of EAC or ESCC. In a multivariate analysis, patients with EAC carrying the het-
erozygous MDM2 (rs2279744) T/G genotype had signifi cantly improved disease free survival 
as compared with patients carrying the wild-type genotype. Patients with EAC harbouring 
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the homozygous CDH1 (rs5030625) GA/GA genotype had a signifi cantly reduced survival 
as compared with patients carrying the wild-type genotype. Additional prospective studies 
are necessary to validate both associations and to study the prognostic signifi cance of both 
germ-line variants.
CONCLUSIONS
1) Cell line TE-7 is not an EAC but a squamous cell carcinoma cell line (Chapter 2).
2) Cell lines TE-2, -3, -7, -12 and -13 shared the same genotype and should therefore be 
regarded as one single squamous cell carcinoma cell line of an unknown origin (Chapter 2).
3) Cell lines SEG-1 and BIC-1 (used in more than 100 publications) and the SK-GT-5 cell line 
are in fact cell lines from other tumor types (Chapter 3).
4) Cell lines FLO-1, KYAE-1, SK-GT-4, OE19, OE33, JH-EsoAd1, OACP4C, OACM5.1, ESO26, and 
ESO51 are derived from human EACs (Chapter 3).
5) Homozygous deletion is one of the mechanisms by which the CDH1 and CDH3 gene is 
inactivated in EAC (Chapter 4).
6) Homozygous deletions aff ecting the ITGAV and RUNX1 gene implicate a tumor suppressor 
function of these genes involved in the carcinogenesis of EAC (Chapter 4).
7) Curative treatment of patients with carcinoma of the distal esophagus and celiac lymph 
node with preoperative chemotherapy is feasible and contributes in a subset of patients 
to prolonged survival (Chapter 5).
8) Preoperative chemotherapy with a combination of etoposide and cisplatin signifi cantly 
improved overall survival in patients with ESCC (Chapter 6).
9) Inter-individual diff erences in germ-line DNA have an impact on disease free survival of 
patients with EAC (Chapter 7).
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HUMAN ESOPHAGEAL ADENOCARCINOMA CELL LINES
In the fi rst part of this thesis, we focused on adenocarcinoma of the esophagus, the end-
stage of the metaplasia - dysplasia - adenocarcinoma sequence. EACs harbour all genetic 
abnormalities that have been acquired during this multi-step process. The genetic aberra-
tions identifi ed in EACs could subsequently be investigated in earlier stages of the disease. 
In this context, cell lines could be powerful tools in the search for genetic alterations that are 
potentially involved in the carcinogenesis of EAC (as for example shown in chapter 4 of this 
thesis). These pure populations of tumor cells make detection of genetic changes includ-
ing gene mutations, deletions, amplifi cations and translocations much easier. As reviewed 
in chapter 1 of this thesis, the use of EAC cell lines has emerged in the last fi ve years and 
contributed to our knowledge about signaling pathways and the eff ects of diff erent targeted 
therapies. However, there remains considerable skepticism in the scientifi c community about 
the validity resulting from the use of cell lines (1-4). Here, we will discuss four major concerns 
regarding the use of human cancer cells lines, namely genetic instability during long time 
culture, selective growth of subpopulations, lack of interaction with stroma and infl amma-
tory cells, and cross-contamination or misidentifi cation.
Genetic instability
Genomic instability is a characteristic of probably all human cancers. In sporadic cancers, the 
molecular basis of genomic instability remains unclear. There are various forms of genomic 
instability. Most cancers have a form that is called chromosomal instability (CIN) which refers 
to the high rate by which chromosome structure and number changes over time in cancer 
cells compared with normal cells (6). Almost all EAC arise in association with CIN that leads 
to gains, partial loss of chromosomal regions and complete loss of chromosomes (7-9). 
Chromosomal instability might be caused by TP53 mutations (10). Inactivation of TP53 leads 
to centrosome duplication and these abnormally amplifi ed centrosomes profoundly aff ect 
mitotic fi delity, resulting in unequal segregation of chromosomes. The presence of TP53 mu-
tations in all original tumors of which the EAC cell lines were derived, indicate that genomic 
instability is already present at time the cell lines were established. This inherent genomic 
instability and the considerably shorter population-doubling times of cell lines may result in 
an increased frequency of mutational changes during in vitro growth. Only a few studies have 
compared mutations identifi ed in long-cultured cell lines with their corresponding tumor 
tissues and demonstrated that the mutation rate during prolonged cell culture is limited (11, 
12). More recently, it has been shown that the process of cell culture in vitro does not lead to 
new clonal mutations into colorectal tumor cell lines (13). These fi ndings are in line with ob-
servations in cell lines with high rates of ongoing structural and/or numerical chromosomal 
instability. These cell lines showed a relative stability of the consensus karyotype over many 
generations (14). 
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Selective growth of subpopulations
Cancer cell lines constantly generate variants with phenotypic and/or genotypic diff erences 
from the predominant population caused by exposure to diff erent conditions (such as media, 
sera, trypsin, carbon dioxide levels, humidity and temperature). Similar to tumor cells in vivo, 
cells in vitro adapt their phenotype, by epigenetic (potentially reversible) or genetic mecha-
nisms (irreversible), to the conditions to which they are exposed (15). Variants that are better 
adapted to the new conditions are likely to be selected. 
Little is known about the principles guiding genetic evolution of established cancer cell 
lines (16). Based on the genetic heterogeneity of most in vivo tumors and ongoing genetic 
instability, it can be assumed that human cancer cell lines are genetically heterogeneous, 
consisting of multiple sub-clones that can be defi ned by their genomic profi les. This assump-
tion is needed to understand how cancer cell lines maintain and may change in genotype 
during in vitro growth. Under standard culture conditions the fi tness of cells having acquired 
novel chromosome aberrations, is too low to provide them a survival benefi t as compared to 
the bulk of cell line population. This could also explain the more or less fi xed chromosomal 
instability in tumor cell lines when cultured over time. However, in any situation when the 
proliferating population is reduced to a very small number of cells (infection, starvation, and 
other changes in growth conditions), any genetically distinct sub-population that normally 
would have a prevalence level too low for detection by genomic screening of the original 
bulk cell line can potentially re-grow into a new population with a diff erent genomic profi le 
than the original bulk. Although this phenomenon rarely occurs in generally fast proliferating 
cells, one example of a change in genotype is provided by breast cancer cell line MCF7. Analy-
ses of diff erent sub-lines from this cell line, obtained from three independent laboratories, 
showed that there was a wide genetic variation among the diff erent lines with respect to 
genomic imbalances and expression profi les (17).
Lack of interaction with stroma and infl ammatory cells
EACs are composed of an ecosystem of evolving subpopulations, competing and cooper-
ating with each other and other cells in their microenvironment. Cells in culture lack the 
architectural and cellular complexity of in vivo tumors, which include infl ammatory cells, 
vasculature, and other cellular and non-cellular components. Cell line xenografts facilitate 
research on the complex tumor cell –stromal interactions that facilitate tumor formation and 
progression. However, the requirement for immuno-compromised hosts, transplantation of 
human EAC cells into a foreign microenvironment and a lack of co-evolvement of the epithe-
lial and stromal compartments of the tumor hamper translation of results into the human in 
vivo situation. 
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Cross-contamination or misidentifi cation
In Chapter 2 & 3 of this thesis we verifi ed all to us known EAC cell lines, by comparing the 
genotype of the cell lines with that of their corresponding original tissue. Despite these 
eff orts, cross-contamination or misidentifi cation of EAC cell lines is a continuous threat. To 
prevent use of cross-contaminated cell lines, the short tandem repeat (STR) profi les of all 
EAC cell lines provide a useful reference against which investigators can compare data. DNA 
profi ling provides a simple, cheap and universal solution applicable to all human cell lines. 
With proper and regular monitoring for provenance and contamination, cell lines admixture 
can be largely prevented or detected and corrected before it causes major harm.
Genetic instability, artifi cial and selective growth of subpopulations, and lack of interaction 
with stromal components are inherent features of human cancer cell lines. These features 
should be taken into account when using cell lines as model for original tumors. The best 
prevention to overcome, at least partially, most of these concerns is to use early passage 
cell cultures. However, from most cell lines early passage cultures are not available and the 
available cell cultures have been passaged hundreds to thousands of times. So this precau-
tion may be applied in the future with newly generated cell lines but does not apply to the 
currently available cell lines from the past.
Future directions
Although studies of cancer lines have made major contributions to our understanding of EAC 
biology and pathogenesis and to translational research, several issues need to be addressed:
1) More EAC cell lines need to be established, especially cell lines from more diff erentiated 
tumors.
2) Eff orts should be undertaken to compare genetic alterations present in the cell lines with 
that in the original primary tumor. This could possibly add to the discussion on how close 
these EAC cell lines resemble the original in vivo tumors. 
3) New culture systems need to be developed to study the interaction between tumor cells 
and non-malignant cells (for example tumor-derived fi broblasts). 
4) Methods for the identifi cation, isola tion, and manipulation of the stem cell component of 
cultured tumor cells are needed. 
5) A public database is needed to store data from genome-wide sequencing studies on these 
cell lines that are currently available and/or expected in the near future.
CLINICAL ASPECTS OF ESOPHAGEAL CANCER TREATMENT
In the second part of this thesis, we addressed various aspects of esophageal cancer treatment 
(comprising squamous cell carcinoma and adenocarcinoma). Here, we focus on strategies 
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that translate molecular biology fi ndings to clinical applications which may improve treat-
ment and ultimately lead to prolonged survival of patients with cancer of the esophagus. 
Identifying patients at risk for esophageal cancer
Individual variation in cancer risk has not only been related to environmental factors, includ-
ing life style, but also to the genetic constitution. Sequence analysis of the human genome 
has disclosed a wide array of genetic variation, or polymorphisms, with the single nucleotide 
polymorphism (SNP) as the most common type. It has been speculated that combinations 
of polymorphisms or low-penetrance alleles can contribute to an individual’s cancer risk. 
Genome wide association studies (GWAS) are proving adept at identifying common variants 
contributing to the inherited component of common diseases (18, 19). In this respect, genome 
wide association studies GWAS, like the Rotterdam Study (a prospective, population-based 
cohort study), that link genetic variation across the entire human genome to for example 
esophageal cancer, could potentially lead to the identifi cation of set of polymorphisms that 
determine esophageal cancer risk. However, the number of esophageal cancer cases within 
these population-based studies is low (due to the relatively low incidence of esophageal 
cancer), which hampers the interpretation of diff erences in genotype distribution of SNPs 
between cases and controls. Therefore, consortia, like the Barrett’s and Esophageal Adeno-
carcinoma Consortium (BEACON; http://tlvnet.net/beacon/) that combines data from the 
vast majority of the well-designed largely population-based studies in the world, are needed 
to determine a genetic risk profi le for the development of esophageal cancer. 
Population wide screening for patients with undiagnosed Barrett’s esophagus could also 
contribute to early identifi cation of patients at risk for esophageal adenocarcinoma. However, 
there are major feasibility and cost implications for the wide-scale application of screening 
using the “gold standard” endoscopy. Recently, a non-endoscopic screening test for Barrett’s 
esophagus has been introduced (20, 21). A cytology sponge is compressed and encased in a 
gelatin capsule attached to a string. The capsule is swallowed and after a few minutes in the 
stomach, the liberated sponge is dragged back up the esophagus. Then the cytology sample 
is stained for trefoil factor 3, which is a strong diagnostic marker of esophageal columnar 
metaplastic cells (20). A pilot study in 96 controls and 36 BE patients found this test to have a 
sensitivity of 78% and a specifi city of 94% for presence of Barrett’s esophagus. Generalisation 
of these results requires a multicenter study to provide more robust estimates of diagnostic 
accuracy and to perform an in-depth cost eff ectiveness analysis. 
Improving patient selection for neoadjuvant chemo(radio)therapy
Because not all patients with advanced esophageal cancer do benefi t from preoperative 
chemo(radio)therapy, identifi cation of subsets of patients who do or do not benefi t from 
such a treatment is warranted. Identifying host genetic variations that contribute to drug 
effi  cacy and/or the risk of toxicity will provide a means with which to tailor therapy. Genetic 
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polymorphisms in genes involved in drug metabolism, drug targets, and DNA repair may 
contribute signifi cantly to the variability of drug effi  cacy and toxicity (22). It is quite rare 
that a SNP result in signifi cant changes in the ability to metabolize drugs. A combination 
of several SNPs in components of a ‘biological’ pathway or ‘pharmacological’ pathway 
might signifi cantly infl uence therapeutic response. Till now, all pharmacogenetic studies on 
esophageal cancer are hypothesis driven and used a candidate gene approach that links the 
eff ects of only one or a few SNPs in one or more specifi c gene(s) to clinical outcome (23, 24). 
New pharmacogenetic studies using a whole-genome approach are needed and may be a 
major step towards individualized cancer therapy. Phase III studies, as for example the CROSS 
trial (25), could be used to link genome-wide variants (using SNP arrays) to toxicity or drug 
effi  cacy. 
Understanding the molecular characteristics of a patient’s tumor can increase the likelihood 
of selecting the treatment most likely to help. Somatic acquired mutations in the cancer 
genome are most likely to aff ect drug response. High throughput technology has allowed 
the complete sequencing of the cancer genome (26, 27), and may be used to investigate 
the association between genome wide acquired alterations and response to chemo(radio)
therapy. This technique could be applied on preoperative tumor biopsies obtained from a 
cohort of patients that is randomized between surgery alone and preoperative chemo(radio)
therapy (such as the CROSS trial). However, these biopsies do not contain the large amounts 
of high quality DNA that is needed. With great advances in the technique of genome-wide 
sequencing, it is to be expected that sequencing on lower amounts of DNA will become 
feasible in the near future (28). 
Although gene-expression profi ling of esophageal cancer patients has led to the establish-
ment of a prognostic signature of four genes that is able to identify a cohort of patients with 
a 5-year survival of 58% (29), a reliable predictive gene expression signature for response 
to neoadjuvant treatment has not yet been identifi ed. It seems that response to anticancer 
drugs is more diffi  cult to predict by molecular tests than prognosis is. One of the main reasons 
for this diffi  culty is that resistance to anticancer agents can result from a variety of mecha-
nisms. Probably, there is not a single gene-expression profi le that correlates with resistance 
to a certain chemotherapeutic drug (30). However, in analogy with breast cancer (31), the 
esophageal cancer prognostic signature could also have a response prediction value.
Discovery of new cancer drugs in patients with esophageal cancer
An array of new high-throughput technologies (such as DNA sequencing, single-nucleotide 
polymorphism genotyping and gene expression microarrays) has been implemented in drug 
development eff orts. This led to the identifi cation of diff erent cellular targets for treatment of 
esophageal cancer (as reviewed by (32)). However, a drawback of most of these approaches 
is that the data generated are mostly correlative and therefore do not directly identify the 
driver event among the many genetic alterations present in each cancer. Functional genetic 
Jurjen Boomstra bw.indd   141 03-10-11   15:45
Chapter 9
142
approaches, such as loss-of-function genetic screens, could contribute to the identifi cation 
of completely new classes of drug targets for treatment of esophageal cancer (33). There are 
four approaches to fi nding novel drug targets through RNAi based genetic screens: pathway, 
phenotype, synthetic lethal and in vivo screens (34). These loss-of-function genetic screens 
in cultured cells (as for example esophageal cancer cell lines) use short hairpin RNA (shRNa) 
libraries to target a specifi c gene family or a subset of vectors comprising components of a 
molecular pathway of interest. shRNA are processed intracellularly into short duplex RNAs 
having short interfering RNA-like properties that lead to silencing of specifi c gene expression. 
A large population of cultured cells (as for example esophageal cancer cells) is infected with a 
shRNA library and divided into two populations. After suffi  cient numbers of cells are infected 
(in order to have the entire library of vectors represented) two replicate cell populations are 
created. One population is used as reference and left untreated, whereas the other popula-
tion is treated with the stimulus of interest. After phenotypic selection has taken place a bar 
code identifi er, specifi c for each shRNA, can be retrieved by PCR. Hybridization of the bar 
code identifi er to a specifi c microarray reveals the abundance of shRNA in both the reference 
and experimental population. This approach could lead to the identifi cation of druggable 
genes in esophageal cancer relevant pathways.  
Individualized cancer treatment for esophagel cancer patients
Probably the most tailored and individualized form of translational drug development is a 
“personalized tumorgraft” (35). Tumors taken from patients are implanted directly into im-
munodefi cient mice. Mice carrying the patient’s tumor are then treated with several cancer 
drugs and drug combinations to help identify which treatment regimen is likely to be most 
eff ective for the specifi c cancer. This concept has been proven successful in patients with 
pancreatic cancer (36), but could also be applied in patients with esophageal cancer. How-
ever, it is time consuming (the total process takes 6 – 8) and very costly (commercial prize of 
personalized tumorgrafts for one individual costs about $100,000 (37)). 
Very recently, a new initiative has been launched by the center for personalized cancer 
treatment (CPCT), a collaborative eff ort between the UMC Utrecht, Netherlands Cancer 
Institute, Amsterdam and the Erasmus MC, University Medical Center Rotterdam. The goal 
is to integrate exome sequencing of 2000 genes with clinical decision making. The muta-
tional profi le, which should be obtained within two weeks after a diagnostic biopsy has been 
taken, enables the clinician to determine which cancer therapy suits best for the individual 
patient. Also esophageal cancer patients will be included in this initiative. However, it is to 
be expected that it will take years to speed up the process of sequence analyses and to link 
mutation profi les to response on therapy. 
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SUMMARY AND CONCLUSIONS
Genome wide sequencing will speed up the identifi cation of genetic variants in the germline 
that can contribute to risk stratifi cation for esophageal cancer. For example, comparison of 
these variants between a control cohort of asymptomatic individuals (perfectly matched for 
age, smoking, alcohol, body-mass index and race) and a population with Barrett’s esophagus 
could result in the establishment of a genetic risk profi le for Barrett’s esophagus. This ge-
netic signature could contribute to the identifi cation of patients with undiagnosed Barrett’s 
esophagus, which ultimately reduce the morality of EAC. In parallel, such a profi le could also 
be established of patients with Barrett’s esophagus at low risk of neoplastic progression. This 
allows the identifi cation of the large proportion of people who are unlikely to develop EAC, 
allowing them to avoid or minimize worrisome, costly and risky endoscopic surveillance and 
interventions.
Genome wide sequencing shall also rapidly increase the number of genetic alterations de-
tected in the esophageal cancer genome. It will be challenging to distinguish “driver” muta-
tions underlying carcinogenesis of esophageal cancer from biologically neutral “passenger” 
alterations. Ultimately, identifi cation of these driver mutations will result in the development 
of biomarkers that can contribute to early disease detection. New chemotherapeutic drugs 
will be developed targeting these driver mutations. Because the failure rate following cur-
rent multimodality strategies remains unacceptably high, these targeting agents might be 
integrated rapidly into current clinical trial design. In addition, these essential genetic altera-
tions in the esophageal cancer genome could also serve as predictive markers for response 
to chemo(radio)therapy and allow treatment to be tailored to individual patients rather than 
the current ‘one fi ts all’ approach. 
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SAMENVATTING
Slokdarmkanker is de zevende aan kanker gerelateerde doodsoorzaak in de westerse wereld. 
De twee belangrijkste histologische subtypen van slokdarmkanker zijn adeno- en plaveise-
celcarcinomen. In Nederland worden per jaar ongeveer 1500 patiënten gediagnosticeerd 
met een tumor in de slokdarm (http://www.nationaalkompas.nl). De laatste decennia neemt 
de incidentie van slokdarmkanker snel toe. Dit is voornamelijk het gevolg van een stijging 
van het aantal patiënten met een adenocarcinoom van de gastro-oesophageale overgang 
(zowel het adenocarcinoom van distale slokdarm als de maagcardia). De belangrijkste risico-
factor voor het ontwikkelen van een adenocarcinoom van de gastro-oesophageale overgang 
is (langdurige) refl ux van maagzuur en duodenumsappen in de slokdarm. Dit kan uiteindelijk 
resulteren in een zogenaamde Barrett’s slokdarm, waarbij het normale plaveiselcel epi-
theel van de slokdarm is vervangen door metaplastisch cilindrisch epitheel. Er zijn sterke 
aanwijzingen dat adenocarcinomen van de gastro-oesophageale overgang ontstaan uit dit 
(premaligne) Barrett epitheel door een opeenstapeling van genetische veranderingen die 
in de loop van de tijd plaatsvinden. De meeste fundamentele en translationele studies heb-
ben als doel een beter inzicht te krijgen in de genetische veranderingen die ten grondslag 
liggen aan het adenocarcinoom van de slokdarm-maag overgang (het eindstadium van de 
“metaplasie – dysplasie – carcinoom” sequentie). Dit heeft geleid tot meer kennis over de mo-
leculaire mechanismen die ten grondslag liggen aan het ontstaan van een adenocarcinoom 
van de slokdarm, maar translatie van deze resultaten in betere patiënten zorg en prognose 
is vooralsnog beperkt.
De studies in het eerste gedeelte van deze thesis hebben als doel de authenticiteit van alle 
slokdarm adenocarcinoom cellijnen te onderzoeken om zo een betrouwbare set cellijnen 
samen te stellen die vervolgens kunnen worden gebruikt voor fundamenteel en translatio-
neel onderzoek. Studies in het tweede gedeelte van deze thesis richten zich op verschillende 
aspecten van behandeling van patiënten met slokdarmkanker. 
Slokdarm adenocarcinoom cellijnen
Er bestaan een aantal strategieën om de genetische veranderingen, die ten grondslag lig-
gen aan het ontstaan van tumoren, te bestuderen. Een van de manieren om meer inzicht te 
krijgen in welke genen betrokken zijn bij het de carcinogenese van adenocarcinomen van 
de slokdarm, is erfelijkheidsonderzoek (in analogie van het mamma- en coloncarcinoom). 
Echter het familiair voorkomen van slokdarm adenocarcinomen (al dan niet in combinatie 
met een Barrett’s slokdarm) is zelden gerapporteerd. Een ander strategie is het bestuderen 
van diermodellen, maar tot op heden is geen geschikt diermodel beschikbaar. Voor onder-
zoek naar de genetische achtergrond van dit type kanker is men voornamelijk aangewezen 
op (gearchiveerd) patiënten materiaal. Een veel gebruikt onderzoeksmodel, dat een directe 
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afgeleide is van patiënten materiaal, zijn cellijnen. Cellijnen zijn zeer geschikte modellen om 
de biologische en moleculaire afwijkingen van kankercellen te onderzoeken. Een belangrijk 
voordeel van menselijke kankercellijnen is de beschikbaarheid van pure populaties kanker-
cellen zonder bijmenging van normaal weefsel (dit vereenvoudigd de detectie van geneti-
sche afwijkingen). Een ander voordeel is dat cellijnen een oneindige bron van materiaal zijn. 
Daarnaast kunnen cellijnen dienen als model voor het testen van conventionele en nieuwe 
behandelingsmodaliteiten. Er kleven ook nadelen aan het gebruik van cellijnen, zoals de 
selectie van (kleine) subpopulaties van cellen die kan optreden tijdens het kweken waardoor 
de cellen niet meer representatief zijn voor de oorspronkelijke tumor. Daarnaast ontbreekt 
de interactie tussen tumorcellen en stromale cellen (zoals fi broblasten en macrofagen), die in 
de originele tumor wel aanwezig is.
In Hoofdstuk 1 wordt een overzicht gegeven van de beschikbare slokdarm adenocarcinoom 
cellijnen. Tevens wordt de bijdrage die deze cellijnen hebben geleverd aan de huidige inzich-
ten in de genetische achtergrond en de ontwikkeling van nieuwe behandelingsstrategieën 
beschouwd. Er zijn relatief weinig slokdarm adenocarcinoom cellijnen beschikbaar voor 
fundamenteel onderzoek. Hiervoor zijn een tweetal redenen. Ten eerste is het maken van 
cellijnen gebaseerd op trial en error, waarbij het continue zoeken is naar de ideale omstan-
digheden waaronder de kankercellen in vitro willen groeien. Het succes percentage is laag, 
waardoor het veel geld, tijd en inspanning kost om dergelijke cellijnen te maken. Ten tweede, 
de grote beschikbaarheid van tumorweefsel (uit receptiepreparaten) maakt dat onderzoekers 
veel minder gemotiveerd zijn om cellijnen te vervaardigen. In de afgelopen decennia hebben 
slokdarm adenocarcinoom cellijnen een belangrijke rol gespeeld bij functioneel onderzoek 
naar onco- en tumor suppressor genen zoals ERBB2 en c-MET. Daarnaast spelen ze een cruci-
ale rol bij het onderzoek naar de eff ecten van maagzuur en galzouten op tumor cellen. Zo is 
gebleken dat de arachidonzuur cascade (met als belangrijkste gen Cyclooxygenase-2 (COX-2) 
gen) geactiveerd is in tumorcellen die worden blootgesteld aan maagzuur en galzouten. 
De cellijnen vervullen ook een belangrijke rol bij de ontwikkeling van nieuwe “targeted 
therapies” voor het adenocarcinoom van de slokdarm (geneesmiddelen die zich richten op 
specifi eke afwijkingen in tumorcellen), zoals trastuzumab (monoclonaal antilichaam tegen 
ERBB2), bortezomib (proteasoomremmer) en alvocidib (cycline-dependent kinase remmer). 
Een belangrijke voorwaarde voor onderzoek met cellijnen is de authenticiteit van de ge-
bruikte cellijnen, omdat een verkeerde identiteit van een cellijn kan leiden tot het trekken 
van verkeerde conclusies. Uit onderzoek is gebleken dat ongeveer 30% van alle cellijnen in 
de wereld zijn afkomstig van een ander tumor type dan wordt verondersteld. Een van de 
oorzaken is cross-contaminatie tussen cellijnen. Dit kan het resultaat zijn van een slechte 
kweek techniek, waarbij de ene cellijn wordt gecontamineerd met een andere cellijn, maar 
ook van een administratieve fout waardoor bijvoorbeeld cellijnen verkeerd worden gelabeld. 
In Hoofdstuk 2 & 3 wordt de authenticiteit van alle slokdarm adenocarcinoom cellijnen 
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onderzocht. De belangrijkste technieken die hiervoor werden gebruikt zijn short tandem 
repeat (STR) profi ling, xenografi ng en mutatie analyse. Met behulp STR profi ling (ook wel 
DNA fi ngerprinting genoemd), een techniek die afkomstig is uit forensisch onderzoek, werd 
het genotype van de cellijnen bepaald. Het fenotype van de cellijnen werd onderzocht door 
cellen subcutaan te implanteren bij immuun-defi ciënte naakte muis (ook wel xenografting 
genoemd). Beschreven mutaties werden gebruikt om verschillen dan wel overeenkomsten 
aan te tonen tussen cellijnen. In Hoofdstuk 2 wordt de authenticiteit van slokdarm adenocar-
cinoom cellijn TE-7 onderzocht. Deze cellijn is onderdeel van een serie van 15 cellijnen welke, 
behoudens cellijn TE-7, allen afkomstig zijn van plaveiselcelcarcinomen van de slokdarm. Xe-
nografting van cellijn TE-7 toonde niet het fenotype van een adenocarcinoom, maar dat van 
een plaveiselcelcarcinoom. Daarnaast bleek dat het genotype van cellijn TE-7 overeenkomt 
met dat van vier andere TE-cellijnen. Ook mutatie analyse van het CYCLIND1 gen bevestigde 
dat vijf TE-cellijnen een dezelfde mutatie bezitten. Het gevonden genotype van cellijn TE-7 
werd bevestigd door een aantal andere laboratoria in de wereld, die ook cellijn TE-7 gebruik-
ten als in vitro model van het slokdarm adenocarcinoom. Op basis van deze gegevens kan 
worden geconcludeerd dat cellijn TE-7 niet representatief is voor een adenocarcinoom van 
de slokdarm. Een vroege passage van cellijn TE-7 toonde hetzelfde genotype als dat van de 
huidige TE-7 cellijn. Hieruit kan worden afgeleid dat cross-contaminatie waarschijnlijk al 
vroeg heeft plaatsgevonden, mogelijk al in het laboratorium waar de cellijn is gemaakt of in 
een vroege uitwisseling met andere laboratoria. 
In Hoofdstuk 3 wordt de authenticiteit van alle beschikbare slokdarm adenocarcinoom cel-
lijnen onderzocht. In samenwerking met de makers van de cellijnen werd van bijna alle cel-
lijnen het originele patiënten materiaal opgespoord. De beschikbaarheid van dit materiaal 
maakt het mogelijk het genotype van de cellijn te vergelijken met dat van de patiënt waar de 
cellijn van afgeleid is. Uit dit onderzoek blijkt dat twee veel gebruikte cellijnen SEG-1 en BIC-1, 
geen slokdarm adenocarcinoom cellijnen te zijn maar longkanker cellijn H460 en dikkedarm 
kanker cellijn SW620, respectievelijk. Daarnaast blijkt dat het genotype van SK-GT-5 overeen-
komt met dat van maag adenocarcinoom cellijn SK-GT-2. De onderzoeker die cellijnen SEG-1 
en BIC-1 heeft gemaakt bevestigde dat contaminatie heeft plaatsgevonden in de eerste pas-
sages van de cellijnen. Experimentele resultaten gebaseerd op het gebruik van deze gecon-
tamineerde cellijnen heeft geleid tot klinische trials bij patiënten met een adenocarcinoom 
van de slokdarm. Daarnaast zijn zeker drie Amerikaanse onderzoeksbeurzen, 11 patenten en 
meer de 100 wetenschappelijke publicaties gebaseerd op werk met deze cellijnen. Van tien 
slokdarm adenocarcinoom cellijnen kon worden bevestigd dat ze daadwerkelijk zijn afgeleid 
van het originele patiënten materiaal. Onder deze cellijnen bevinden zich twee nieuwe cel-
lijnen (ESO26 & ESO51). De gevalideerde cellijnen worden gedoneerd aan een internationale 
cellijn bank (ATCC) om het onderzoek naar slokdarm adenocarcinomen te stimuleren. 
Hoofdstuk 4 beschrijft het identifi ceren van homozygote deleties in de gevalideerde set 
slokdarm adenocarcinoom cellijnen en negen xenografts. Wanneer op beide chromosomen 
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een stuk erfelijk materiaal (DNA) weg is, spreekt men van een homozygote deletie (HDs). 
Gebieden die homozygoot gedeleteerd raken kunnen belangrijke aanwijzing zijn voor de 
lokalisatie van een tumor suppressor gen in dat betreff ende gebied. Cellijnen en xenografts 
zijn pure populaties kankercellen (dit in tegenstelling tot patiënten materiaal dat naast 
tumorcellen ook een substantiële hoeveelheid normale cellen bevat) waardoor detectie van 
HDs wordt vereenvoudigd. Single nucleotide polymorphism (SNP) arrays werden gebruikt 
om HDs in kaart te brengen. In totaal werden 61 HDs gedetecteerd, waarvan er 26 HDs ge-
legen waren in zogenaamde breekbare regio’s (gebieden die gevoelig zijn voor breuken in 
het DNA), acht HDs waren gelokaliseerd in gebieden zonder bekende genen. Van de 27 HDs 
in gebieden die een of meerdere genen bevatten, lagen er 22 in gebieden met potentieel 
nieuwe tumor suppressor genen. Twee van deze gebieden, die de genen ITGAV (coderend 
voor de integrin alpha chain V) en RUNX1 (coderend voor runt-related transcription factor 
1) gedeeltelijk omvatten, werden in meerdere sampels aangetoond. Deze twee deleties 
werden met behulp van fl uorescence in situ hybridization (FISH) gevalideerd in het origi-
nele patiënten materiaal waarvan de van de cellijnen en de xenografts waren afgeleid. De 
potentiële rol van deze twee nieuwe tumor suppressor genen in de carcinogenese van het 
adenocarcinoom van de slokdarm verdient verder vervolgonderzoek. 
Klinische aspecten van slokdarmkanker behandeling
De behandeling van patiënten met een slokdarm is complex en dient multidisciplinair te 
worden benaderd. Chirurgische resectie van de tumor is en blijft de belangrijkste hoeksteen 
voor curatieve behandeling voor patiënten zonder metastasen op afstand en/of lokaal irre-
sectabele tumorgroei. Tegenwoordig worden de meeste patiënten met alleen lokale tumor-
uitbreiding behandeld met preoperatieve chemotherapie of chemoradiotherapie. Ondanks 
dat wereldwijd (en ook in Nederland) steeds meer gekozen wordt voor preoperatieve behan-
deling met chemoradiotherapie, worden patiënten in bijvoorbeeld het Verenigd Koninkrijk 
standaard behandeld met preoperatieve chemotherapie. De gedachte is dat preoperatieve 
chemotherapie niet alleen bijdraagt aan loco-regionale controle, maar dat door het systemi-
sche eff ect ook micrometastasen kunnen worden geëlimineerd en zo kan bijdragen aan een 
verbetering van overleving.
In Hoofdstuk 5 wordt onderzocht wat de bijdrage is van preoperatieve chemotherapie 
bij patiënten met een tumor in de distale slokdarm en voor tumor verdachte lymfklieren 
nabij de truncus coeliacus. Volgens de huidige TNM classifi catie worden deze lymfklieren 
geduid als metastasen op afstand (M1a). Er bestaat discussie of deze categorie patiënten 
nog in aanmerking komt voor in opzet curatieve behandeling. In een periode van acht jaar 
werden 38 patiënten met een tumor in het distale gedeelte van de slokdarm en voor tumor 
verdachte lymfklieren nabij de truncus coeliacus (met een diameter >1.5cm) behandeld met 
preoperatieve chemotherapie. De mediane overleving van alle patiënten was 16 maanden. 
In totaal kwamen 26 patiënten in aanmerking voor resectie, waarbij in 68% een microscopi-
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sche radicale resectie werd bereikt. Histo-pathologisch onderzoek toonde bij 12 patiënten 
geen tumor aan in de lymfklier(en) nabij de truncus coeliacus. Bij acht van hen waren er 
duidelijk tekenen van tumor regressie (door chemotherapie). Deze acht patiënten hadden 
een signifi cant betere overleving dan patiënten met tumor positieve coeliacus klieren in 
het resectiepreparaat. Samenvattend, patiënten met een tumor in de distale slokdarm en 
voor tumor verdachte lymfklieren nabij de truncus coeliacus hebben een slechte prognose. 
Preoperatieve chemotherapie kan tumor positieve lymfklieren nabij de truncus coeliacus 
steriliseren en daarmee bijdragen aan een verlengde overleving na chirurgische resectie. 
Het opnieuw stadieren van deze lymfklieren na chemotherapie, door bijvoorbeeld endo-
echografi sch geleide punctie, zou kunnen bijdragen aan het selecteren van patiënten die het 
meeste voordeel hebben van chirurgische resectie. 
Hoofdstuk 6 beschrijft de lange termijn resultaten van een gerandomiseerde studie waar-
bij patiënten met plaveiselcelcarcinoom van de slokdarm werden gerandomiseerd voor 
preoperatieve chemotherapie gevolgd door chirurgische resectie of alleen chirurgische 
resectie. Deze studie laat een signifi cant overlevingsvoordeel zien voor patiënten die worden 
behandeld met preoperatieve chemotherapie (P=0.03). In tegenstelling tot de algemene 
veronderstelling dat chemotherapie systemische micrometastase elimineert, tonen de resul-
taten van deze studie, dat het eff ect van preoperatieve chemotherapie met name is gelegen 
in het reduceren van tumor-volume en dat daarmee de kans op een radicale resectie wordt 
vergroot. De resultaten van deze studie, die in de vroege jaren negentig is uitgevoerd, zijn 
alleen in abstract vorm beschreven. De vele citaties van dit abstract en de voort durende dis-
cussie over de waarde van preoperatieve chemotherapie in patiënten met slokdarmkanker 
maken dat publicatie van de studieopzet en de uiteindelijke resultaten nog steeds relevant 
zijn. 
In Hoofdstuk 7 wordt de relatie onderzocht tussen zes SNPs in verschillende onco- en 
tumorsuppressor genen en ziekte vrije overleving bij patiënten die chirurgische resectie on-
dergingen in verband met een adeno- of plaveiselcelcarcinoom van de slokdarm. De genen 
waarin de onderzochte polymorphismen gelokaliseerd zijn, zijn allen betrokken bij de carci-
nogenese van slokdarmkanker. De SNPs die werden geselecteerd, AURKA (rs2273535), ERBB2 
(rs1136201), MDM2 (rs2279744), CDH1 (rs5030625), CDKN2A (rs11515) en TP73 (rs2273953), 
leiden tot functionele veranderingen in genexpressie. In deze retrospectieve studie werden 
346 patiënten, die tussen 1996 en 2001 een resectie van de slokdarm ondergingen in verband 
met slokdarmkanker, gegenotypeerd. Muli-variate analyse (met correctie voor preoperatief 
gewichtsverlies, tumor lengte, aanwezigheid van Barrett’s epitheel, radicaliteit van de resec-
tie en het pathologische TNM stadium) toonde aan dat patiënten met een adenocarcinoom 
van de slokdarm die het heterozygote MDM2 T/G genotype bezitten een signifi cant langere 
ziekte-vrije overleving hebben dan patiënten met het wild-type MDM2 (T/T) genotype. Pati-
enten met een adenocarcinoom van de slokdarm en het homozygote CDH1 GA/GA genotype 
hadden een signifi cant kortere ziekte-vrije overleving vergeleken met patiënten met het 
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wild-type CDH1 G/G genotype. Deze studie laat zien dat de genetische constitutie van de 
patiënt ook medebepalend kan zijn voor de klinische uitkomst na na chirugische resectie. 
Ook hiervoor geldt dat het niet waarschijnlijk is dat een variant, maar een combinatie en een 
veelvoud van verschillende varianten, mede een bijdrage levert aan ziekte-vrije overleving. 
Additionele prospectieve studies zijn nodig om de beschreven associaties te valideren. 
CONCLUSIES
1) Cellijn TE-7 is geen slokdarm adenocarcinoom cellijn, maar een plaveiselcelcarcinoom 
cellijn (Hoofdstuk 2).
2) Cellijn TE-3, -3, -7, -12 en -13 hebben hetzelfde genotype en moeten daarom worden 
beschouwd als een plaveiselcel carcinoom cellijn van onbekende oorsprong (Hoofdstuk 2).
3) Cellijnen SEG-1, BIC-1 en SK-GT-5 zijn cellijnen van andere tumortypen (Hoofdstuk 3).
4) Cellijnen FLO-1, KYAE-1, SK-GT-4, OE19, OE33, JH-EsoAd1, OACP4C, OACM5.1, ESO26, and 
ESO51 zijn afkomstig van adenocarcinomen van de slokdarm (Hoofdstuk 3).
5) Homozygote deleties zijn een van de mechanismen waarop de genen CDH1 en CDH3 kun-
nen worden geïnactiveerd in adenocarcinomen van de slokdarm (Hoofdstuk 4).
6) Homozygote deleties van gebieden waarin de genen ITGAV en RUNX1 gelegen zijn wijzen 
op een mogelijke tumor suppressor rol van beide genen in de ontwikkeling van een 
adenocarcinoom van de slokdarm (Hoofdstuk 4). 
7) Patienten met een carcinoom in het distale deel van de slokdarm met uitzaaiingen naar 
lymfklieren rond de truncus coeliacus komen in aanmerking voor in opzet curatieve be-
handeling (Hoofdstuk 5).
8) Preoperatieve chemotherapie met een combinatie van etoposide en cisplatinum verbetert 
de overleving van patiënten met een plaveiselcelcarcinoom van de slokdarm signifi cant 
(Hoofdstuk 6).
9) Individuele verschillen in germ-line DNA hebben impact op de ziekte-vrije overleving van 
patiënten met een adenocarcinoom van de slokdarm (Hoofdstuk 7).
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is gekomen. Ook uw steun, nadat ik de keus had gemaakt geen chirurg te worden maar “MDL-
dokter”, waardeer ik enorm. Dat pleit enorm voor de brede kijk die u op de wereld heeft. 
Professor Oosterhuis, gewaardeerde promotor, tijdens mijn onderzoeksperiode hebben we 
misschien niet veel contact gehad, maar u hebt indirect een belangrijke rol gespeeld bij de 
totstandkoming van dit proefschrift. Voor het faciliteren van mijn onderzoek op de afdeling 
pathologie in het Josephine Nefkens Instituut ben ik u dank verschuldigd. Dank voor de 
bereidheid om mijn tweede promotor te zijn. 
Dr Dinjens, zeer gewaardeerde co-promotor, beste Winand, dank voor je geweldige begelei-
ding. Je bent een fantastisch mens, altijd enthousiast, stimulerend en inspirerend. De relaxte 
en ongedwongen sfeer op het laboratorium maakte dat ik mij er direct thuis voelde. In deze 
ambiance voelde ik mij ook altijd vrij om zeer laagdrempelig met nieuwe ideeën te komen, 
die altijd in alle openheid werden besproken en vaak ook leidde tot mooie resultaten. Met 
jouw geweldige contactuele eigenschappen heb je een enorm netwerk opgebouwd waar-
van je ook mij hebt laten profi teren. Heel veel dank hiervoor. Ondanks het feit dat je een 
“DNA-boer” bent, heb je ook veel oog voor ontwikkeling van andere velden van onderzoek. 
Jouw zorgvuldige wetenschappelijke manier van werken, namelijk het links en rechtsom 
bevestigen van je resultaten, neem ik graag van jouw over. Ontzettend bedankt voor drie 
onvergetelijke jaren van onderzoek! Hopelijk kunnen wij onze samenwerking op de een of 
andere manier blijven continueren.
De leden van de kleine commissie, prof. dr. Fodde, prof. dr. van Lanschot en prof. dr. Kuipers, 
dank voor uw bereidheid om dit dit proefschrift op zijn wetenschappelijke waarde te beoor-
delen en voor het geven van waardevol commentaar. De leden van de grote commissie, de 
hooggeleerden prof. dr. Bosman, prof. dr. Trapman en dr. Wijnhoven, dank voor uw bereid-
heid om zitting te nemen in de grote commissie. 
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Daarnaast wil ik de afdeling heelkunde van het Erasmus MC bedanken. Professor van Lan-
schot, uw komst naar het Erasmus MC heeft een extra impuls gegeven aan het onderzoek 
naar slokdarmkanker. De rechtdoorzee benadering van u waardeer ik zeer. Dr Wijnhoven, 
beste Bas, dank dat je als deskundige in mijn promotie commissie wilt plaatsnemen. Het is 
een eer te participeren in een onderzoekslijn waarin jij ook ooit bent begonnen. In dit kader 
wil ik ook dr Koppert bedanken, beste Linetta, dank voor je nuttige adviezen vooral in het 
begin van mijn onderzoekstijd. Beste Anneke, dank voor je begeleiding bij het administra-
tieve gedeelte van de laatste loodjes. Beste Conny, dank voor het altijd snel reageren op alle 
vragen die ik je stelde omtrent de Rotterdamse slokdarm database. 
Ook wil ik de afdeling pathologie bedanken. Allereerste alle medewerkers van het Dinjens 
laboratorium. Beste Ronald, jij verdient ook een ere plaats in dit dankwoord. Zonder jou inzet 
was dit boekje er (nog) niet geweest. Jouw technische kennis en kunde waren onmisbaar. 
Als ik weer iets (te) snel af wilde hebben was je altijd bereid om te helpen. Vooral je kennis 
van CGH, SNP-arrays en FISH is goud waard! Jou en Brechtje moet ik ook bedanken voor de 
wekelijkse slokdarmwerkbespreking, waarin alle resultaten en onderzoeksplannen de revue 
passeerden. Erik Jan, beste kamergenoot, dank voor de gezellige jaren. Jij staat altijd open 
voor een praatje of discussie over van alles en nog wat. Hoe jij je hoofd boven weet te houden 
in deze moeilijke tijden, verdient diep respect. Verder ben ik dank verschuldigd aan Erwin, 
Peggy, Lotte, Ina, Kees, en iedereen die ik nu vergeet. Ludo, dank voor al die blokjes die je 
voor mij hebt gesneden, je bent onnavolgbaar. Dank voor alle gezelligheid. Ook de mede-
werkers van de weefselbank, beste Peter, Monique en Bas, jullie hebben een grote bijdrage 
geleverd aan de illustraties in dit proefschrift door vele coupes voor mij in te scannen. Dank 
hiervoor! Beste dr. van Dekken, beste Herman, inmiddels al een tijdje vertrokken naar het 
Amsterdamse, maar ik ben je dank verschuldigd voor het beoordelen van alle coupes. 
Beste collega’s van het St. Antonius Ziekenhuis Nieuwegein, wat een fantastische jaren 
hebben we al gehad. Maatschap Interne Geneeskunde, beste dr. Geers, dank dat u mij de 
tijd heeft gegund om in mijn opleidingstijd dit proefschrift af te kunnen schrijven. Hulde 
voor jullie wetenschappelijke belangstelling. Gelukkig mag ik mij de komende twee jaar nog 
Antoniaan noemen!
Beste Bram, dank voor je lange trouwe vriendschap. Wat een mooie tijd hebben we samen 
gehad in het Groningse. Dit is een van mijn mijlpalen waar ik je graag bij wil betrekken. Super 
dat je mijn paranimf wil zijn!
Lieve Eric en Sylvia, ik had mij geen grotere betrokkenheid van mijn schoonouders kunnen 
wensen. Dank voor jullie nimmer afnemende belangstelling, maar bovenal jullie gezellig-
heid. Beste Olav, Nicole en Hugo, dank voor jullie warme belangstelling en gezelligheid. 
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Lieve Anneke en Sjoerd, lieve broer en zus, dank voor al jullie steun welke ik niet met een 
pen kan beschrijven. In dit kader mag ik natuurlijk Fabienne, Sebastiaan en Juna ook niet 
vergeten te bedanken voor jullie grenzeloze gastvrijheid en hartelijkheid. 
Lieve Ray, lieve pap, je hebt me altijd gesteund in al mijn keuzes ook in het schrijven van dit 
proefschrift, dank hiervoor. Lieve Annemarie, lieve mam, dank voor alles!
Lieve Hester, jou ben ik het meeste dank verschuldigd. De uren die je alleen hebt doorge-
bracht toen ik boven deze artikelen zat te schrijven, kun je nooit meer inhalen. Eindelijk is het 
zover: het boekje is af! Daarnaast verdien je alle credits voor het runnen van ons gezinnetje. 
Lieve Isabel en Esmee, mijn twee kleine meiden, jullie vader heeft vanaf nu alle tijd voor jullie. 
Ik heb jullie lief!
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CUR RICULUM VITAE
Jurjen Boonstra werd geboren op 31 mei 1981 te Holten. In 1999 behaalde hij zijn VWO 
diploma op scholengemeenschap de Waerdenborch te Holten. Datzelfde jaar werd hij uit-
geloot voor de studie Geneeskunde en startte met de studie Farmacie te Groningen. Na een 
aantal maanden kwam hij erachter dat zijn interesse toch echt bij patiënten ligt en niet bij 
het fabriceren van pillen, waarna hij zijn studie opgaf en ging werken (als verkoper in een 
buitensportzaak). Het jaar erop (2000) werd hij alsnog ingeloot voor de studie Geneeskunde 
aan de Rijksuniversiteit Groningen. Zijn keuze co-schap doorliep hij in het Erasmus Medisch 
Centrum Rotterdam op de afdeling gastro-intestinale chirurgie onder leiding van prof. dr. 
H. W. Tilanus. In augustus 2006 behaalde hij zijn doctoraal en arts-examen (dit laatste cum 
laude). Vanaf september 2006 t/m december 2009 was hij werkzaam als arts-onderzoeker op 
de afdeling heelkunde en pathologie (prof. dr. H. W. Tilanus en dr. W. N. M. Dinjens). Tijdens 
dit promotietraject verrichte hij twee maanden onderzoek naar de herkomst van slokdarm 
adenocarcinoom cellijnen in het laboratorium van de afdeling pathologie in het Memorial 
Sloan Kettering Cancer Center, New York (dr. L. Tang en prof. dr. D. Klimstra).  Gedurende 
de jaren groeide zijn voorkeur voor een meer beschouwend specialisme. Gezien zijn grote 
interesse in maag-, darm-, en leverziekten (MDL), koos hij ervoor om zich verder te speciali-
seren tot MDL-arts. Sinds 1 januari 2010 is hij gestart met zijn opleiding in het St. Antonius 
Ziekenhuis te Nieuwegein (dr. T. Geers/dr. R. Timmer) en zet zijn laatste 2 jaar van zijn MDL-
opleiding voort in het UMC Utrecht (prof. dr. P. D.  Siersema). 
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PHD P ORTFOLIO
Name PhD student: J. J. Boonstra PhD period: 2006-2011
Erasmus MC Department: Surgery/Pathology Promotor(s): Prof. Dr. H. W. Tilanus 
Research School: Molecular medicine Supervisor: Dr. W. N. M. Dinjens
1. PhD training
Year Workload
(Hours/ECTS)
General courses 
- Stralingshygiëne, deskundigheidsniveau 5B 2006 4.0 ECTS
- NIHES “Prognosis Research” 2007 4.0 ECTS
- NIHES “Survival Analysis for Clinicians” 2008 4.0 ECTS
Presentations
- Various presentation at research meetings of the department 
of surgery and pathology
2007-2010
Presentations (inter)national conferences
- European Society of Surgical Reseach, Rotterdam
“Mistaken identity of widely used esophageal carcinoma cell 
lines”
2007 1.0 ECTS
- International Society for Diseases of the Esophagus, Dublin
“Single Nucleotide Polymorphisms and Susceptibility for 
Cancer of the Esophagus and the Gastro-Esophageal Junc-
tion”
2007 1.0 ECTS
- 12th Molecular Medicine Day, Rotterdam 
“Mistaken identity of widely used esophageal adenocarci-
noma cell lines TE-7”
2008 1.0 ECTS
- Nederlandse Vereniging voor Gastroenterologie, Veldhoven
“The MDM2 promoter SNP285C/SNP309G haplotype is as-
sociated with susceptibility for oesophageal squamous cell 
carcinoma and related to poor overall survival after surgical 
resection”
2009 1.0 ECTS
Poster presentations
- Frontiers in Gastrointestinal Cancer, Keystone Symposia, Beijing
“Single nucleotide polymorphisms and susceptibilty for can-
cer of the esophagus and the gastro-esophageal junction”
2007 1.0 ECTS
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- Frontiers in Gastrointestinal Cancer: Keystone Symposia, 
Beijing
“Mistaken identity of widely used esophageal adenocarci-
noma cell lines TE-7”
2007 1.0 ECTS
- World Congress of the International Society for the Diseases 
of the Esophagus, Budapest
“Activation of the Mammalian Target of Rapamycin (mTOR) in 
Esophageal Adenocarcinoma”
2008 1.0 ECTS
- United Gastroenterology Week, Wenen
“Mistaken identity of widely used oesophageal adenocarci-
noma cell lines”
2008 1.0 ECTS
- United Gastroenterology Week, Londen
“The MDM2 promoter SNP285C/SNP309G haplotype is as-
sociated with susceptibility for oesophageal squamous cell 
carcinoma and related to poor overall survival after surgical 
resection”
2009 1.0 ECTS
- United Gastroenterology Week, Londen
“Inhibition of mTOR in oesophageal adenocarcinoma cell 
lines seems to be more eff ective in cell lines with aberrations 
in the PI3K/PTEN/mTOR pathway”
2009 1.0 ECTS
- United Gastroenterology Week, Barcelona
“Screening for homozygous deletions in verifi ed oesopha-
geal adenocarcinoma cell lines and xenografts”
2010 1.0 ECTS
- Nederlandse Vereniging voor Gastroenterologie, Veldhoven
“Verifi cation and Unmasking of Human Esophageal Adeno-
carcinoma Cell Lines”
2009 1.0 ECTS
Other
- Research stage at the Memorial Sloan Kettering Cancer 
Center (Prof. dr. Klimstra, Dr L. Tang), New York 
2008
2. Teaching
Other Year Workload
(Hours/ECTS)
- Supervising second year medical students 
Elective “Kanker: van kliniek tot diagnostiek”
2007 t/m 
2009
6x0.5 = 3.0 
ECTS
- Supervising third year medical students
“Research elective”
2008-2009 3.0 ECTS
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TA BLES
Appendix Table 1. Short tandem repeat profi le of eight short tandem repeat (STR) loci in the original tis-
sues from which the cell lines were derived*
No. of repeats at each locus
  Short tandem repeat locus
Primary tissue D21S11 TH01 D3S1358 FGA TPOX D8S1179 vWA D5S818
FLO-1 30, 32.2 6, 9.3 15 21 9, 11 13 16 12, 14
KYAE-1 NA 6, 9 15, 16 18 8 NA 14 10, 13
OE19 28, 30 8, 9 15, 18 23, 26 8 13, 15 17, 18 11, 14
OE33 NA 7, 8 18 22, 23 8, 11 10, 12 14, 17 11
OACM5.1 NA 6, 9.3 16, 17 22 8 13, 14 19 12
OACP4C NA 6, 9 14, 18 20 9, 11 13, 14 16 9, 12
SK-GT-4 NA 6, 9.3 16, 17 22, 23 8, 10 NA 17 12
JH-EsoAd1* NA 6, 7 NA NA 8, 9 NA 18, 19 11
ESO26 30, 31.2 9 15 21 7, 9 13, 14 14, 18 11, 12
ESO51 30, 33.2 9 15, 16 21, 22 8, 11 10, 11, 12 14, 15 11, 13
*JH-EsoAd1 repeat number at additonal STR loci; CSF1PO: 9, 10; Amelogenin: X, Y; D13S317: 11; D16S539: 
10, 12; D7S820: 10,12.  NA = no available data due to technical failure. 
Appendix Table 2. Short tandem repeat profi le of eight STR loci and TP53 mutations in the original tissue 
from which the cell lines SK-GT-2 and SK-GT-5 are derived
  Short tandem repeat locus TP53 mutation
Primary 
Tissue D21S11 TH01 D3S1358 FGA TPOX D8S1179 vWA D5S818    
SK-GT-2 29, 32,2 8, 9 15, 17 25, 26 9, 12 13, 15 15, 18 10, 12 c.524G>A 
SK-GT-5 28, 32.2 9 15, 17 21, 22 7, 8 10, 13 17 12   c.916C>T
Indicated are the repeat numbers at each locus 
The currently used EAC cell line SK-GT-5 (see supplementary table 1) is in fact the gastric 
fundus carcinoma cell line SK-GT-2
Jurjen Boomstra bw.indd   168 03-10-11   15:45
169
Appendices
A
pp
en
di
x 
Ta
bl
e 
3.
 C
lin
ic
al
 c
ha
ra
ct
er
is
tic
s 
of
 v
er
ifi 
ed
 h
um
an
 e
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a 
ce
ll 
lin
es
Ce
ll 
Li
ne
Ch
ar
ac
te
ris
tic
s
FL
O
-1
KY
AE
-1
OE
19
OE
33
OA
CM
5.
1
OA
CP
4C
SK
-G
T-
4
JH
-E
so
Ad
1
ES
O2
6
ES
O5
1
Pa
tie
nt
Se
x
M
al
e
M
al
e
M
al
e
Fe
m
al
e
Fe
m
al
e
M
al
e
M
al
e
M
al
e
M
al
e
M
al
e
Ag
e
68
60
72
73
47
55
89
66
56
74
Et
ni
cit
y
Ca
uc
as
ia
n
As
ia
n
Ca
uc
as
ia
n
Ca
uc
as
ia
n
Ca
uc
as
ia
n
Ca
uc
as
ia
n
Ca
uc
as
ia
n
Ca
uc
as
ia
n
Ca
uc
as
ia
n
Ca
uc
as
ia
n
Ne
oa
dj
uv
an
t t
re
at
m
en
t
No
CT
X/
RT
X
No
No
No
No
No
No
No
No
Tu
m
or Ba
rre
tt
No
No
No
Ye
s
Ye
s
No
Ye
s
Ye
s
No
Ye
s
Tu
m
or
 lo
ca
tio
n
Di
st
al
 EA
C
Di
st
al
 EA
C
Ca
rd
ia
 A
C
Di
st
al
 EA
C
Di
st
al
 EA
C
Ca
rd
ia
 A
C
Di
st
al
 EA
C
Di
st
al
 EA
C
Ca
rd
ia
 A
C
Di
st
al
 EA
C
No
da
l in
vo
lve
m
en
t
Ye
s
Ye
s
Ye
s
No
Ye
s
Ye
s
Ye
s
No
Ye
s
Ye
s
Di
st
an
t m
et
as
ta
se
s 
No
Ye
s (
Lu
ng
)
Un
kn
ow
n
Un
kn
ow
n
Ye
s (
Pl
eu
ra
)
Ye
s (
Pl
eu
ra
)
Un
kn
ow
n
Un
kn
ow
n
Ye
s (
Pl
eu
ra
)
Un
kn
ow
n
pT
NM
pT
2N
1M
0
pT
4N
1M
1
pT
3N
1M
x
pT
3N
0M
x
pT
3N
1M
1
pT
3N
1M
1
T2
N1
M
x
pT
3N
0M
x
pT
4N
1M
1
pT
3N
1M
x
Ce
ll l
in
e
Ye
ar
 o
f e
st
ab
lis
hm
en
t
19
91
20
01
19
93
19
93
19
96
19
96
19
89
19
97
20
00
20
00
Si
te
 o
f o
rig
in
Pr
im
ar
y  
Pl
eu
ra
l 
Pr
im
ar
y  
Pr
im
ar
y  
M
et
as
ta
tic
Pr
im
ar
y  
Pr
im
ar
y  
Pr
im
ar
y  
Pr
im
ar
y  
Pr
im
ar
y  
Tu
m
or
Eff
 u
sio
n
Tu
m
or
Tu
m
or
Ly
m
ph
 N
od
e
Tu
m
or
Tu
m
or
Tu
m
or
Tu
m
or
Tu
m
or
Xe
no
gr
af
t
No
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
TP
53
 m
ut
at
io
n
c.8
30
G>
T
c.4
55
C>
T
c.9
29
du
pA
c.4
04
G>
A
c.1
64
de
lC
c.5
74
C>
T
c.2
98
C>
T
c.7
97
G>
A
c.7
42
C>
T
c.5
24
G>
A 
 
 
 
 
 
 
c.7
43
G>
A
 
 
 
 
 
Id
en
tic
al
 T
P5
3 
m
ut
at
io
ns
 (G
en
ba
nk
 a
cc
es
si
on
 n
um
be
r A
F3
07
85
1.
1)
 w
er
e 
ob
se
rv
ed
 in
 a
ll 
ce
ll 
lin
es
 a
nd
 th
ei
r c
or
re
sp
on
di
ng
 p
rim
ar
y 
tis
su
es
.
A
bb
re
vi
at
io
ns
: C
TX
/R
TX
, C
he
m
or
ad
io
th
er
ap
y;
 d
is
ta
l E
AC
, D
is
ta
l E
so
ph
ag
ea
l A
de
no
ca
rc
in
om
a;
 C
ar
di
a 
AC
, C
ar
di
a 
Ad
en
oc
ar
ci
no
m
a.
Jurjen Boomstra bw.indd   169 03-10-11   15:45
170
Appendices
A
pp
en
di
x 
Ta
bl
e 
4.
 R
ep
or
ts
 in
 w
hi
ch
 o
nl
y 
ce
ll 
lin
es
 S
EG
-1
 a
nd
/o
r B
IC
-1
 h
av
e 
be
en
 u
se
d,
 w
ith
ou
t e
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a 
(E
AC
) c
el
l l
in
es
 a
nd
 o
r h
um
an
Au
th
or
s
Pu
bl
ica
tio
n 
da
te
Ce
ll 
lin
e(
s)
Es
op
ha
gu
s r
el
at
ed
 
ce
ll 
lin
e(
s)
O
th
er
 ce
ll 
lin
e(
s)
Xe
no
gr
af
t
St
ud
y t
itl
e
Av
iss
ar
, e
t a
l.
20
09
SE
G-
1
Bi
le
 ac
id
 o
r i
n 
co
m
bi
na
tio
n 
w
ith
 ac
id
 in
du
ce
s C
DX
2 
ex
pr
es
sio
n 
th
ro
ug
h 
ac
tiv
at
io
n 
of
 
th
e 
EG
FR
W
an
g,
 et
 al
.
20
08
SE
G-
1
TA
E2
26
, a
 d
ua
l in
hi
bi
to
r f
or
 FA
K 
an
d 
IG
F-
IR
, h
as
 in
hi
bi
to
ry
 e
ff e
ct
s o
n 
m
TO
R 
sig
na
lin
g 
in
 EA
 ce
lls
De
lg
ad
o,
 et
 al
.
20
08
SE
G-
1
So
ra
fe
ni
b 
tri
gg
er
s a
nt
ip
ro
lif
er
at
ive
 an
d 
pr
o-
ap
op
to
tic
 si
gn
al
s i
n 
hu
m
an
 EA
 ce
lls
W
u,
 et
 al
.
20
08
SE
G-
1
De
ox
yc
ho
lic
 ac
id
 in
du
ce
s t
he
 o
ve
re
xp
re
ss
io
n 
of
 in
te
st
in
al
 m
uc
in
, M
UC
2,
 vi
a N
F-
kB
 
sig
na
lin
g 
pa
th
w
ay
 in
 h
um
an
 EA
 ce
lls
Su
n,
 et
 al
.
20
08
SE
G-
1
EC
A-
10
9
An
tip
ro
lif
er
at
io
n 
an
d 
ap
op
to
sis
 in
du
ct
io
n 
of
 p
ae
on
ol
 in
 h
um
an
 e
so
ph
ag
ea
l c
an
ce
r 
ce
ll l
in
es
Pa
ta
er
, e
t a
l.
20
08
SE
G-
1;
 B
IC
-1
A5
49
; H
12
99
Ad
en
ov
ira
l e
nd
op
la
sm
ic 
re
tic
ul
um
-ta
rg
et
ed
 m
da
-7
/in
te
rle
uk
in
-2
4 
ve
ct
or
 e
nh
an
ce
s 
hu
m
an
 ca
nc
er
 ce
ll k
illi
ng
Ke
sw
an
i, e
t a
l.
20
08
SE
G-
1
So
ra
fe
ni
b 
in
hi
bi
ts
 M
AP
K-
m
ed
ia
te
d 
pr
ol
ife
ra
tio
n 
in
 a 
Ba
rre
tt’
s e
so
ph
ag
ea
l 
ad
en
oc
ar
cin
om
a 
Zh
an
g,
 et
 al
.
20
08
SE
G-
1
TE
-2
Tr
ea
tm
en
t o
f r
ad
io
re
sis
ta
nt
 st
em
-li
ke
 e
so
ph
ag
ea
l c
an
ce
r c
el
ls 
by
 an
 ap
op
to
tic
 g
en
e-
ar
m
ed
, t
el
om
er
as
e-
sp
ec
ifi 
c o
nc
ol
yt
ic 
ad
en
ov
iru
s
Kr
es
ty
, e
t a
l.
20
08
SE
G-
1
Cr
an
be
rry
 p
ro
an
th
oc
ya
ni
di
ns
 in
du
ce
 ap
op
to
sis
 an
d 
in
hi
bi
t a
cid
-in
du
ce
d 
pr
ol
ife
ra
tio
n 
of
 h
um
an
 e
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a c
el
ls
M
cF
ad
de
n,
 
et
 al
.
20
08
SE
G-
1;
 B
IC
-1
Co
rn
-d
er
ive
d 
ca
rb
oh
yd
ra
te
 in
os
ito
l h
ex
ap
ho
sp
ha
te
 in
hi
bi
ts
 B
ar
re
tt’
s 
ad
en
oc
ar
cin
om
a g
ro
w
th
 b
y p
ro
-a
po
pt
ot
ic 
m
ec
ha
ni
sm
s
W
an
g,
 et
 al
.
20
08
SE
G-
1
NI
H3
T3
SE
G-
1/
NI
H3
T3
Th
e 
ad
en
oc
ar
cin
om
a-
as
so
cia
te
d 
an
tig
en
, A
GR
2,
 p
ro
m
ot
es
 tu
m
or
 g
ro
w
th
, c
el
l 
m
ig
ra
tio
n,
 an
d 
ce
llu
la
r t
ra
ns
fo
rm
at
io
n
Si
, e
t a
l.
20
08
SE
G-
1
ST
AT
5 
m
ed
ia
te
s P
AF
-in
du
ce
d 
NA
DP
H 
ox
id
as
e 
NO
X5
-S
 e
xp
re
ss
io
n 
in
 B
ar
re
tt’
s 
es
op
ha
ge
al
 ad
en
oc
ar
cin
om
a c
el
ls
Ba
gu
m
a-
Ni
ba
sh
ek
a, 
et
 al
.
20
07
SE
G-
1;
 B
IC
-1
Se
le
ct
ive
 cy
clo
ox
yg
en
as
e-
2 
in
hi
bi
tio
n 
su
pp
re
ss
es
 b
as
ic 
fi b
ro
bl
as
t g
ro
w
th
 fa
ct
or
 
ex
pr
es
sio
n 
in
 h
um
an
 e
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a
Le
vy
, e
t a
l.
20
07
SE
G-
1
Ha
Ca
T; 
29
3T
; N
IH
3T
3
Ar
ka
di
a a
ct
iv
at
es
 Sm
ad
3/
Sm
ad
4-
de
pe
nd
en
t t
ra
ns
cr
ip
tio
n 
by
 tr
ig
ge
rin
g 
sig
na
l-
in
du
ce
d 
Sn
oN
 d
eg
ra
da
tio
n
Hu
, e
t a
l.
20
07
SE
G-
1
HE
T-
1A
 ; H
KE
SC
-1
; 
HK
ES
C-
2
Th
e 
pa
th
og
en
es
is 
of
 B
ar
re
tt’
s e
so
ph
ag
us
: s
ec
on
da
ry
 b
ile
 ac
id
s u
pr
eg
ul
at
e 
in
te
st
in
al
 
di
ff e
re
nt
ia
tio
n 
fa
ct
or
 C
DX
2 
ex
pr
es
sio
n 
in
 e
so
ph
ag
ea
l c
el
ls
Jurjen Boomstra bw.indd   170 03-10-11   15:45
171
Appendices
Au
th
or
s
Pu
bl
ica
tio
n 
da
te
Ce
ll 
lin
e(
s)
Es
op
ha
gu
s r
el
at
ed
 
ce
ll 
lin
e(
s)
O
th
er
 ce
ll 
lin
e(
s)
Xe
no
gr
af
t
St
ud
y t
itl
e
Hu
, e
t a
l.
20
07
SE
G-
1
HE
T-
1A
 ; H
KE
SC
-1
; 
HK
ES
C-
2
Pa
th
og
en
es
is 
of
 B
ar
re
tt 
es
op
ha
gu
s: 
de
ox
yc
ho
lic
 ac
id
 u
p-
re
gu
la
te
s g
ob
le
t-s
pe
cifi
 c
 
ge
ne
 M
UC
2 
in
 co
nc
er
t w
ith
 C
DX
2 
in
 h
um
an
 e
so
ph
ag
ea
l c
el
ls
Dv
or
ak
, e
t a
l.*
20
07
SE
G-
1
HE
T-
1A
; C
P-
D
Bi
le
 ac
id
s i
n 
co
m
bi
na
tio
n 
w
ith
 lo
w
 p
H 
in
du
ce
 o
xid
at
ive
 st
re
ss
 an
d 
ox
id
at
ive
 D
NA
 
da
m
ag
e:
 re
le
va
nc
e 
to
 th
e 
pa
th
og
en
es
is 
of
 B
ar
re
tt’
s o
es
op
ha
gu
s
Si
, e
t a
l.
20
07
SE
G-
1
hT
ER
T 
NS
E
NA
DP
H 
ox
id
as
e 
NO
X5
-S
 m
ed
ia
te
s a
cid
-in
du
ce
d 
cy
clo
ox
yg
en
as
e-
2 
ex
pr
es
sio
n 
vi
a 
ac
tiv
at
io
n 
of
 N
F-
ka
pp
aB
 in
 B
ar
re
tt’
s e
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a c
el
ls
Ch
ao
, e
t a
l.
20
07
SE
G-
1
SE
G-
1
3’
-d
eo
xy
-3
’-(
18
)F
-fl 
uo
ro
th
ym
id
in
e 
(F
LT
) p
os
itr
on
 e
m
iss
io
n 
to
m
og
ra
ph
y f
or
 e
ar
ly 
pr
ed
ict
io
n 
of
 re
sp
on
se
 to
 ch
em
or
ad
io
th
er
ap
y-
a c
lin
ica
l a
pp
lic
at
io
n 
m
od
el
 o
f 
es
op
ha
ge
al
 ca
nc
er
Dv
or
ak
, e
t a
l.
20
06
SE
G-
1
HE
T-
1A
Es
op
ha
ge
al
 ac
id
 e
xp
os
ur
e 
at
 p
H 
< 
or
 =
 2
 is
 m
or
e 
co
m
m
on
 in
 B
ar
re
tt’
s e
so
ph
ag
us
 
pa
tie
nt
s a
nd
 is
 as
so
cia
te
d 
w
ith
 o
xid
at
ive
 st
re
ss
Ra
ju
, e
t a
l.
20
06
SE
G-
1
Im
pr
ov
em
en
t o
f e
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a c
el
l a
nd
 xe
no
gr
af
t r
es
po
ns
es
 to
 
ra
di
at
io
n 
by
 ta
rg
et
in
g 
cy
cli
n-
de
pe
nd
en
t k
in
as
es
20
06
SE
G-
1
Ea
rly
 d
et
ec
tio
n 
of
 ch
em
or
ad
io
re
sp
on
se
 in
 e
so
ph
ag
ea
l c
ar
cin
om
a b
y 3
’-d
eo
xy
-3
’-3
H-
fl u
or
ot
hy
m
id
in
e 
us
in
g 
pr
ec
lin
ica
l t
um
or
 m
od
el
s
Fu
, e
t a
l.
20
06
SE
G-
1
HE
T-
1A
cA
M
P-
re
sp
on
se
 e
le
m
en
t-b
in
di
ng
 p
ro
te
in
 m
ed
ia
te
s a
cid
-in
du
ce
d 
NA
DP
H 
ox
id
as
e 
NO
X5
-S
 e
xp
re
ss
io
n 
in
 B
ar
re
tt 
es
op
ha
ge
al
 ad
en
oc
ar
cin
om
a c
el
ls
Li,
 et
 al
.
20
06
SE
G-
1;
 B
IC
-1
En
ha
nc
ed
 se
ns
iti
vi
ty
 to
 ch
em
ot
he
ra
py
 in
 e
so
ph
ag
ea
l c
an
ce
r t
hr
ou
gh
 in
hi
bi
tio
n 
of
 
NF
-k
ap
pa
B
Ja
isw
al
, e
t a
l.
20
06
SE
G-
1
hT
ER
T 
NS
E
Bi
le
 sa
lt 
ex
po
su
re
 in
cr
ea
se
s p
ro
lif
er
at
io
n 
th
ro
ug
h 
p3
8 
an
d 
ER
K 
M
AP
K 
pa
th
w
ay
s i
n 
a 
no
n-
ne
op
la
st
ic 
Ba
rre
tt’
s c
el
l li
ne
Ka
ss
is,
 et
 al
.
20
06
SE
G-
1;
 SK
-
GT
-5
A5
49
; C
AL
U-
6;
H2
37
3;
 
H2
05
2
De
pl
et
io
n 
of
 D
NA
 m
et
hy
ltr
an
sfe
ra
se
 1
 an
d/
or
 D
NA
 m
et
hy
ltr
an
sfe
ra
se
 3
b 
m
ed
ia
te
s 
gr
ow
th
 ar
re
st
 an
d 
ap
op
to
sis
 in
 lu
ng
 an
d 
es
op
ha
ge
al
 ca
nc
er
 an
d 
m
al
ig
na
nt
 p
le
ur
al
 
m
es
ot
he
lio
m
a c
el
ls
Sa
ro
si,
 et
 al
.
20
05
SE
G-
1
Ac
id
 in
cr
ea
se
s M
AP
K-
m
ed
ia
te
d 
pr
ol
ife
ra
tio
n 
in
 B
ar
re
tt’
s e
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a 
ce
lls
 vi
a i
nt
ra
ce
llu
la
r a
cid
ifi 
ca
tio
n 
th
ro
ug
h 
a C
l-/
HC
O3
- e
xc
ha
ng
er
vo
n 
Ho
lze
n,
 
et
 al
.
20
05
SE
G-
1;
 B
IC
-1
TT
Ro
le
 fo
r t
he
 d
ou
bl
e-
st
ra
nd
ed
 R
NA
-a
ct
iv
at
ed
 p
ro
te
in
 ki
na
se
 P
KR
 in
 A
d-
TN
F-
al
ph
a 
ge
ne
 th
er
ap
y i
n 
es
op
ha
ge
al
 ca
nc
er
Sh
am
m
as
, e
t a
l.
20
05
SE
G-
1
Te
lo
m
er
as
e 
in
hi
bi
tio
n 
by
 si
RN
A 
ca
us
es
 se
ne
sc
en
ce
 an
d 
ap
op
to
sis
 in
 B
ar
re
tt’
s 
ad
en
oc
ar
cin
om
a c
el
ls:
 m
ec
ha
ni
sm
 an
d 
th
er
ap
eu
tic
 p
ot
en
tia
l
Jurjen Boomstra bw.indd   171 03-10-11   15:45
172
Appendices
Au
th
or
s
Pu
bl
ica
tio
n 
da
te
Ce
ll 
lin
e(
s)
Es
op
ha
gu
s r
el
at
ed
 
ce
ll 
lin
e(
s)
O
th
er
 ce
ll 
lin
e(
s)
Xe
no
gr
af
t
St
ud
y t
itl
e
Vo
na
-D
av
is,
 
et
 al
.
20
05
SE
G-
1;
 B
IC
-1
M
AP
K 
an
d 
PI
3K
 in
hi
bi
tio
n 
re
du
ce
s p
ro
lif
er
at
io
n 
of
 B
ar
re
tt’
s a
de
no
ca
rc
in
om
a i
n 
vi
tro
Vo
na
-D
av
is,
 
et
 al
.
20
04
SE
G-
1
Pr
ot
eo
m
ic 
an
al
ys
is 
of
 SE
G-
1 
hu
m
an
 B
ar
re
tt’
s-a
ss
oc
ia
te
d 
es
op
ha
ge
al
 ad
en
oc
ar
cin
om
a 
ce
lls
 tr
ea
te
d 
w
ith
 ke
yh
ol
e 
lim
pe
t h
em
oc
ya
ni
n
M
cF
ad
de
n,
 et
 al
.
20
04
SE
G-
1;
 B
IC
-1
Pe
pt
id
e Y
Y 
in
hi
bi
ts
 th
e 
gr
ow
th
 o
f B
ar
re
tt’
s e
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a i
n 
vi
tro
So
uz
a, 
et
 al
.
20
04
SE
G-
1
Ac
id
 in
cr
ea
se
s p
ro
lif
er
at
io
n 
vi
a E
RK
 an
d 
p3
8 
M
AP
K-
m
ed
ia
te
d 
in
cr
ea
se
s i
n 
cy
clo
ox
yg
en
as
e-
2 
in
 B
ar
re
tt’
s a
de
no
ca
rc
in
om
a c
el
ls
To
rq
ua
ti,
 et
 al
.
20
04
SE
G-
1
RU
NX
3 
in
hi
bi
ts
 ce
ll p
ro
lif
er
at
io
n 
an
d 
in
du
ce
s a
po
pt
os
is 
by
 re
in
st
at
in
g 
tra
ns
fo
rm
in
g 
gr
ow
th
 fa
ct
or
 b
et
a r
es
po
ns
ive
ne
ss
 in
 e
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a c
el
ls
Ja
isw
al
, e
t a
l.
20
04
SE
G-
1
Bi
le
 sa
lt 
ex
po
su
re
 ca
us
es
 p
ho
sp
ha
tid
yl-
in
os
ito
l-3
-k
in
as
e-
m
ed
ia
te
d 
pr
ol
ife
ra
tio
n 
in
 a 
Ba
rre
tt’
s a
de
no
ca
rc
in
om
a c
el
l li
ne
M
oo
re
, e
t a
l.
20
04
SE
G-
1;
 B
IC
-1
SK
-G
T-
4
AG
S-
B;
 A
R4
2J
; 
CH
O;
 G
B
Ga
st
rin
 st
im
ul
at
es
 re
ce
pt
or
-m
ed
ia
te
d 
pr
ol
ife
ra
tio
n 
of
 h
um
an
 e
so
ph
ag
ea
l 
ad
en
oc
ar
cin
om
a c
el
ls
Vo
na
-D
av
is,
et
 al
.
20
04
SE
G-
1;
 B
IC
-1
KY
SE
-1
50
; K
YS
E-
41
0
An
tip
ro
lif
er
at
ive
 an
d 
ap
op
to
tic
 e
ff e
ct
s o
f r
of
ec
ox
ib
 o
n 
es
op
ha
ge
al
 ca
nc
er
 in
 vi
tro
Sh
am
m
as
, e
t a
l.
20
04
SE
G-
1;
 B
IC
-1
Gr
ow
th
 ar
re
st
, a
po
pt
os
is,
 an
d 
te
lo
m
er
e 
sh
or
te
ni
ng
 o
f B
ar
re
tt’
s-a
ss
oc
ia
te
d 
ad
en
oc
ar
cin
om
a c
el
ls 
by
 a 
te
lo
m
er
as
e 
in
hi
bi
to
r
M
or
ga
n,
 et
 al
.
20
04
SE
G-
1
In
 vi
tro
 ac
id
 e
xp
os
ur
e 
ha
s a
 d
iff 
er
en
tia
l e
ff e
ct
 o
n 
ap
op
to
tic
 an
d 
pr
ol
ife
ra
tiv
e 
pa
th
w
ay
s i
n 
a B
ar
re
tt’
s a
de
no
ca
rc
in
om
a c
el
l li
ne
So
m
as
un
da
r,
et
 al
.
20
03
SE
G-
1;
 B
IC
-1
Le
pt
in
 st
im
ul
at
es
 e
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a g
ro
w
th
 b
y n
on
ap
op
to
tic
 m
ec
ha
ni
sm
s
M
cF
ad
de
n,
 et
 al
.
20
03
SE
G-
1;
 B
IC
-1
Ke
yh
ol
e 
lim
pe
t h
em
oc
ya
ni
n,
 a 
no
ve
l im
m
un
e 
st
im
ul
an
t w
ith
 p
ro
m
isi
ng
 an
tic
an
ce
r 
ac
tiv
ity
 in
 B
ar
re
tt’
s e
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a
Jo
e, 
et
 al
.
20
03
SE
G-
1;
 B
IC
-1
 
HC
E-
7
Ex
isu
lin
d 
an
d 
CP
24
8 
in
du
ce
 g
ro
w
th
 in
hi
bi
tio
n 
an
d 
ap
op
to
sis
 in
 h
um
an
 e
so
ph
ag
ea
l 
ad
en
oc
ar
cin
om
a a
nd
 sq
ua
m
ou
s c
ar
cin
om
a c
el
ls
Gu
pt
a, 
et
 al
.
20
03
SE
G-
1;
 B
IC
-1
Se
le
ct
ive
 g
en
e 
ex
pr
es
sio
n 
us
in
g 
a D
F3
/M
UC
1 
pr
om
ot
er
 in
 a 
hu
m
an
 e
so
ph
ag
ea
l 
ad
en
oc
ar
cin
om
a m
od
el
Gu
pt
a, 
et
 al
.
20
02
SE
G-
1
SE
G-
1
Co
m
bi
ne
d 
ge
ne
 th
er
ap
y a
nd
 io
ni
zin
g 
ra
di
at
io
n 
is 
a n
ov
el
 ap
pr
oa
ch
 to
 tr
ea
t h
um
an
 
es
op
ha
ge
al
 ad
en
oc
ar
cin
om
a
Jurjen Boomstra bw.indd   172 03-10-11   15:45
173
Appendices
Au
th
or
s
Pu
bl
ica
tio
n 
da
te
Ce
ll 
lin
e(
s)
Es
op
ha
gu
s r
el
at
ed
 
ce
ll 
lin
e(
s)
O
th
er
 ce
ll 
lin
e(
s)
Xe
no
gr
af
t
St
ud
y t
itl
e
Jo
e, 
et
 al
.
20
02
SE
G-
1;
 B
IC
-1
SW
48
0;
 M
CF
7;
 H
CE
7;
 
HL
60
Re
sv
er
at
ro
l in
du
ce
s g
ro
w
th
 in
hi
bi
tio
n,
 S-
ph
as
e 
ar
re
st
, a
po
pt
os
is,
 an
d 
ch
an
ge
s i
n 
bi
om
ar
ke
r e
xp
re
ss
io
n 
in
 se
ve
ra
l h
um
an
 ca
nc
er
 ce
ll l
in
es
M
au
ce
ri,
 et
 al
.
20
01
SE
G-
1
SQ
-2
0B
SE
G-
1;
 SQ
-2
0B
Tr
ea
tm
en
t o
f h
ea
d 
an
d 
ne
ck
 an
d 
es
op
ha
ge
al
 xe
no
gr
af
ts
 e
m
pl
oy
in
g 
Al
im
ta
 an
d 
co
nc
ur
re
nt
 io
ni
zin
g 
ra
di
at
io
n
Fa
ng
, e
t a
l.
20
01
BI
C-
1
Tr
an
slo
ca
tio
n 
br
ea
kp
oi
nt
s i
n 
FH
IT
 an
d 
FR
A3
B 
in
 b
ot
h 
ho
m
ol
og
s o
f c
hr
om
os
om
e 
3 
in
 
an
 e
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a
Sa
llo
um
, e
t a
l.
20
00
SE
G-
1
SQ
-2
0B
LL
C;
 U
37
3 
M
G
U3
73
 M
G
NM
-3
, a
n 
iso
co
um
ar
in
, in
cr
ea
se
s t
he
 an
tit
um
or
 e
ff e
ct
s o
f r
ad
io
th
er
ap
y w
ith
ou
t 
to
xic
ity
Go
rs
ki
, e
t a
l.
19
99
SE
G-
1
SQ
-2
0B
LL
C;
 U
1
SE
G-
1
Bl
oc
ka
ge
 o
f t
he
 va
sc
ul
ar
 e
nd
ot
he
lia
l g
ro
w
th
 fa
ct
or
 st
re
ss
 re
sp
on
se
 in
cr
ea
se
s t
he
 
an
tit
um
or
 e
ff e
ct
s o
f i
on
izi
ng
 ra
di
at
io
n
* 
A
ls
o 
hu
m
an
 ti
ss
ue
 s
am
pl
es
 w
er
e 
us
ed
Es
op
ha
gu
s 
re
la
te
d 
ce
ll 
lin
es
:
H
ET
-1
A
: N
on
-c
an
ce
r d
er
iv
ed
, S
V4
0 
im
m
or
ta
liz
ed
 s
qu
am
ou
s 
ep
ith
el
ia
l c
el
l l
in
e 
(e
st
ab
lis
he
d 
by
 H
ar
ris
 e
t a
l.)
hT
ER
T 
N
SE
: h
TE
RT
 im
m
or
ta
liz
ed
 s
qu
am
ou
s 
ep
ith
el
ia
l c
el
l l
in
e:
 h
TE
RT
 N
SE
 (e
st
ab
lis
he
d 
by
 S
pe
ch
le
r e
t a
l.)
CP
-A
; C
P-
C;
 C
P-
D
: h
TR
T 
im
m
or
ta
liz
ed
 B
ar
re
tt
’s 
es
op
ha
gu
s 
de
riv
ed
 c
el
l l
in
es
 (e
st
ab
lis
he
d 
by
 R
ab
in
ov
itc
h 
et
 a
l.)
Es
op
ha
ge
al
 s
qu
am
ou
s 
ce
ll 
ca
rc
in
om
a 
ce
ll 
lin
es
:
KY
SE
-s
er
ie
s;
 T
E-
se
rie
s;
 E
CA
-1
09
; H
KE
SC
-1
; H
KE
SC
-2
; T
T;
 H
CE
-7
; S
Q
-2
0B
Jurjen Boomstra bw.indd   173 03-10-11   15:45
174
Appendices
A
pp
en
di
x 
Ta
bl
e 
5.
 R
ep
or
ts
 in
 w
hi
ch
 S
EG
-1
 a
nd
 o
r B
IC
-1
 h
av
e 
be
en
 u
se
d 
in
 c
om
bi
na
tio
n 
w
ith
 o
th
er
 e
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a 
ce
ll 
lin
es
 a
nd
 o
r h
um
an
 ti
ss
ue
s
Au
th
or
s
Pu
bl
ica
tio
n 
da
te
Ce
ll 
lin
e(
s)
EA
C 
ce
ll 
lin
e(
s)
Es
op
ha
gu
s r
el
at
ed
 ce
ll 
lin
es
Pa
tie
nt
 ti
ss
ue
 sa
m
pl
es
St
ud
y t
itl
e
Be
al
es
, e
t a
l.
20
09
BI
C-
1
OE
33
CP
-?
Gl
yc
in
e-
ex
te
nd
ed
 g
as
tri
n 
in
hi
bi
ts
 ap
op
to
sis
 in
 B
ar
re
tt’
s 
es
op
ha
ge
al
 an
d 
EA
 ce
lls
 th
ro
ug
h 
JA
K2
/S
TA
T3
 ac
tiv
at
io
n
va
n 
De
kk
en
, e
t a
l.
20
08
SE
G-
1
OE
19
; O
E3
3;
 B
E-
3;
 ES
O-
51
; 
KY
AE
-1
; P
4C
E; 
OA
CM
5.
1;
 SK
GT
-
4;
 SK
GT
-5
EA
C;
 G
AC
M
ol
ec
ul
ar
 d
iss
ec
tio
n 
of
 th
e 
ch
ro
m
os
om
e 
ba
nd
 
7q
21
 am
pl
ico
n 
in
 g
as
tro
es
op
ha
ge
al
 ju
nc
tio
n 
ad
en
oc
ar
cin
om
as
 id
en
tifi
 e
s c
yc
lin
-d
ep
en
de
nt
 ki
na
se
 6
 
at
 b
ot
h 
ge
no
m
ic 
an
d 
pr
ot
ei
n 
ex
pr
es
sio
n 
le
ve
ls
Sh
am
m
as
, e
t a
l.†
20
08
SE
G-
1:
 B
IC
-1
FL
O-
1
No
rm
al
; B
ar
re
tt;
 EA
C
Te
lo
m
er
e m
ai
nt
en
an
ce
 in
 la
se
r c
ap
tu
re
 m
icr
od
iss
ec
tio
n-
pu
rifi
 e
d 
Ba
rre
tt’
s a
de
no
ca
rc
in
om
a c
el
ls 
an
d 
eff
 e
ct
 o
f 
te
lo
m
er
as
e 
in
hi
bi
tio
n 
in
 vi
vo
Bo
ul
t, 
et
 al
.
20
08
SE
G-
1
Ba
rre
tt;
 EA
C
Oe
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a i
s a
ss
oc
ia
te
d 
w
ith
 a 
de
re
gu
la
tio
n 
in
 th
e 
M
YC
/M
AX
/M
AD
 n
et
w
or
k
Br
et
on
, e
t a
l.
20
08
SE
G-
1;
 B
IC
-1
FL
O-
1;
 O
E3
3
KY
SE
-3
0;
 O
E2
1;
 H
ET
1A
; C
P-
A;
 
CP
-C
; C
P-
D
Pr
ot
eo
m
ic 
sc
re
en
in
g 
of
 a 
ce
ll l
in
e 
m
od
el
 o
f e
so
ph
ag
ea
l 
ca
rc
in
og
en
es
is 
id
en
tifi
 e
s c
at
he
ps
in
 D
 an
d 
al
do
-k
et
o 
re
du
ct
as
e 
1C
2 
an
d 
1B
10
 d
ys
re
gu
la
tio
n 
in
 B
ar
re
tt’
s 
es
op
ha
gu
s a
nd
 e
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a
Og
un
w
ob
i, e
t a
l.*
20
08
BI
C-
1
FL
O;
 O
E3
3;
 O
E1
9
Gl
ob
ul
ar
 ad
ip
on
ec
tin
, a
ct
in
g 
vi
a a
di
po
ne
ct
in
 
re
ce
pt
or
-1
, in
hi
bi
ts
 le
pt
in
-st
im
ul
at
ed
 o
es
op
ha
ge
al
 
ad
en
oc
ar
cin
om
a c
el
l p
ro
lif
er
at
io
n
Og
un
w
ob
i, e
t a
l.
20
08
BI
C-
1
OE
33
St
at
in
s i
nh
ib
it 
pr
ol
ife
ra
tio
n 
an
d 
in
du
ce
 ap
op
to
sis
 in
 
Ba
rre
tt’
s e
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a c
el
ls
Ye
n,
 et
 al
.
20
08
SE
G-
1
BE
-3
; S
K-
GT
-4
CP
-A
; C
P-
C
Bi
le
 ac
id
 e
xp
os
ur
e 
up
-re
gu
la
te
s t
ub
er
ou
s s
cle
ro
sis
 
co
m
pl
ex
 1
/m
am
m
al
ia
n 
ta
rg
et
 o
f r
ap
am
yc
in
 p
at
hw
ay
 in
 
Ba
rre
tt’
s a
ss
oc
ia
te
d 
es
op
ha
ge
al
 ad
en
oc
ar
cin
om
a
Je
th
w
a, 
et
 al
.‡
20
08
SE
G-
1
OE
33
TE
-7
No
rm
al
; B
ar
re
tt;
 EA
C
Ov
er
ex
pr
es
sio
n 
of
 Sl
ug
 is
 as
so
cia
te
d 
w
ith
 m
al
ig
na
nt
 
pr
og
re
ss
io
n 
of
 e
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a
Cl
ém
en
t, 
et
 al
.‡
20
08
SE
G-
1;
 B
IC
-1
OE
19
; O
E3
3;
 
TE
-7
No
rm
al
; B
ar
re
tt;
 EA
C
Ep
ig
en
et
ic 
al
te
ra
tio
n 
of
 th
e W
nt
 in
hi
bi
to
ry
 fa
ct
or
-1
 
pr
om
ot
er
 o
cc
ur
s e
ar
ly
 in
 th
e 
ca
rc
in
og
en
es
is 
of
 B
ar
re
tt’
s 
es
op
ha
gu
s
Bo
ul
t, 
et
 al
.
20
08
SE
G-
1
OE
33
ES
CC
Ov
er
ex
pr
es
sio
n 
of
 ce
llu
la
r i
ro
n 
im
po
rt 
pr
ot
ei
ns
 is
 
as
so
cia
te
d 
w
ith
 m
al
ig
na
nt
 p
ro
gr
es
sio
n 
of
 e
so
ph
ag
ea
l 
ad
en
oc
ar
cin
om
a
Jurjen Boomstra bw.indd   174 03-10-11   15:45
175
Appendices
Au
th
or
s
Pu
bl
ica
tio
n 
da
te
Ce
ll 
lin
e(
s)
EA
C 
ce
ll 
lin
e(
s)
Es
op
ha
gu
s r
el
at
ed
 ce
ll 
lin
es
Pa
tie
nt
 ti
ss
ue
 sa
m
pl
es
St
ud
y t
itl
e
W
at
ts
, e
t a
l.‡
20
07
SE
G-
1;
 B
IC
-1
TE
-7
No
rm
al
; B
ar
re
tt
Id
en
tifi
 c
at
io
n 
of
 Fn
14
/T
W
EA
K 
re
ce
pt
or
 as
 a 
po
te
nt
ia
l 
th
er
ap
eu
tic
 ta
rg
et
 in
 e
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a
Zh
an
g,
 et
 al
.
20
07
SE
G-
1
EA
C
Al
te
rn
at
ive
 sp
lic
in
g 
of
 th
e 
FG
F a
nt
ise
ns
e 
ge
ne
: 
di
ff e
re
nt
ia
l s
ub
ce
llu
la
r l
oc
al
iza
tio
n 
in
 h
um
an
 ti
ss
ue
s 
an
d 
es
op
ha
ge
al
 ad
en
oc
ar
cin
om
a
Jin
, e
t a
l.
20
07
SE
G-
1;
 B
IC
-1
OE
33
KY
SE
-se
rie
s
EA
C;
 ES
CC
Hy
pe
rm
et
hy
la
tio
n 
of
 ta
ch
yk
in
in
-1
 is
 a 
po
te
nt
ia
l 
bi
om
ar
ke
r i
n 
hu
m
an
 e
so
ph
ag
ea
l c
an
ce
r
va
n 
Du
in
, e
t a
l.
20
07
SE
G-
1;
 B
IC
-1
OE
19
; O
E3
3;
 B
E-
3;
 ES
O-
26
; 
ES
O-
51
; F
LO
-1
; K
YA
E-
1;
 P
4C
E; 
OA
CM
5.
1;
 SK
-G
T-
4;
 SK
-G
T-
5
Hi
gh
-re
so
lu
tio
n 
ar
ra
y c
om
pa
ra
tiv
e 
ge
no
m
ic 
hy
br
id
iza
tio
n 
of
 ch
ro
m
os
om
e 
8q
: e
va
lu
at
io
n 
of
 p
ut
at
ive
 
pr
og
re
ss
io
n 
m
ar
ke
rs
 fo
r g
as
tro
es
op
ha
ge
al
 ju
nc
tio
n 
ad
en
oc
ar
cin
om
as
Jin
, e
t a
l.
20
07
SE
G-
1;
 B
IC
-1
OE
33
KY
SE
-se
rie
s
No
rm
al
; B
ar
re
tt;
 EA
C;
 
ES
CC
Hy
pe
rm
et
hy
la
tio
n 
of
 th
e 
ne
l-l
ike
 1
 g
en
e 
is 
a c
om
m
on
 
an
d 
ea
rly
 e
ve
nt
 an
d 
is 
as
so
cia
te
d 
w
ith
 p
oo
r p
ro
gn
os
is 
in
 e
ar
ly-
st
ag
e 
es
op
ha
ge
al
 ad
en
oc
ar
cin
om
a
Ha
o,
 et
 al
.‡
20
07
SE
G-
1
OE
33
OE
21
; T
E-
7
Ba
rre
tt
Ge
ne
 e
xp
re
ss
io
n 
ch
an
ge
s a
ss
oc
ia
te
d 
w
ith
 B
ar
re
tt’
s 
es
op
ha
gu
s a
nd
 B
ar
re
tt’
s-a
ss
oc
ia
te
d 
ad
en
oc
ar
cin
om
a 
ce
ll l
in
es
 af
te
r a
cid
 o
r b
ile
 sa
lt 
ex
po
su
re
Liu
, e
t a
l.
20
07
SE
G-
1;
 B
IC
-1
FL
O1
; S
KG
T4
; B
E3
HE
T-
1A
Re
gu
la
tio
n 
of
 C
dx
2 
ex
pr
es
sio
n 
by
 p
ro
m
ot
er
 
m
et
hy
la
tio
n,
 an
d 
eff
 e
ct
s o
f C
dx
2 
tra
ns
fe
ct
io
n 
on
 m
or
ph
ol
og
y a
nd
 g
en
e 
ex
pr
es
sio
n 
of
 h
um
an
 
es
op
ha
ge
al
 e
pi
th
el
ia
l c
el
ls
Lin
, e
t a
l.‡ 
20
06
SE
G-
1;
 B
IC
-1
FL
O-
1;
 O
E3
3;
 
H8
0-
T; 
L2
0-
T; 
BA
1
HE
T-
1A
;
S9
5-
B
No
rm
al
; B
ar
re
tt;
 EA
C
Ex
pr
es
sio
n 
an
d 
eff
 e
ct
 o
f i
nh
ib
iti
on
 o
f t
he
 
ub
iq
ui
tin
-c
on
ju
ga
tin
g 
en
zy
m
e 
E2
C 
on
 e
so
ph
ag
ea
l 
ad
en
oc
ar
cin
om
a
W
at
so
n,
 et
 al
.*
20
06
SE
G-
1;
 B
IC
-1
FL
O-
1
In
hi
bi
tio
n 
of
 c-
M
et
 as
 a 
th
er
ap
eu
tic
 st
ra
te
gy
 fo
r 
es
op
ha
ge
al
 ad
en
oc
ar
cin
om
a
Si
m
s-M
ou
rta
da
, 
et
 al
.†
20
06
SE
G-
1;
 B
IC
-1
SK
GT
4;
 B
E-
3
EA
C
He
dg
eh
og
: a
n 
at
tri
bu
te
 to
 tu
m
or
 re
gr
ow
th
 af
te
r 
ch
em
or
ad
io
th
er
ap
y a
nd
 a 
ta
rg
et
 to
 im
pr
ov
e 
ra
di
at
io
n 
re
sp
on
se
Ha
m
ilt
on
, e
t a
l.
20
06
SE
G-
1;
 B
IC
-1
OE
33
KY
SE
-se
rie
s
Ba
rre
tt;
 EA
C
Re
pr
im
o 
m
et
hy
la
tio
n 
is 
a p
ot
en
tia
l b
io
m
ar
ke
r o
f 
Ba
rre
tt’
s-A
ss
oc
ia
te
d 
es
op
ha
ge
al
 n
eo
pl
as
tic
 p
ro
gr
es
sio
n
Jurjen Boomstra bw.indd   175 03-10-11   15:45
176
Appendices
Au
th
or
s
Pu
bl
ica
tio
n 
da
te
Ce
ll 
lin
e(
s)
EA
C 
ce
ll 
lin
e(
s)
Es
op
ha
gu
s r
el
at
ed
 ce
ll 
lin
es
Pa
tie
nt
 ti
ss
ue
 sa
m
pl
es
St
ud
y t
itl
e
Re
es
, e
t a
l.‡
20
06
BI
C-
1
OE
33
 
TE
-7
EA
C
In
 vi
vo
 an
d 
in
 vi
tro
 e
vi
de
nc
e 
fo
r t
ra
ns
fo
rm
in
g 
gr
ow
th
 
fa
ct
or
-b
et
a1
-m
ed
ia
te
d 
ep
ith
el
ia
l t
o 
m
es
en
ch
ym
al
 
tra
ns
iti
on
 in
 e
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a
Su
, e
t a
l.‡
20
06
SE
G-
1;
 B
IC
-1
OE
19
KY
SE
-3
0;
 O
E-
21
; H
5E
97
3;
 TE
-7
Co
m
pa
ra
tiv
e 
ge
no
m
ic 
hy
br
id
iza
tio
n 
of
 e
so
ph
ag
ea
l 
ad
en
oc
ar
cin
om
a a
nd
 sq
ua
m
ou
s c
el
l c
ar
cin
om
a c
el
l 
lin
es
Ha
o,
 et
 al
.‡
20
06
SE
G-
1
OE
33
OE
-2
1;
 TE
-7
Ba
rre
tt;
 EA
C
Ge
ne
 e
xp
re
ss
io
n 
pr
ofi
 li
ng
 re
ve
al
s s
tro
m
al
 g
en
es
 
ex
pr
es
se
d 
in
 co
m
m
on
 b
et
w
ee
n 
Ba
rre
tt’
s e
so
ph
ag
us
 
an
d 
ad
en
oc
ar
cin
om
a
Ch
an
g,
 et
 al
.†
20
06
SE
G-
1
SK
-G
T-
5;
 SK
-G
T-
4 
Tu
m
or
-sp
ec
ifi 
c a
po
pt
ot
ic 
ge
ne
 ta
rg
et
in
g 
ov
er
co
m
es
 
ra
di
at
io
n 
re
sis
ta
nc
e 
in
 e
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a
Lin
, e
t a
l.
20
06
SE
G-
1
FL
O-
1
HE
T-
1A
EA
C
M
ul
tip
le
 fo
rm
s o
f g
en
et
ic 
in
st
ab
ilit
y w
ith
in
 a 
2-
M
b 
ch
ro
m
os
om
al
 se
gm
en
t o
f 3
q2
6.
3-
q2
7 
ar
e 
as
so
cia
te
d 
w
ith
 d
ev
el
op
m
en
t o
f e
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a
Yo
un
es
, e
t a
l.
20
06
SE
G-
1;
 B
IC
-1
EA
C
Fu
nc
tio
na
l e
xp
re
ss
io
n 
of
 TR
AI
L r
ec
ep
to
rs
 TR
AI
L-
R1
 an
d 
TR
AI
L-
R2
 in
 e
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a
W
at
so
n,
 et
 al
.†
20
06
SE
G-
1;
 B
IC
-1
FL
O-
1
Ad
-IR
F-
1 
in
du
ce
s a
po
pt
os
is 
in
 e
so
ph
ag
ea
l 
ad
en
oc
ar
cin
om
a
M
ille
r, e
t a
l.
20
06
SE
G-
1;
 B
IC
-1
FL
O-
1;
 O
E3
3
EA
C
Ge
no
m
ic 
am
pl
ifi 
ca
tio
n 
of
 M
ET
 w
ith
 b
ou
nd
ar
ie
s w
ith
in
 
fra
gi
le
 si
te
 FR
A7
G 
an
d 
up
re
gu
la
tio
n 
of
 M
ET
 p
at
hw
ay
s i
n 
es
op
ha
ge
al
 ad
en
oc
ar
cin
om
a
Ab
da
lla
, e
t a
l.
20
05
SE
G-
1;
 B
IC
-1
OE
33
OE
-2
1 
Ba
rre
tt;
 EA
C
Eff
 e
ct
 o
f i
nfl
 a
m
m
at
io
n 
on
 cy
clo
ox
yg
en
as
e 
(C
OX
)-2
 
ex
pr
es
sio
n 
in
 b
en
ig
n 
an
d 
m
al
ig
na
nt
 o
es
op
ha
ge
al
 ce
lls
Zo
u,
 et
 al
.
20
05
SE
G-
1;
 B
IC
-1
OE
33
No
rm
al
; B
ar
re
tt;
 EA
C
Ab
er
ra
nt
 m
et
hy
la
tio
n 
of
 se
cr
et
ed
 fr
izz
le
d-
re
la
te
d 
pr
ot
ei
n 
ge
ne
s i
n 
es
op
ha
ge
al
 ad
en
oc
ar
cin
om
a a
nd
 
Ba
rre
tt’
s e
so
ph
ag
us
On
w
ue
gb
us
i,
et
 al
.‡
20
05
SE
G-
1;
 B
IC
-1
FL
O-
1;
 O
E3
3
CP
-A
; C
P-
C;
 C
P-
D;
 TE
-7
Ba
rre
tt;
 EA
C
Im
pa
ire
d 
tra
ns
fo
rm
in
g 
gr
ow
th
 fa
ct
or
 b
et
a s
ig
na
llin
g 
in
 B
ar
re
tt’
s c
ar
cin
og
en
es
is 
du
e 
to
 fr
eq
ue
nt
 SM
AD
4 
in
ac
tiv
at
io
n
Sc
hu
lm
an
n,
 et
 al
.
20
05
BI
C-
1
Ba
rre
tt;
 EA
C
In
ac
tiv
at
io
n 
of
 p
16
, R
UN
X3
, a
nd
 H
PP
1 
oc
cu
rs
 e
ar
ly 
in
 
Ba
rre
tt’
s-a
ss
oc
ia
te
d 
ne
op
la
st
ic 
pr
og
re
ss
io
n 
an
d 
pr
ed
ict
s 
pr
og
re
ss
io
n 
ris
k
Jurjen Boomstra bw.indd   176 03-10-11   15:45
177
Appendices
Au
th
or
s
Pu
bl
ica
tio
n 
da
te
Ce
ll 
lin
e(
s)
EA
C 
ce
ll 
lin
e(
s)
Es
op
ha
gu
s r
el
at
ed
 ce
ll 
lin
es
Pa
tie
nt
 ti
ss
ue
 sa
m
pl
es
St
ud
y t
itl
e
Da
rn
to
n,
 et
 al
.
20
05
SE
G-
1;
 B
IC
-1
FL
O-
1;
 O
E3
3
EA
C
Ti
ss
ue
 in
hi
bi
to
r o
f m
et
al
lo
pr
ot
ei
na
se
-3
 (T
IM
P-
3)
 g
en
e 
is 
m
et
hy
la
te
d 
in
 th
e 
de
ve
lo
pm
en
t o
f e
so
ph
ag
ea
l 
ad
en
oc
ar
cin
om
a: 
lo
ss
 o
f e
xp
re
ss
io
n 
co
rre
la
te
s w
ith
 
po
or
 p
ro
gn
os
is
Ha
ns
el
, e
t a
l.
20
05
SE
G-
1;
 B
IC
-1
KY
AE
-1
; O
E3
3
Ba
rre
tt;
 EA
C
CD
C2
/C
DK
1 
ex
pr
es
sio
n 
in
 e
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a 
an
d 
pr
ec
ur
so
r l
es
io
ns
 se
rv
es
 as
 a 
di
ag
no
st
ic 
an
d 
ca
nc
er
 
pr
og
re
ss
io
n 
m
ar
ke
r a
nd
 p
ot
en
tia
l n
ov
el
 d
ru
g 
ta
rg
et
Zo
u,
 et
 al
.
20
05
SE
G-
1;
 B
IC
-1
OE
33
 
No
rm
al
; B
ar
re
tt;
 EA
C
Fr
eq
ue
nt
 m
et
hy
la
tio
n 
of
 e
ye
s a
bs
en
t 4
 g
en
e 
in
 B
ar
re
tt’
s 
es
op
ha
gu
s a
nd
 e
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a
M
ah
id
ha
ra
, e
t a
l.
20
05
SE
G-
1;
 B
IC
-1
FL
O-
1
HE
T-
1A
 
EA
C
Al
te
re
d 
tra
ffi  
ck
in
g 
of
 Fa
s a
nd
 su
bs
eq
ue
nt
 re
sis
ta
nc
e 
to
 Fa
s-m
ed
ia
te
d 
ap
op
to
sis
 o
cc
ur
s b
y a
 w
ild
-ty
pe
 
p5
3 
in
de
pe
nd
en
t m
ec
ha
ni
sm
 in
 e
so
ph
ag
ea
l 
ad
en
oc
ar
cin
om
a
He
rre
ra
, e
t a
l.
20
05
SE
G-
1;
 B
IC
-1
FL
O-
1
HE
T-
1A
EA
C
Th
e 
HG
F r
ec
ep
to
r c
-M
et
 is
 o
ve
re
xp
re
ss
ed
 in
 e
so
ph
ag
ea
l 
ad
en
oc
ar
cin
om
a
Lin
, e
t a
l.‡  
20
04
SE
G-
1;
 B
IC
-1
FL
O-
1;
 O
E3
3;
 
H8
0-
T; 
L2
0-
T; 
BA
1
HE
T-
1A
 ; S
95
-B
 
EA
C
M
el
an
om
a-
as
so
cia
te
d 
an
tig
en
s i
n 
es
op
ha
ge
al
 
ad
en
oc
ar
cin
om
a: 
id
en
tifi
 c
at
io
n 
of
 n
ov
el
 M
AG
E-
A1
0 
sp
lic
e 
va
ria
nt
s
Lin
, e
t a
l.‡ 
20
04
SE
G-
1;
 B
IC
-1
FL
O-
1;
 O
E3
3;
 
H8
0-
T; 
L2
0-
T; 
BA
1
HE
T-
1A
; 
S9
5-
B 
EA
C
L-
ty
pe
 am
in
o 
ac
id
 tr
an
sp
or
te
r-1
 o
ve
re
xp
re
ss
io
n 
an
d 
m
el
ph
al
an
 se
ns
iti
vi
ty
 in
 B
ar
re
tt’
s a
de
no
ca
rc
in
om
a
Ki
m
, e
t a
l.
20
03
SE
G-
1;
 B
IC
-1
OE
33
KY
SE
-?
; 
OE
-2
1
Tr
an
sfo
rm
in
g 
gr
ow
th
 fa
ct
or
-b
et
a i
s a
n 
en
do
ge
no
us
 
ra
di
or
es
ist
an
ce
 fa
ct
or
 in
 th
e 
es
op
ha
ge
al
 
ad
en
oc
ar
cin
om
a c
el
l li
ne
 O
E-
33
M
ille
r, e
t a
l.
20
03
SE
G-
1;
 B
IC
-1
FL
O-
1
HE
T-
1A
EA
C
Ge
ne
 am
pl
ifi 
ca
tio
n 
in
 e
so
ph
ag
ea
l a
de
no
ca
rc
in
om
as
 
an
d 
Ba
rre
tt’
s w
ith
 h
ig
h-
gr
ad
e 
dy
sp
la
sia
So
uz
a, 
et
 al
.
20
02
SE
G-
1
Ba
rre
tt
Ac
id
 e
xp
os
ur
e 
ac
tiv
at
es
 th
e 
m
ito
ge
n-
ac
tiv
at
ed
 p
ro
te
in
 
ki
na
se
 p
at
hw
ay
s i
n 
Ba
rre
tt’
s e
so
ph
ag
us
Ar
lt,
 et
 al
.*
20
02
SE
G-
1;
 B
IC
-1
FL
O-
1
M
ol
ec
ul
ar
 ch
ar
ac
te
riz
at
io
n 
of
 FR
AX
B 
an
d 
co
m
pa
ra
tiv
e 
co
m
m
on
 fr
ag
ile
 si
te
 in
st
ab
ilit
y i
n 
ca
nc
er
 ce
lls
W
ei
se
r, e
t a
l.
20
01
SK
-G
T-
5
BE
-3
TE
-se
rie
s
In
du
ct
io
n 
of
 M
AG
E-
3 
ex
pr
es
sio
n 
in
 lu
ng
 an
d 
es
op
ha
ge
al
 ca
nc
er
 ce
lls
Jurjen Boomstra bw.indd   177 03-10-11   15:45
178
Appendices
Au
th
or
s
Pu
bl
ica
tio
n 
da
te
Ce
ll 
lin
e(
s)
EA
C 
ce
ll 
lin
e(
s)
Es
op
ha
gu
s r
el
at
ed
 ce
ll 
lin
es
Pa
tie
nt
 ti
ss
ue
 sa
m
pl
es
St
ud
y t
itl
e
So
uz
a, 
et
 al
.
20
00
SE
G-
1;
 B
IC
-1
FL
O-
1
Se
le
ct
ive
 in
hi
bi
tio
n 
of
 cy
clo
ox
yg
en
as
e-
2 
su
pp
re
ss
es
 
gr
ow
th
 an
d 
in
du
ce
s a
po
pt
os
is 
in
 h
um
an
 e
so
ph
ag
ea
l 
ad
en
oc
ar
cin
om
a c
el
ls
Ag
ga
rw
al
, e
t a
l.
20
00
SE
G-
1;
 B
IC
-1
FL
O-
1
No
rm
al
;
Ba
rre
tt;
 EA
C
In
do
m
et
ha
cin
-in
du
ce
d 
ap
op
to
sis
 in
 e
so
ph
ag
ea
l 
ad
en
oc
ar
cin
om
a c
el
ls 
in
vo
lve
s u
pr
eg
ul
at
io
n 
of
 B
ax
 
an
d 
tra
ns
lo
ca
tio
n 
of
 m
ito
ch
on
dr
ia
l c
yt
oc
hr
om
e 
C 
in
de
pe
nd
en
t o
f C
OX
-2
 e
xp
re
ss
io
n
Co
m
pt
on
, e
t a
l.
19
99
SE
G-
1;
 B
IC
-1
FL
O-
1
HE
T-
1A
No
rm
al
;
Ba
rre
tt
In
du
ct
io
n 
of
 g
lu
ta
th
io
ne
 s-
tra
ns
fe
ra
se
-p
i in
 B
ar
re
tt’
s 
m
et
ap
la
sia
 an
d 
Ba
rre
tt’
s a
de
no
ca
rc
in
om
a c
el
l li
ne
s
So
ld
es
, e
t a
l.
19
99
SE
G-
1;
 B
IC
-1
FL
O-
1
HE
T-
1A
Ba
rre
tt;
 EA
C
Di
ff e
re
nt
ia
l e
xp
re
ss
io
n 
of
 H
sp
27
 in
 n
or
m
al
 o
es
op
ha
gu
s, 
Ba
rre
tt’
s m
et
ap
la
sia
 an
d 
oe
so
ph
ag
ea
l a
de
no
ca
rc
in
om
as
Sc
hr
um
p,
 et
 al
.
19
98
SK
-G
T-
5
SK
-G
T-
4;
 SK
-G
T-
2
HC
E-
4
Fla
vo
pi
rid
ol
 m
ed
ia
te
s c
el
l c
yc
le
 ar
re
st
 an
d 
ap
op
to
sis
 in
 
es
op
ha
ge
al
 ca
nc
er
 ce
lls
Hu
gh
es
, e
t a
l.
19
97
SE
G-
1;
 B
IC
-1
FL
O-
1
 
EA
C
Fa
s/
AP
O-
1 
(C
D9
5)
 is
 n
ot
 tr
an
slo
ca
te
d 
to
 th
e 
ce
ll 
m
em
br
an
e 
in
 e
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a
A
bb
re
vi
at
io
ns
: E
AC
, E
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a;
 E
SC
C,
 E
so
ph
ag
ea
l s
qu
am
ou
s 
ce
ll 
ca
rc
in
om
a;
 G
AC
, G
as
tr
ic
 a
de
no
ca
rc
in
om
a
* 
A
ls
o 
ce
ll 
lin
e(
s)
 fr
om
 o
th
er
 s
pe
ci
es
 o
r c
an
ce
r t
yp
es
 w
er
e 
us
ed
† 
A
ls
o 
SE
G
-1
 x
en
og
ra
ft
s 
w
er
e 
us
ed
‡ 
Ce
ll 
lin
es
 H
80
-T
; L
20
-T
 e
st
ab
lis
he
d 
by
 B
ee
r e
t a
l. 
do
 n
ot
 g
ro
w
 in
 v
itr
o 
(p
er
so
na
l c
om
m
un
ic
at
io
n)
‡ 
Ce
ll 
lin
e 
BA
-1
 e
st
ab
lis
he
d 
by
 d
r R
ut
te
n 
do
es
 n
ot
 g
ro
w
 in
 v
itr
o 
an
d 
or
ig
in
 is
 u
nk
no
w
n 
(p
er
so
na
l c
om
m
un
ic
at
io
n)
‡ 
Ce
ll 
lin
e 
TE
-7
 is
 n
ot
 a
n 
es
op
ha
ge
al
 a
de
no
ca
rc
in
om
a 
ce
ll 
lin
e,
 b
ut
 a
 s
qu
am
ou
s 
ce
ll 
ca
rc
in
om
a 
ce
ll 
lin
e 
of
 u
nk
no
w
n 
or
ig
in
 (a
s 
re
po
rt
ed
 b
y 
Bo
on
st
ra
, e
t a
l.)
Es
op
ha
gu
s 
re
la
te
d 
ce
ll 
lin
es
:
H
ET
-1
A
: N
on
-c
an
ce
r d
er
iv
ed
, S
V4
0 
im
m
or
ta
liz
ed
 s
qu
am
ou
s 
ep
ith
el
ia
l c
el
l l
in
e 
(e
st
ab
lis
he
d 
by
 H
ar
ris
 e
t a
l.)
hT
ER
T 
N
SE
: h
TE
RT
 im
m
or
ta
liz
ed
 s
qu
am
ou
s 
ep
ith
el
ia
l c
el
l l
in
e:
 h
TE
RT
 N
SE
 (e
st
ab
lis
he
d 
by
 S
pe
ch
le
r e
t a
l.)
CP
-A
; C
P-
C;
 C
P-
D
: h
TR
T 
im
m
or
ta
liz
ed
 B
ar
re
tt
’s 
es
op
ha
gu
s 
de
riv
ed
 c
el
l l
in
es
 (e
st
ab
lis
he
d 
by
 R
ab
in
ov
itc
h 
et
 a
l.)
S9
5-
B;
 E
6/
E7
 re
tr
ov
ira
l i
m
m
or
ta
liz
ed
 B
ar
re
tt
’s 
es
op
ha
gu
s 
de
riv
ed
 c
el
l l
in
e
Es
op
ha
ge
al
 s
qu
am
ou
s 
ce
ll 
ca
rc
in
om
a 
ce
ll 
lin
es
:
KY
SE
-s
er
ie
s;
 T
E-
se
rie
s;
 O
E2
1;
 H
5E
97
3;
 H
CE
-4
Jurjen Boomstra bw.indd   178 03-10-11   15:45
179
Appendices
Appendix Table 6. Homozygous deletion aff ecting common fragile sites
Cytoband Start Stop Size (bp) Sample Fragile site Genes
3p14.2 60254740 61191150 936410 ESO26; ESO51; JH-EsoAd1; KYAE-1; P100x; 
P101x; P102x; P117x; P140x; P171x; 
P175x; P58x
FRA3B FHIT
3p14.2 60409270 60437190 27920 OACM5.1 FRA3B FHIT
3p14.2 60145820 60489260 343440 OE33 FRA3B FHIT
4q22.1 91661770 91808390 146620 FLO-1; P100x FRA4F FAM190A/TMSL3
4q22.1 92239940 92562840 322900 P100x FRA4F FAM190A/TMSL3
7q36.3 157136920 157283380 146460 P101x FRA7I PTPRN2
16q23.1 77137560 77411730 274170 ESO26; KYAE-1; OE33; P100x FRA16D WWOX
20p12.1 14729690 14794610
64920
SK-GT-4; ESO26; P101x FRA20B
MACROD2 
(C20orf133)
20p12.1 14791900 15129670
337770
FLO-1 FRA20B
MACROD2 
(C20orf133)
Appendix Table 7. Homozygous deletion aff ecting regions without genes
Cytoband Start Stop Size (bp) Sample
1q31.2 191517870 191604510 86640 KYAE-1
4q22.3 97309470 97470920 161450 P101x
8q21.3 90003095 90183062 179967 P4CE
9p21.2 26480277 26744888 264611 P58x
12q21.2 75058720 75205180 146460 OE33
16q21 61996620 62338360 341740 KYAE-1
17p12 14272780 14596780 324000 FLO-1
21q21.1 15579170 15795570 216400 OE19
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